

CITATION REPORT

List of articles citing

Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge

DOI: 10.1161/01.cir.76.1.142
Circulation, 1987, 76, 142-54.

Source: <https://exaly.com/paper-pdf/19187323/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2094	Advances in thrombolytic therapy for acute myocardial infarction. 1987 , 27, 735-45		13
2093	The FDA Advisory Panel's decision on rt-PA. 1987 , 27, 730-4		2
2092	Community hospital administration of intravenous tissue plasminogen activator in acute myocardial infarction: improved timing, thrombolytic efficacy and ventricular function. 1987 , 10, 1173-7		75
2091	Safety and efficacy of tissue-type plasminogen activator produced by recombinant DNA technology. 1987 , 10, 40B-44B		13
2090	Coronary angioplasty after recombinant tissue-type plasminogen activator in acute myocardial infarction: a report from the Thrombolysis in Myocardial Infarction (TIMI) Trial. 1987 , 10, 45B-50B		17
2089	The Thrombolysis in Myocardial Infarction (TIMI) phase II pilot study: tissue plasminogen activator followed by percutaneous transluminal coronary angioplasty. 1987 , 10, 51B-64B		109
2088	Efficacy of a two-hour infusion of 150-mg tissue plasminogen activator in acute myocardial infarction. 1987 , 60, 1225-9		12
2087	Session 2: Thrombolysis for acute myocardial infarction. 1988 , 17, 1166-1167		
2086	Emergency thrombolysis in acute myocardial infarction. 1988 , 17, 1168-75		8
2085	Experience with the use of tPA in the treatment of acute myocardial infarction. 1988 , 17, 1176-89		4
2084	The investigational use of tPA for stroke. 1988 , 17, 1202-5		28
2083	The farmer and the cowman should be friends: emergency physicians and cardiologists must work together to ensure rapid initiation of thrombolytic therapy. 1988 , 17, 653-4		5
2082	New strategies in the development of thrombolytic agents. 1988 , 57, 147-62		9
2081	EDITORIAL REVIEW. 1988 , 1, 231-235		1
2080	Anistreplase (APSAC) and Future Trends in Thrombolytic Therapy. 1988 , 1, 285-290		1
2079	Thrombolytic Agents for Acute Myocardial Infarction. 1988 , 6, 1-19		1
2078	Antithrombotic therapy for patients with cardiac disease. 1988 , 13, 430-513		1

2077	Reperfusion therapy of acute myocardial infarction. 1988 , 30, 235-66	30
2076	The uncertain role of thrombolytic angioplasty within the treatment strategy for myocardial infarction. 1988 , 62, 21K-24K	1
2075	Intravenous streptokinase in acute myocardial infarction at the community hospital: a six-year experience. 1988 , 62, 25K-27K	9
2074	Six- and twelve-month follow-up of the phase I Thrombolysis in Myocardial Infarction (TIMI) trial. 1988 , 62, 179-85	204
2073	Impact of thrombolytic therapy on left ventricular mural thrombi in acute myocardial infarction. 1988 , 62, 310-1	38
2072	Dependence of assessment of coronary artery reperfusion during acute myocardial infarction on angiographic criteria and interobserver variability. 1988 , 62, 538-42	29
2071	Percutaneous transluminal coronary angioplasty in patients with intracoronary thrombus. 1988 , 62, 474-6	53
2070	Dissimilar systemic and local adverse effects of thrombolytic therapy. 1988 , 61, 1344-6	7
2069	Effect of reperfusion on electrocardiographic and enzymatic infarct size: results of a randomized multicenter study of intravenous anisoylated plasminogen streptokinase activator complex (APSAC) versus intracoronary streptokinase in acute myocardial infarction. 1988 , 116, 903-14	40
2068	Appraisal of various thrombolytic agents in the treatment of acute myocardial infarction. 1988 , 84, 980-3	
2067	The reply. 1988 , 84, 982-983	
2066	Bolus dose response characteristics of single chain urokinase plasminogen activator and tissue plasminogen activator in a dog model of arterial thrombosis. 1988 , 52, 295-312	25
2065	Thrombolysis in Myocardial Infarction (TIMI) Trial--phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. 1988 , 11, 1-11	1077
2064	Multicenter reperfusion trial of intravenous anisoylated plasminogen streptokinase activator complex (APSAC) in acute myocardial infarction: controlled comparison with intracoronary streptokinase. 1988 , 11, 1153-63	127
2063	Unresolved clinical pharmacologic questions in thrombolytic therapy for acute myocardial infarction. 1988 , 12, 519-25	14
2062	Reply. 1988 , 11, 672	
2061	Administration of thrombolytic therapy in the community hospital: established principles and unresolved issues. 1988 , 12, 32A-43A	20
2060	Reperfusion therapy in inferior myocardial infarction. 1988 , 12, 44A-51A	33

2059	The risk of reperfusion strategies in the treatment of patients with acute myocardial infarction. 1988 , 12, 52A-57A		14
2058	Cost and procedure implications of thrombolytic therapy for acute myocardial infarction. 1988 , 12, 58A-68A		17
2057	Antithrombotic therapy after myocardial reperfusion in acute myocardial infarction. 1988 , 12, 78A-84A		44
2056	Thrombolytic reperfusion of acute myocardial infarction: resolved and unresolved issues. 1988 , 12, 85A-92A		26
2055	Tissue plasminogen activator. 1988 , 319, 925-31		167
2054	RANDOMISED TRIAL OF INTRAVENOUS STREPTOKINASE, ORAL ASPIRIN, BOTH, OR NEITHER AMONG 17 187 CASES OF SUSPECTED ACUTE MYOCARDIAL INFARCTION: ISIS-2. 1988 , 332, 349-360		356
2053	Thrombolysis with tissue plasminogen activator in acute myocardial infarction: no additional benefit from immediate percutaneous coronary angioplasty. 1988 , 1, 197-203		537
2052	Thrombolysis after myocardial infarction. 1988 , 1, 763		8
2051	Thrombolytic therapy: current status (1). 1988 , 318, 1512-20		445
2050	Characteristics and outcome of patients in whom reperfusion with intravenous tissue-type plasminogen activator fails: results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) I trial. <i>Circulation</i> , 1988 , 77, 1090-9	16.7	138
2049	Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation. <i>Circulation</i> , 1988 , 77, 670-7	16.7	374
2048	Treatment of canine embolic pulmonary hypertension with recombinant tissue plasminogen activator. Efficacy of dosing regimes. <i>Circulation</i> , 1988 , 78, 214-20	16.7	40
2047	Immediate vs delayed catheterization and angioplasty following thrombolytic therapy for acute myocardial infarction. TIMI II A results. The TIMI Research Group. 1988 , 260, 2849-58		337
2046	Prevention of coronary artery reocclusion and reduction in late coronary artery stenosis after thrombolytic therapy in patients with acute myocardial infarction. A randomized study of maintenance infusion of recombinant human tissue-type plasminogen activator. <i>Circulation</i> , 1988 , 78, 546-56	16.7	101
2045	Characterization in vivo of the fibrin specificity of activators of the fibrinolytic system. <i>Circulation</i> , 1988 , 78, 592-7	16.7	20
2044	Thrombolytic therapy. 1988 , 319, 1543-7		1
2043	Therapy to reduce free radicals during early reperfusion does not limit the size of myocardial infarcts caused by 90 minutes of ischemia in dogs. <i>Circulation</i> , 1988 , 78, 473-80	16.7	106
2042	Coronary arterial thrombolysis with combined infusion of recombinant tissue-type plasminogen activator and urokinase in patients with acute myocardial infarction. <i>Circulation</i> , 1988 , 77, 1100-7	16.7	196

2041	Interactions of tissue-type plasminogen activator with plasma inhibitors and their pharmacologic implications. <i>Circulation</i> , 1988 , 77, 660-9	16.7	138
2040	Serum cholesterol precursors, cholestanol, and plant sterols in primary biliary cirrhosis. 1988 , 23, 967-72		22
2039	Chapter 12. Plasminogen Activators. 1988 , 23, 111-120		5
2038	Alteplase: a tissue plasminogen activator for acute myocardial infarction. 1988 , 22, 6-14		10
2037	Evolving concepts in the treatment of acute myocardial infarction. 1988 , 296, 143-52		
2036	Authors' Reply. 1988 , 22, 427-428		
2035	Alteplase for acute myocardial infarction. 1988 , 22, 425-8		
2034	To the Editor. 1988 , 22, 426-426		
2033	Comment: cost-effectiveness methodology. 1988 , 22, 428-9		
2032	An Update on Cardiac Enzymes. <i>Cardiology Clinics</i> , 1988 , 6, 97-109	2.5	10
2031	Percutaneous Transluminal Coronary Angioplasty During Acute Myocardial Infarction. <i>Cardiology Clinics</i> , 1988 , 6, 139-152	2.5	1
2030	Drug-Use Evaluation of Thrombolytic Agents: A Challenge to Pharmacists. 1988 , 45, 2192-2198		
2029	A randomised dose ranging study of recombinant tissue plasminogen activator in acute myocardial infarction. 1988 , 296, 1768-71		17
2028	Acute Myocardial infarction: Treatment with Thrombolytic Therapy. <i>Cardiology Clinics</i> , 1989 , 7, 827-836	2.5	3
2027	Percutaneous Transluminal Coronary Angioplasty for Acute Myocardial Infarction. <i>Cardiology Clinics</i> , 1989 , 7, 837-851	2.5	2
2026	Creatine kinase isoforms in ischemic heart disease.. 1989 , 35, 7-13		56
2025	Use of Hemodynamics to Differentiate Pathophysiologic Causes of Cardiogenic Shock. 1989 , 1, 589-602		1
2024	A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction. <i>Circulation</i> , 1989 , 79, 281-6	16.7	276

2023	Correlation between template bleeding times and spontaneous bleeding during treatment of acute myocardial infarction with recombinant tissue-type plasminogen activator. <i>Circulation</i> , 1989 , 80, 581-8	16.7	98
2022	Clot-selective coronary thrombolysis with pro-urokinase. <i>Circulation</i> , 1989 , 79, 776-82	16.7	35
2021	Influence of inflation pressure and balloon size on the development of intimal hyperplasia after balloon angioplasty. A study in the atherosclerotic rabbit. <i>Circulation</i> , 1989 , 80, 1029-40	16.7	155
2020	Thrombolysis in microvascular surgery using tissue-type plasminogen activator. 1989 , 115, 1318-21		13
2019	Increased thromboxane biosynthesis during coronary thrombolysis. Evidence that platelet activation and thromboxane A2 modulate the response to tissue-type plasminogen activator in vivo. 1989 , 65, 83-94		161
2018	Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial. 1989 , 320, 618-27		1084
2017	Pharmacodynamics of thrombolysis with recombinant tissue-type plasminogen activator. Correlation with characteristics of and clinical outcomes in patients with acute myocardial infarction. The TAMI Study Group. <i>Circulation</i> , 1989 , 80, 1222-30	16.7	119
2016	Feasibility of tomographic ^{99m} Tc-hexakis-2-methoxy-2-methylpropyl-isonitrile imaging for the assessment of myocardial area at risk and the effect of treatment in acute myocardial infarction. <i>Circulation</i> , 1989 , 80, 1277-86	16.7	283
2015	A decision scheme for coronary angiography after acute myocardial infarction. <i>Circulation</i> , 1989 , 79, 292-303	16.7	63
2014	Thrombolytic therapy in acute myocardial infarction. 1989 , 40, 181-200		17
2013	Effect of intravenous streptokinase as compared with that of tissue plasminogen activator on left ventricular function after first myocardial infarction. 1989 , 320, 817-21		163
2012	Comparison of Tissue Plasminogen Activator and Streptokinase in the Management of Acute Myocardial Infarction. 1989 , 95, 265S-269S		1
2011	Therapeutic options in acute myocardial infarction. 1989 , 95, 1309-15		3
2010	Thrombolytic agents in acute myocardial infarction. 1989 , 320, 861-4		35
2009	Streptokinase or tissue plasminogen activator and left ventricular function after myocardial infarction. 1989 , 321, 687-9		1
2008	Thrombolysis in myocardial infarction (TIMI) randomized studies versus TIMI open label studies. 1989 , 10, 245S-256S		
2007	Relation of plasma D-dimer concentrations to coronary artery reperfusion before and after thrombolytic treatment in patients with acute myocardial infarction. 1989 , 63, 1179-84		22
2006	Incidence and predictors of early recurrent ischemia after successful percutaneous transluminal coronary angioplasty for acute myocardial infarction. 1989 , 63, 263-8		20

2005	Left main coronary angioplasty: early and late results of 127 acute and elective procedures. 1989 , 64, 144-7	178
2004	Prognosis after acute myocardial infarction in patients with and without residual anterograde coronary blood flow. 1989 , 64, 155-60	166
2003	Early and late results of coronary angioplasty without antecedent thrombolytic therapy for acute myocardial infarction. 1989 , 64, 1221-30	201
2002	Correlation of baseline plasminogen activator inhibitor activity with patency of the infarct artery after thrombolytic therapy in acute myocardial infarction. 1989 , 64, 1231-5	71
2001	Calcium antagonists and myocardial protection. 1989 , 64, 10F-17F	10
2000	Variables predictive of good functional outcome following thrombolytic therapy in the Thrombolysis in Myocardial Infarction phase II (TIMI II) pilot study. 1989 , 63, 503-12	14
1999	Comparison of thrombolytic agents: selected hematologic, vascular and clinical events. 1989 , 64, 2A-7A; discussion 24A-26A	10
1998	Reperfusion, patency and reocclusion with anistreplase (APSAC) in acute myocardial infarction. 1989 , 64, 12A-17A; discussion 24A-26A	18
1997	Unanswered questions in thrombolysis. 1989 , 64, 34A-40A; discussion 41A-42A	10
1996	Surface electrocardiogram in the detection of transmural myocardial ischemia during coronary artery occlusion. 1989 , 63, 21-6	97
1995	Early intravenous thrombolytic therapy for acute myocardial infarction in patients with prior coronary artery bypass grafts. 1989 , 63, 102-4	17
1994	[Arrhythmia as an indicator for reperfusion following acute myocardial infarct?]. 1989 , 67, 1199-204	4
1993	Coronary thrombolysis. 1989 , 14, 1-54	4
1992	Patient selection for thrombolytic therapy. 1989 , 64, 17B-21B	8
1991	Tissue plasminogen activator synthesis by trabecular cells and its implications for fibrinolytic therapy of the eye. 1989 , 18, 245-254	13
1990	Myocardial infarction and sudden death after sport: acute coronary angiographic findings. 1989 , 17, 193-7	10
1989	Staged thrombolysis and percutaneous transluminal coronary angioplasty for unstable and postinfarction angina. 1989 , 18, 67-72	5
1988	Hyperdense middle cerebral artery: incidence and quantitative significance. 1989 , 31, 312-5	68

1987	The Role of Invasive Therapy of Acute Myocardial Infarction after TIMI II-B. 1989 , 2, 1-3	2
1986	Single- and Double-Chain Recombinant Tissue Plasminogen Activator: A Review of Efficacy and Safety. 1989 , 2, 63-67	
1985	Efficacy and Safety of Thrombolysis with Intravenous Streptokinase Initiated Prior to Ambulance Transport from Community Hospital to Tertiary Health Care Center. 1989 , 2, 157-160	
1984	Associated reactions during and immediately after rtPA infusion. 1989 , 18, 234-9	9
1983	Angioplasty after thrombolysis in the treatment of evolving myocardial infarction. 1989 , 43, 107-12	
1982	Desmopressin and thrombosis. 1989 , 2, 675-6	74
1981	Comparison of regional and global left ventricular function by serial echocardiograms after reperfusion in acute myocardial infarction. 1989 , 2, 315-23	56
1980	Left-ventricular function as an end-point. 1989 , 2, 676	1
1979	The impact of coronary thrombolysis on myocardial infarction. 1989 , 3, 1-15	53
1978	Thrombolytic therapy for superior vena cava syndrome. 1989 , 1, 1200-1	7
1977	Thrombolytic therapy and acute myocardial infarction. 1989 , 43, 79-85	
1976	Clinical and instrumental evaluation of patients with ischemic stroke within the first six hours. 1989 , 91, 311-21	375
1975	Favorable early and long-term prognosis following coronary bypass surgery therapy for myocardial infarction: results of a multicenter trial. TAMI Study Group. 1989 , 118, 199-207	14
1974	Nonacute thrombolytic therapy: an adjunct to coronary angioplasty in patients with large intravascular thrombi. 1989 , 118, 662-7	12
1973	Management of myocardial infarction shock: current status. 1989 , 117, 435-43	14
1972	Coronary angioplasty and thrombolysis for acute myocardial infarction: is two a crowd?. 1989 , 86, 259-61	2
1971	Serum lipids and cholesterol metabolism during guar gum, plantago ovata and high fibre treatments. 1989 , 183, 253-62	69
1970	Late thrombolytic therapy preserves left ventricular function in patients with collateralized total coronary occlusion: primary end point findings of the Second Mount Sinai-New York University Reperfusion Trial. 1989 , 14, 58-64	90

1969	Antecedent angina: a predictor of residual stenosis after thrombolytic therapy. 1989 , 14, 91-5	16
1968	A new thrombolytic regimen for acute myocardial infarction using combination half dose tissue-type plasminogen activator with full dose streptokinase: a pilot study. KAMIT Study Group. 1989 , 14, 573-80	56
1967	Increased serum levels of fibrinogen degradation products due to treatment with recombinant tissue-type plasminogen activator for acute myocardial infarction are related to bleeding complications, but not to coronary patency. European Co-operative Study Groups for rt-PA. 1989 , 14, 581-8	43
1966	Data for cardiovascular modeling. 1989 , 14, 60A-64A	1
1965	Long-term results of thrombolytic therapy with and without percutaneous transluminal coronary angioplasty. 1989 , 14, 276-85; discussion 286-8	37
1964	Quantitative radionuclide assessment of regional ventricular function after thrombolytic therapy for acute myocardial infarction: results of phase I Thrombolysis in Myocardial Infarction (TIMI) trial. 1989 , 13, 998-1005	42
1963	Tissue plasminogen activator: why the backlash?. 1989 , 13, 1477-80	15
1962	Reperfusion momentum: lessons from the randomized trials of immediate coronary angioplasty for myocardial infarction. 1989 , 14, 1572-8	14
1961	The use of tissue-type plasminogen activator for acute myocardial infarction in the elderly: results from thrombolysis in myocardial infarction Phase I, open label studies and the Thrombolysis in Myocardial Infarction Phase II pilot study. The TIMI Investigators. 1989 , 14, 1159-65	51
1960	After coronary thrombolysis and reperfusion, what next?. 1989 , 14, 837-49	28
1959	Coronary thrombolysis and the new biology. 1989 , 14, 850-60	27
1958	Serial quantitative planar technetium-99m isonitrile imaging in acute myocardial infarction: efficacy for noninvasive assessment of thrombolytic therapy. 1989 , 14, 861-73	179
1957	Combined tissue-type plasminogen activator and prostacyclin therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 4 Study Group. 1989 , 14, 877-84	91
1956	Thrombolysis and Angioplasty in Myocardial Infarction (TAMI-1) trial: influence of infarct location on arterial patency, left ventricular function and mortality. 1989 , 13, 12-8	87
1955	Thrombolysis. An approach still on the move. 1989 , 37, 116-22	3
1954	Thrombolysis in the management of acute myocardial infarction and unstable angina pectoris. 1989 , 37, 191-204	5
1953	Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent. 1989 , 38, 346-88	95
1952	Use of thrombolytic drugs in non-coronary disorders. 1989 , 38, 801-21	25

1951	Serial angiographic assessment of coronary artery obstruction and collateral flow in acute myocardial infarction. Report from the second Mount Sinai-New York University Reperfusion Trial. <i>Circulation</i> , 1989 , 80, 1166-75	16.7	141
1950	Coronary thrombolysis. 1989 , 95, 73S-87S		22
1949	Thrombolytic therapy in acute myocardial infarction: Part II--rt-PA. 1989 , 73, 387-407		4
1948	Thrombolysis in acute MI: recent randomized trials. 1989 , 24 Suppl 1, 8-12; discussion 28-32		
1947	Decreased incidence of ventricular late potentials after successful thrombolytic therapy for acute myocardial infarction. 1989 , 321, 712-6		188
1946	Therapies to limit infarct size. Timing, dosage, and effectiveness. 1989 , 86, 54-9, 63		
1945	Drugs affecting blood coagulation and hemostasis. 1989 , 13, 321-327		
1944	Acute myocardial infarction. Options on arrival at the hospital. 1989 , 85, 131-2, 135-42		3
1943	Hemorrhagic complications of thrombolytic therapy in the treatment of myocardial infarction and venous thromboembolism. 1989 , 95, 88S-97S		43
1942	Thrombolysis and the general practitioner. 2. Useful after careful evaluation of patients. 1990 , 300, 869-70		5
1941	In vivo thrombin inhibition enhances and sustains arterial recanalization with recombinant tissue-type plasminogen activator. 1990 , 67, 1552-61		75
1940	The role of perfusion data. 1990 , 11 Suppl F, 10-4		7
1939	Anistreplase: a novel thrombolytic agent for acute myocardial infarction. 1990 , 24, 607-15		1
1938	Coronary thrombolysis: streptokinase or recombinant tissue-type plasminogen activator?. 1990 , 112, 529-38		92
1937	Therapy of acute myocardial infarction in the 1990s. 1990 , 299, 415-24		5
1936	A Randomized Trial of Intravenous Streptokinase Versus Tissue Plasminogen Activator for the Treatment of Acute Myocardial Infarction: Results Using an Aggressive Approach. 1990 , 3, 69-74		1
1935	The Ideal Thrombolytic Agent: GISSI-2 and ISIS-3. 1990 , 3, 157-168		
1934	Reperfusion Adjunctive Therapy: Heparin. 1990 , 3, 217-223		7

1933 Cardiovascular options for the 1990s. **1990**, 11, 187-90

1932 Fibrinolytic therapy in coronary artery disease. **1990**, 3, 745-79

1931 The portable programmable microprocessor-driven real-time 12-lead electrocardiographic monitor: a preliminary report of a new device for the noninvasive detection of successful reperfusion or silent coronary reocclusion. **1990**, 65, 143-8 97

1930 New approaches to treatment of myocardial infarction. **1990**, 65, 12C-19C 18

1929 Impact of field-transmitted electrocardiography on time to in-hospital thrombolytic therapy in acute myocardial infarction. **1990**, 66, 786-91 148

1928 Randomized controlled trial of late in-hospital angiography and angioplasty versus conservative management after treatment with recombinant tissue-type plasminogen activator in acute myocardial infarction. **1990**, 66, 538-45 77

1927 Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction. **1990**, 66, 1412-7 248

1926 Comparison of coronary and myocardial morphologic findings in patients with and without thrombolytic therapy during fatal first acute myocardial infarction. The TIMI Investigators. **1990**, 66, 904-9 51

1925 Cardiac morphologic findings in patients with acute myocardial infarction treated with recombinant tissue plasminogen activator. **1990**, 65, 953-61 30

1924 Heparin and infarct coronary artery patency after streptokinase in acute myocardial infarction. **1990**, 65, 967-72 15

1923 Influence of anterograde flow in the infarct artery on the incidence of late potentials after acute myocardial infarction. **1990**, 65, 554-8 75

1922 Usefulness of high-frequency analysis of signal-averaged surface electrocardiograms in acute myocardial infarction before and after coronary thrombolysis for assessing coronary reperfusion. **1990**, 66, 1196-8 23

1921 Emergency percutaneous transluminal coronary angioplasty for acute myocardial infarction in patients 70 years of age and older. **1990**, 66, 663-7 41

1920 The Western Washington Myocardial Infarction Registry and Emergency Department Tissue Plasminogen Activator Treatment Trial. **1990**, 66, 1298-303 55

1919 The prehospital phase of acute myocardial infarction in the era of thrombolysis. **1990**, 65, 1411-5 96

1918 Usefulness of angioplasty during acute myocardial infarction in patients with prior coronary artery bypass grafting. **1990**, 65, 698-702 36

1917 Percutaneous transluminal coronary angioplasty after non-Q-wave acute myocardial infarction. **1990**, 65, 835-9 21

1916 From the editor. **1990**, 13, 1-2

1915	Reperfusion therapy in acute myocardial infarction: present status and controversy. 1990 , 13, 239-46	6
1914	Management of the patient following coronary thrombolysis. 1990 , 13, 591-609	1
1913	Pharmacology of anistreplase. 1990 , Suppl 5, V3-10; discussion V27-32	20
1912	Variability of thrombolytic coronary reperfusion: an angiographic study of streptokinase and anistreplase. 1990 , Suppl 5, V15-9; discussion V27-32	3
1911	Summary of U.S. clinical trials program for evaluation of anistreplase. 1990 , Suppl 5, V33-8; discussion V67-72	1
1910	Expanding indications for the use of thrombolytic agents in acute myocardial infarction. 1990 , Suppl 5, V53-61; discussion V67-72	6
1909	Efficient use of endpoints in clinical trials: a clinical perspective. 1990 , 9, 155-60	5
1908	Tissue-type plasminogen activator: intracoronary applications. 1990 , 19, 108-15	6
1907	Prediction of coronary artery reperfusion after tissue plasminogen activator infusion. 1990 , 20, 99-102	
1906	Intracranial hemorrhage after use of tissue plasminogen activator for coronary thrombolysis. 1990 , 112, 17-21	81
1905	Findings on the Efficacy and Safety of Thrombolytic Therapy: An Analysis of Key Clinical Trials. 1990 , 2, 663-671	
1904	Therapeutic management of acute myocardial infarction. 1990 , 47, S5-S10	
1903	Thrombolytic Therapy and the Nursing Profession: Results of a Statewide Survey. 1990 , 2, 643-650	
1902	Use of alteplase for myocardial infarction in two community hospitals. 1990 , 47, 1535-1540	
1901	Thrombolytic Agents: Balancing Cost, Efficacy, and Side Effects. 1990 , 13, VI-37-VI-41	2
1900	A randomized dose-ranging study of rt-PA in acute myocardial infarction. Effects on coronary patency and fibrinolytic parameters. 1990 , 11, 730-9	14
1899	Quantitation of venous clot lysis with the D-dimer immunoassay during fibrinolytic therapy requires correction for soluble fibrin degradation. <i>Circulation</i> , 1990 , 81, 1818-25	16.7 34
1898	Intravenous streptokinase for acute myocardial infarction reduces the occurrence of ventricular late potentials. <i>Heart</i> , 1990 , 64, 5-8	5.1 32

1897	Lack of diurnal variation in the onset of non-Q wave infarction. <i>Circulation</i> , 1990 , 81, 548-55	16.7	48
1896	Investigational use of tissue plasminogen activator (t-PA) for occluded central venous catheters. 1990 , 14, 310-1		63
1895	Antiplatelet antibody [7E3 F(ab') ₂] prevents rethrombosis after recombinant tissue-type plasminogen activator-induced coronary artery thrombolysis in a canine model. <i>Circulation</i> , 1990 , 81, 617-27	16.7	79
1894	Painful Purpura: An Adverse Effect to a Thrombolysin. 1990 , 126, 690		2
1893	Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. TAMI Study Group. <i>Circulation</i> , 1990 , 82, 781-91	16.7	398
1892	Thrombolytic Therapy in Acute Myocardial Infarction. 1990 , 3, 332-348		
1891	Reduction in ST segment elevation after thrombolysis predicts either coronary reperfusion or preservation of left ventricular function. <i>Heart</i> , 1990 , 64, 113-7	5.1	82
1890	Use of tissue plasminogen activator in the coronary care unit for acute closure after coronary angioplasty. 1990 , 97, 1241-2		
1889	Acceleration of recombinant tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by the combination of heparin and the Arg-Gly-Asp-containing peptide bitistatin in a canine model of coronary thrombosis. <i>Circulation</i> , 1990 , 82, 169-77	16.7	68
1888	ACC/AHA guidelines for the early management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (subcommittee to develop guidelines for the early management of patients with acute myocardial infarction). <i>Circulation</i> , 1990 , 82, 162-707	16.7	200
1887	Prevention of thrombosis and rethrombosis. New approaches. <i>Circulation</i> , 1990 , 82, 655-7	16.7	14
1886	Intravenous streptokinase. A reappraisal of its therapeutic use in acute myocardial infarction. 1990 , 39, 693-719		20
1885	Efficacy and selectivity of tissue-type and urokinase-type plasminogen activators in a humanised pulmonary embolism model. 1990 , 4, 87-94		3
1884	MEDICAL SCIENCE GISSI-2: A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12 490 patients with acute myocardial infarction. 1990 , 336,		47
1883	From The Lancet. 1990 , 336, 75-76		
1882	GISSI-2 and the heparin controversy. 1990 , 336, 297-8		45
1881	Benzene in petrol: a continuing hazard. 1990 , 336, 1076-7		7
1880	Reperfusion in acute myocardial infarction. 1990 , 65, 549-64		15

1879	In-hospital mortality and clinical course of 20 891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. 1990 , 336, 71-75	523
1878	Lipid peroxidation associated with successful thrombolysis. 1990 , 335, 741-3	94
1877	Lack of association between raised serum Lp(a) concentration and unsuccessful thrombolysis after acute myocardial infarction. 1990 , 336, 1077	15
1876	Reduction of infarct size estimated enzymatically in patients with acute myocardial infarction after treatment with recombinant tissue type plasminogen activator or after spontaneous coronary recanalisation: A randomised, placebo controlled study. 1990 , 4, 95-99	6
1875	New developments in thrombolytic therapy. 1990 , 10, 105-31	25
1874	Thrombolytic therapy in acute myocardial infarction. 1990 , 3, 31-7	
1873	Measurement of myocardium at risk and salvage in myocardial infarction with ST-segment depression. 1990 , 65, 1222-6	1
1872	Platelets and thrombolytic therapy. 1990 , 322, 33-42	440
1871	Superiority of warfarin over aspirin long term after thrombolytic therapy for acute myocardial infarction. 1990 , 119, 1238-44	9
1870	Intravenous nitroglycerin-induced heparin resistance: a qualitative antithrombin III abnormality. 1990 , 119, 1254-61	69
1869	Effects of thrombolysis on the 12-lead signal-averaged ECG in the early postinfarction period. 1990 , 120, 495-502	17
1868	Time delays in the diagnosis and treatment of acute myocardial infarction: a tale of eight cities. Report from the Pre-hospital Study Group and the Cincinnati Heart Project. 1990 , 120, 773-80	161
1867	Comparison of coronary angiography and early oral dipyridamole thallium-201 scintigraphy in patients receiving thrombolytic therapy for acute myocardial infarction. 1990 , 120, 839-47	1
1866	Clinical characteristics and coronary angiographic findings of patients with unstable angina, acute myocardial infarction, and survivors of sudden ischemic death occurring during and after sport. 1990 , 120, 1267-78	36
1865	Outlook after acute myocardial infarction in the very elderly compared with that in patients aged 65 to 75 years. 1990 , 16, 784-92	108
1864	Clinical judgment and therapeutic decision making. 1990 , 15, 1-14	40
1863	Improved infarct-related arterial patency after high dose, weight-adjusted, rapid infusion of tissue-type plasminogen activator in myocardial infarction: results of a multicenter randomized trial of two dosage regimens. 1990 , 15, 915-21	65
1862	The Thrombolysis in Myocardial Infarction (TIMI) Trial phase II: additional information and perspectives. 1990 , 15, 1188-92	16

1861	Thrombolysis in Myocardial Infarction (TIMI) phase II trial: outcome comparison of a "conservative strategy" in community versus tertiary hospitals. The TIMI Research Group. 1990 , 16, 1529-34	37
1860	Effects of late administration of tissue-type plasminogen activator on left ventricular remodeling and function after myocardial infarction. 1990 , 16, 1561-8	37
1859	Comparative effects of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet glycoprotein IIb/IIIa antibody on coronary artery reperfusion, reocclusion and bleeding with recombinant tissue-type plasminogen activator in a canine preparation. 1990 , 16, 714-22	124
1858	Reperfusion, specific thrombin inhibition and reocclusion after thrombolysis. 1990 , 16, 723-5	2
1857	Coronary reperfusion studies with pro-urokinase in acute myocardial infarction: evidence for synergism of low dose urokinase. 1990 , 16, 733-8	14
1856	Optimal utilization of thrombolytic therapy for acute myocardial infarction: concepts and controversies. 1990 , 16, 223-31	185
1855	Guidelines for the early management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee to Develop Guidelines for the Early Management of Patients with Acute Myocardial Infarction). 1990 , 16, 249-92	302
1854	Reinfarction after thrombolytic therapy for acute myocardial infarction followed by conservative management: incidence and effect of smoking. 1990 , 16, 340-8	87
1853	Primary angioplasty in myocardial infarction: assessment of improved myocardial perfusion with technetium-99m isonitrite. 1991 , 17, 365-72	63
1852	A randomized placebo-controlled trial of combined early intravenous captopril and recombinant tissue-type plasminogen activator therapy in acute myocardial infarction. 1991 , 17, 467-73	87
1851	Factors determining improvement in left ventricular function after reperfusion therapy for acute myocardial infarction: primacy of baseline ejection fraction. 1991 , 17, 613-20	21
1850	Treatment of recurrent ischemia after thrombolysis and successful reperfusion for acute myocardial infarction: effect on in-hospital mortality and left ventricular function. 1991 , 17, 752-7	32
1849	Assessment of coronary artery patency after thrombolytic therapy: accurate prediction utilizing the combined analysis of three noninvasive markers. 1991 , 18, 44-9	100
1848	Electrocardiographic prediction of myocardial area at risk. 1991 , 66, 985-90	25
1847	Factors responsible for the differential procoagulant effects of diverse plasminogen activators in plasma. 1991 , 5, 217-224	32
1846	Thrombolysis and myocardial infarction. 1991 , 5, 1-15	21
1845	Overview: Current Status of Thrombolytic Therapy in Acute Myocardial Infarction. 1991 , 1, 747-759	
1844	Possible mechanism of vascular reocclusion after initially successful thrombolysis with recombinant tissue-type plasminogen activator. 1991 , 121, 1618-27	6

1843	Late streptokinase infusion and antithrombotic treatment in myocardial infarction reduce subsequent myocardial ischemia. 1991 , 121, 737-45	8
1842	Dynamic QRS complex and ST segment vectorcardiographic monitoring can identify vessel patency in patients with acute myocardial infarction treated with reperfusion therapy. 1991 , 122, 943-8	79
1841	Relation between flow grade after thrombolytic therapy and the effect of angioplasty on left ventricular function: a prospective randomized trial. 1991 , 121, 407-16	25
1840	Recombinant tissue-type plasminogen activator: current concepts and guidelines for clinical use in acute myocardial infarction. Part I. 1991 , 121, 220-44	15
1839	Factors determining the occurrence of late potentials on the signal-averaged electrocardiogram after a first myocardial infarction: a multivariate analysis. 1991 , 18, 1638-42	29
1838	Safety and efficacy of a new regimen of intravenous recombinant tissue-type plasminogen activator potentially suitable for either prehospital or in-hospital administration. 1991 , 18, 1774-8	10
1837	Thrombolysis: the need for a critical review. 1991 , 18, 1573-8	14
1836	Creation of the recombinant tissue plasminogen activator (rt-PA) image and its influence on practice habits. 1991 , 18, 1579-82	12
1835	Reasons for the lack of benefit of immediate angioplasty during recombinant tissue plasminogen activator therapy for acute myocardial infarction: a regional wall motion analysis. European Cooperative Study Group. 1991 , 17, 11-21	32
1834	Effect of coronary reocclusion after initial reperfusion on ventricular function and infarct size. 1991 , 18, 879-85	15
1833	Comparison of the effects of streptokinase and tissue plasminogen activator on regional wall motion after first myocardial infarction: analysis by the centerline method with correction for area at risk. 1991 , 17, 1039-46	23
1832	Noninvasive detection of reperfusion in acute myocardial infarction based on plasma activity of creatine kinase MB subforms. 1991 , 17, 1047-52	35
1831	Bleeding time prolongation and bleeding during infusion of recombinant tissue-type plasminogen activator in dogs: potentiation by aspirin and reversal with aprotinin. 1991 , 17, 1213-22	24
1830	Anistreplase in early acute myocardial infarction and the one-year follow-up. 1991 , 31, 39-49	3
1829	Thrombolytic therapy. 1991 , 614, 259-69	3
1828	Cardiogenic shock after acute myocardial infarction. Incidence and mortality from a community-wide perspective, 1975 to 1988. 1991 , 325, 1117-22	384
1827	Pharmacokinetic and Hemostatic Properties of the Recombinant Plasminogen Activator BM 06.022 in Healthy Volunteers. 1991 , 66, 569-574	46
1826	Recombinant tissue-type plasminogen activator. 1991 , 19, 197-223	

1825	Studies of controlled reperfusion after ischemia. 1991 , 101, 455-464	7
1824	Nuclear Imaging an Acute Cardiac Care. <i>Cardiology Clinics</i> , 1991 , 9, 733-759	2.5 2
1823	Prolonged myocardial stunning after thrombolysis: can left ventricular function be assessed definitely at hospital discharge?. 1991 , 12, 214-7	42
1822	Prevention of reocclusion following tissue type plasminogen activator-induced thrombolysis by the RGD-containing peptide, echistatin, in a canine model of coronary thrombosis. 1991 , 42, 340-8	23
1821	Prognosis following interventional therapy for acute myocardial infarction: utility of dipyridamole thallium scintigraphy. 1991 , 79, 73-80	7
1820	Coronary thrombolysis with recombinant tissue plasminogen activator. Intracoronary vs intravenous administration. 1991 , 100, 201-6	10
1819	Reducing time delays in the administration of thrombolytic therapy to patients with acute myocardial infarction. 1991 , 25, 1096-100	
1818	Streptokinase versus recombinant tissue-type plasminogen activator. 1991 , 25, 1271-2	
1817	The controversy of heparin therapy as an adjunct to thrombolysis in acute myocardial infarction. 1991 , 25, 613-6	
1816	Thrombolytic treatment for recurrent myocardial infarction. 1991 , 302, 429-30	21
1815	Thrombolytic therapy for acute myocardial infarction. 1991 , 90, 52-6, 61-2, 65-7	
1814	Thrombolytic Therapy Within One Hour of the Onset of Acute Myocardial Infarction. 1991 ,	
1813	[Fibrinolytic therapy in sudden deafness with recombinant tissue-type plasminogen activator. Hemorheologic and therapeutic effects]. 1991 , 70, 353-8	6
1812	Possible role of vascular intima for generation of coagulant activity in patients undergoing coronary thrombolysis with recombinant tissue-type plasminogen activator. A randomized, placebo-controlled study. 1991 , 51, 581-90	5
1811	Outcomes of direct coronary angioplasty for acute myocardial infarction in candidates and non-candidates for thrombolytic therapy. 1991 , 67, 7-12	100
1810	Goals of thrombolytic therapy. 1991 , 68, 67C-71C	4
1809	Patency of the infarct-related coronary artery and ventricular geometry. 1991 , 68, 41D-51D	39
1808	Importance of the pharmacological profile of thrombolytic agents in clinical practice. 1991 , 68, 3E-7E	5

1807	Overview of patency as an end point of thrombolytic therapy. 1991 , 68, 11E-16E	138
1806	Thrombolysis, anticoagulation, and reocclusion. 1991 , 68, 17E-22E	44
1805	Experience with low-dose intracoronary recombinant tissue-type plasminogen activator for nonacute total occlusions before percutaneous transluminal coronary angioplasty. 1991 , 68, 1609-13	13
1804	Comparison of intravenous urokinase plus heparin versus heparin alone in acute myocardial infarction. Urochinasì per via Sistemica nell'Infarto Miocardico (USIM) Collaborative Group. 1991 , 68, 585-92	53
1803	Thrombolysis in unstable angina: results of clinical studies. 1991 , 68, 99B-104B	6
1802	Effects of early thrombolytic therapy (anistreplase versus streptokinase) on enzymatic and electrocardiographic infarct size in acute myocardial infarction. TEAM-2 Investigators. 1991 , 68, 848-56	13
1801	Effects of superoxide dismutase on reperfusion arrhythmias and left ventricular function in patients undergoing thrombolysis for anterior wall acute myocardial infarction. 1991 , 67, 765-7	61
1800	Coronary recanalization rate after intravenous bolus of alteplase in acute myocardial infarction. 1991 , 68, 161-5	23
1799	Angiographically assessed coronary arterial patency and reocclusion in patients with acute myocardial infarction treated with anistreplase: results of the anistreplase reocclusion multicenter study (ARMS). 1991 , 68, 296-300	19
1798	Principles and practice of coronary thrombolysis and conjunctive treatment. 1991 , 68, 382-8	22
1797	Prognostic importance of collateral flow and residual coronary stenosis of the myocardial infarct artery after anterior wall Q-wave acute myocardial infarction. 1991 , 67, 1165-9	54
1796	Thrombosis, fibrinolysis, and thrombolytic therapy: a perspective. 1991 , 34, 89-100	6
1795	Towards better thrombolytic therapy. 1991 , 34, 101-12	19
1794	Which thrombolytic agent should one choose?. 1991 , 34, 165-78	19
1793	Metabolic and diagnostic significance of creatine kinase isoenzymes. 1991 , 1, 195-200	18
1792	Which factors determine the development of late potentials after first myocardial infarction? A multifactorial analysis. 1991 , 14, 1998-2003	8
1791	Dose-ranging study of the novel recombinant plasminogen activator BM 06.022 in healthy volunteers. 1991 , 50, 429-36	30
1790	The Gusto trial: is it necessary?. 1991 , 4, 149-53	5

1789	The influence of balloon inflation duration on the acute angiographic result of percutaneous transluminal coronary angioplasty. 1991 , 4, 181-7		7
1788	Thrombolytic Therapy and Alphabet Soup: A Short Lexicon. 1991 , 4, 221-230		2
1787	Lipoprotein (a) levels do not influence the outcome of rt-PA therapy in acute myocardial infarction. 1991 , 62, 141-2		3
1786	Early prognosis after thrombolysis: value of exercise radionuclide ventriculography performed on anti-ischaemic medication. 1991 , 7, 125-31		1
1785	Myocardial accumulation and clearance of technetium 99m teboroxime at 100%, 75%, 50% and zero coronary blood flow in dogs. 1991 , 18, 725-31		1
1784	Myocardial accumulation and clearance of technetium 99m Teboroxime at 100%, 75%, 50% and zero coronary blood flow in dogs. 1991 , 18, 725		
1783	Multicenter patency trial of intravenous anistreplase compared with streptokinase in acute myocardial infarction. The TEAM-2 Study Investigators. <i>Circulation</i> , 1991 , 83, 126-40	16.7	68
1782	Thrombolytic treatment in acute myocardial infarction: neutrophil activation, peripheral leucocyte responses, and myocardial injury. <i>Heart</i> , 1991 , 66, 10-4	5.1	16
1781	Relative importance of thrombin compared with plasmin-mediated platelet activation in response to plasminogen activation with streptokinase. <i>Circulation</i> , 1991 , 84, 1552-60	16.7	45
1780	Influence of coronary collateral vessels on myocardial infarct size in humans. Results of phase I thrombolysis in myocardial infarction (TIMI) trial. The TIMI Investigators. <i>Circulation</i> , 1991 , 83, 739-46	16.7	356
1779	The microcirculation in coronary ischemia. Are native anticoagulant mechanisms a path to new therapies?. <i>Circulation</i> , 1991 , 84, 439-41	16.7	7
1778	Evaluation of combination thrombolytic therapy and timing of cardiac catheterization in acute myocardial infarction. Results of thrombolysis and angioplasty in myocardial infarction--phase 5 randomized trial. TAMI Study Group. <i>Circulation</i> , 1991 , 83, 1543-56	16.7	248
1777	Comparative effects of APSAC and rt-PA on infarct size and left ventricular function in acute myocardial infarction. A multicenter randomized study. <i>Circulation</i> , 1991 , 84, 1107-17	16.7	28
1776	Dipyridamole echocardiography test. A new tool for detecting jeopardized myocardium after thrombolytic therapy. <i>Circulation</i> , 1991 , 84, 1100-6	16.7	40
1775	.		
1774	A prospective, randomized trial comparing combination half-dose tissue-type plasminogen activator and streptokinase with full-dose tissue-type plasminogen activator. Kentucky Acute Myocardial Infarction Trial (KAMIT) Group. <i>Circulation</i> , 1991 , 84, 540-9	16.7	80
1773	A pilot study of the efficacy and safety of bolus administration of alteplase in acute myocardial infarction. <i>Heart</i> , 1991 , 66, 134-8	5.1	26
1772	The quest for the ideal reperfusion strategy continues. <i>Circulation</i> , 1991 , 83, 1818-21	16.7	6

1771	Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion. <i>Circulation</i> , 1991 , 83, 1048-56	16.7	142
1770	Spontaneous pulmonary hemorrhage following coronary thrombolysis. 1992 , 101, 1150-2		19
1769	Coronary thrombolysis. 1992 , 102, 482S-507S		13
1768	Immunogenic Properties of Structurally Modified Human Tissue Plasminogen Activators in Chimpanzees and Mice. 1992 , 19, 555-562		
1767	Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomised double blind European Cooperative Study Group trial. <i>Heart</i> , 1992 , 67, 122-8	5.1	244
1766	Thrombolytic Therapy of Acute Myocardial Infarction. 1992 , 268, 3108		36
1765	Quality of life in the first 100 days after suspected acute myocardial infarction--a suitable trial endpoint?. 1992 , 46, 612-6		14
1764	Vampire bat salivary plasminogen activator promotes rapid and sustained reperfusion without concomitant systemic plasminogen activation in a canine model of arterial thrombosis. 1992 , 12, 212-21		46
1763	Effect of thrombin inhibition on the dynamics of thrombolysis and on platelet function during thrombolytic therapy. 1992 , 70, 829-34		22
1762	A randomized trial of late reperfusion therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction-6 Study Group. <i>Circulation</i> , 1992 , 85, 2090-9	16.7	179
1761	A prospective, placebo-controlled, randomized trial of intravenous streptokinase and angioplasty versus lone angioplasty therapy of acute myocardial infarction. <i>Circulation</i> , 1992 , 86, 1710-7	16.7	142
1760	Clinical and angiographic features of patients from the Indian subcontinent treated with intravenous streptokinase for acute myocardial infarction: experience in Qatar. 1992 , 43, 641-6		2
1759	Inhibition of plasminogen activator inhibitor-1 activity results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis. <i>Circulation</i> , 1992 , 85, 305-12	16.7	172
1758	Acceleration of recombinant tissue-type plasminogen activator-induced reperfusion and prevention of reocclusion by recombinant antistasin, a selective factor Xa inhibitor, in a canine model of femoral arterial thrombosis. 1992 , 70, 1152-60		38
1757	Streptokinase induced defibrination assessed by thrombin time: effects on residual coronary stenosis and left ventricular ejection fraction. <i>Heart</i> , 1992 , 68, 171-5	5.1	3
1756	New developments in thrombolytic therapy. 1992 , 23, 227-62		1
1755	Evidence of increased platelet activation after thrombolysis in patients with acute myocardial infarction. <i>Heart</i> , 1992 , 68, 374-6	5.1	22
1754	Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor, tick anticoagulant peptide. Comparison to hirudin and heparin in a canine model of acute coronary artery thrombosis. <i>Circulation</i> , 1992 , 85, 805-15	16.7	127

1753	Penicillium decumbens. A new cause of fungus ball. 1992 , 101, 1152-3	11
1752	Contemporary use of laboratory tests to monitor safety and efficacy of thrombolytic therapy. 1992 , 101, 985-1055	3
1751	Coronary thrombolysis. Comparative effects of intracoronary administration of recombinant tissue plasminogen activator and urokinase. 1992 , 101, 1684-90	11
1750	Acute myocardial infarction and coronary reperfusion. Serum cardiac markers for the 1990s. 1992 , 97, 217-26	74
1749	Thrombolysis and coronary occlusion: effects upon the non-infarct zone. 1992 , 13, 770-5	
1748	Thrombolytic therapy for acute myocardial infarction. A review. 1992 , 44, 293-325	114
1747	Effects of aspirin on coronary reocclusion and recurrent ischemia after thrombolysis: a meta-analysis. 1992 , 19, 671-7	163
1746	Thrombolytic therapy: reocclusion rates with adjunctive aspirin and its relation to heparin therapy. 1992 , 19, 678-80	6
1745	ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41 299 cases of suspected acute myocardial infarction. 1992 , 339, 753-770	1006
1744	Thrombolyse et infarctus aigu du myocarde chez le patient de plus de 70 ans. 1992 , 1, 403-408	
1743	The efficacy and safety of tissue plasminogen activator in acute ischemic strokes. 1992 , 10, 345-52	3
1742	Thrombolytic therapy for myocardial ischemia and infarction. 1992 , 2, 543-8	
1741	Late adverse effects of streptokinase. 1992 , 22, 106-8	4
1740	Recombinant tissue plasminogen activator in acute myocardial infarction in the Chinese in Hong Kong. 1992 , 36, 169-76	
1739	Association between systemic generation of plasmin and activation of the factor XII-dependent fibrinolytic proactivator system in coronary thrombolysis. 1992 , 6, 57-62	4
1738	Does thrombolysis in myocardial infarction (TIMI) perfusion grade 2 represent a mostly patent artery or a mostly occluded artery? Enzymatic and electrocardiographic evidence from the TEAM-2 study. Second Multicenter Thrombolysis Trial of Eminase in Acute Myocardial Infarction. 1992 , 19, 1-10	218
1737	Randomized angiographic trial of recombinant tissue-type plasminogen activator (alteplase) in myocardial infarction. RAAMI Study Investigators. 1992 , 20, 17-23	77
1736	Recombinant tissue-type plasminogen activator ameliorates ischemic derangements induced by thrombotic occlusion in closed chest anesthetized dogs. 1992 , 20, 218-25	3

1735	Anistreplase versus alteplase in acute myocardial infarction: comparative effects on left ventricular function, morbidity and 1-day coronary artery patency. The TEAM-3 Investigators. 1992 , 20, 753-66	30
1734	Improved early infarct-related vessel patency after thrombolytic therapy. 1992 , 19, 892-3	2
1733	Abrupt vessel closure complicating coronary angioplasty: clinical, angiographic and therapeutic profile. 1992 , 19, 926-35	298
1732	Activation of prothrombin accompanying thrombolysis with recombinant tissue-type plasminogen activator. 1992 , 19, 1065-9	93
1731	The rt-PA versus streptokinase. Controversy--II. 1992 , 19, 1116-9	2
1730	Mechanisms of early death despite thrombolytic therapy: experience from the Thrombolysis in Myocardial Infarction Phase II (TIMI II) study. 1992 , 19, 1129-35	32
1729	Marked systemic hypotension depresses coronary thrombolysis induced by intracoronary administration of recombinant tissue-type plasminogen activator. 1992 , 20, 1626-33	53
1728	Intracranial hemorrhage in association with thrombolytic therapy: incidence and clinical predictive factors. 1992 , 19, 289-94	107
1727	Thrombolysis-related early patency reduces ECG late potentials after acute myocardial infarction. 1992 , 124, 557-64	23
1726	Early and late angiographic findings of the "no-reflow" phenomenon following direct angioplasty as primary treatment for acute myocardial infarction. 1992 , 123, 782-4	50
1725	The effect of late patency of the infarct-related coronary artery on left ventricular morphology and regional function after thrombolysis. 1992 , 124, 265-72	15
1724	Lack of influence of pretreatment antistreptokinase antibody on efficacy in a multicenter patency comparison of intravenous streptokinase and anistreplase in acute myocardial infarction. 1992 , 124, 305-14	36
1723	Assessment of reperfusion after thrombolytic therapy for myocardial infarction. 1992 , 124, 441-7	8
1722	A comparison between intravenous streptokinase and tissue plasminogen activator with early intravenous heparin in acute myocardial infarction. 1992 , 123, 841-6	5
1721	Residual coronary stenoses and calculated transstenotic gradients after intravenous streptokinase versus tissue plasminogen activator. 1992 , 123, 7-14	2
1720	Recurrent myocardial ischemia following thrombolytic therapy: guidelines for practicing clinicians. 1992 , 124, 183-93	3
1719	Reperfusion of the infarct-related coronary artery limits left ventricular expansion beyond myocardial salvage. 1992 , 123, 1157-65	27
1718	Intracranial hemorrhage after coronary thrombolysis with tissue plasminogen activator. 1992 , 92, 384-90	101

1717	Continuous ST- and QRS-vector changes and myoglobin release during streptokinase-treated acute myocardial infarction. 1992 , 13, 511-6	4
1716	The Role of Heparin in the Thrombolytic Treatment of Acute Myocardial Infarction. 1992 , 8, 105-110	1
1715	Influence of the rt-PA dose (1 mg/kg versus 1.5 mg/kg) and duration of administration on the patency of infarct-related coronary arteries in 81 patients. 1992 , 6, 373-7	2
1714	Advances in thrombolytic therapy. 1992 , 6, 111-24	5
1713	Hospital delays and problems with thrombolytic administration in patients receiving thrombolytic therapy: a multicenter prospective assessment. Virginia Thrombolytic Study Group. 1992 , 21, 1215-21	55
1712	Aspirin, Heparin, and Other Ancillary Therapies Following Thrombolysis. 1992 , 5, 117-126	
1711	Thrombolysis for Acute Myocardial Infarction: Making Sense of The Clinical Trials Data. 1992 , 5, 127-136	5
1710	Patterns of myoglobin and MM creatine kinase isoforms release early after intravenous thrombolysis or direct percutaneous transluminal coronary angioplasty for acute myocardial infarction, and implications for the early noninvasive diagnosis of reperfusion. 1992 , 70, 1129-34	28
1709	Survey of practicing cardiologists in Maryland on their choice of thrombolytic therapy for acute myocardial infarction. 1992 , 69, 327-30	5
1708	Effect of coronary angioplasty on late potentials one to two weeks after acute myocardial infarction. 1992 , 70, 1515-9	46
1707	Assessment of global and regional left ventricular performance at rest and during exercise after thrombolytic therapy for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) II Study. 1992 , 69, 1-9	26
1706	Milwaukee Prehospital Chest Pain Project--phase I: feasibility and accuracy of prehospital thrombolytic candidate selection. 1992 , 69, 991-6	78
1705	A patency-oriented strategy for early management of acute myocardial infarction using emergency coronary angiography and selective coronary angioplasty. 1992 , 69, 1383-8	10
1704	Influence of residual blood flow in the infarct-related artery on ventricular tachycardia after myocardial infarction. 1992 , 69, 554-5	2
1703	Clinical benefits of thrombolytic therapy in acute myocardial infarction. 1992 , 69, 3A-11A	9
1702	Thrombolytic therapy: adjuvant mechanical intervention for acute myocardial infarction. 1992 , 69, 60A-70A	13
1701	Holter recording of ventricular arrhythmias during intravenous thrombolysis for acute myocardial infarction. 1992 , 69, 152-9	54
1700	Pharmacological management of acute myocardial infarction. 1992 , 15, 795-803	

1699	What data support our current thrombolytic management of patients with acute myocardial infarction?. 1992 , 34, 367-78	1
1698	Severe acute myocardial infarction during a staphylococcal septicemia with meningoencephalitis. A possible contraindication to thrombolytic treatment. 1992 , 18, 247-9	7
1697	Specificity of an immunochemical reagent for quantifying the isoforms of creatine kinase-MB. 1993 , 7, 220-4	6
1696	Assessing the diagnostic value of an ECG containing leads V4R, V8, and V9: the 15-lead ECG. 1993 , 22, 786-93	83
1695	The choice of thrombolytic agents in the emergency department. 1993 , 22, 845-51	1
1694	Treatment of acute myocardial infarction with prolonged intracoronary urokinase delivery through intracoronary infusion catheter. 1993 , 6, 307-14	
1693	Streptokinase, but not tissue plasminogen activator, attenuates platelet aggregation in patients with acute myocardial infarction. 1993 , 234, 513-9	8
1692	High-frequency electrocardiogram analysis of the entire QRS in the diagnosis and assessment of coronary artery disease. 1993 , 35, 311-28	36
1691	Use of composite endpoints in thrombolysis trials of acute myocardial infarction. 1993 , 72, 3G-12G	23
1690	The open artery: beyond myocardial salvage. 1993 , 72, 85G-90G	4
1689	Left ventricular function after coronary artery reperfusion. 1993 , 72, 91G-97G	4
1688	Ventricular remodeling and infarct expansion. 1993 , 72, 98G-106G	26
1687	Comparison of thrombolysis in myocardial infarction perfusion grades 2 and 3 after anterior wall infarction. 1993 , 71, 428-30	5
1686	Ratio of ST-segment and myoglobin slopes to estimate myocardial salvage during thrombolytic therapy for acute myocardial infarction. 1993 , 71, 1362-5	11
1685	Influence of reperfusion induced by thrombolytic treatment on natural history of left ventricular regional wall motion abnormality in acute myocardial infarction. 1993 , 71, 1015-20	18
1684	Predictors of major ischemic complications after coronary dissection following angioplasty. 1993 , 71, 1402-7	21
1683	ST-segment normalization time and ventricular arrhythmias as electrocardiographic markers of reperfusion during intravenous thrombolysis for acute myocardial infarction. 1993 , 71, 1436-9	8
1682	Direct holmium laser-assisted balloon angioplasty in acute myocardial infarction. 1993 , 71, 1223-5	17

1681	Patency of the infarct-related artery and left ventricular function as the major determinants of survival after Q-wave acute myocardial infarction. 1993 , 71, 1-7	82
1680	Anticoagulant effects of hirulog, a novel thrombin inhibitor, in patients with coronary artery disease. 1993 , 71, 778-82	77
1679	Effectiveness of thrombolysis is associated with a time-dependent increase of malondialdehyde in peripheral blood of patients with acute myocardial infarction. 1993 , 71, 788-93	22
1678	Effects on the signal-averaged electrocardiogram of opening the coronary artery by thrombolytic therapy or percutaneous transluminal coronary angioplasty during acute myocardial infarction. 1993 , 71, 805-9	11
1677	A difference between front-loaded streptokinase and standard-dose recombinant tissue-type plasminogen activator in preserving left ventricular function after acute myocardial infarction (the Central Illinois Thrombolytic Therapy Study). 1993 , 72, 1010-4	9
1676	Lack of usefulness of prolonged bleeding times in predicting hemorrhagic events in patients receiving the 7E3 glycoprotein IIb/IIIa platelet antibody. The TAMI Study Group. 1993 , 72, 1121-5	48
1675	Effect of cigarette smoking on coronary patency after thrombolytic therapy for myocardial infarction. TEAM-2 Investigators. Second Multicenter Thrombolytic Trials of Eminase in Acute Myocardial Infarction. 1993 , 72, 373-8	52
1674	Dose-ranging study with a new two-chain rt-PA in patients with acute myocardial infarction: a multicenter trial. 1993 , 16, 302-10	2
1673	Thrombolytic treatment for massive thrombosis of prosthetic cardiac valves. 1993 , 19, 145-50	4
1672	Immunohistochemical localization of plasminogen activator inhibitor-1 in human coronary atherosclerotic lesions involved in acute myocardial infarction. 1993 , 8, 160-2	13
1671	Cardiogenic shock complicating acute myocardial infarction in patients without heart failure on admission: incidence, risk factors, and outcome. SPRINT Study Group. 1993 , 94, 265-73	109
1670	Importance of ischemic preconditioning and collateral circulation for left ventricular functional recovery in patients with successful intracoronary thrombolysis for acute myocardial infarction. 1993 , 126, 827-31	32
1669	Autonomic correlates of late infarct artery patency after first myocardial infarction. 1993 , 125, 1597-600	6
1668	Endothelial dysfunction in acute myocardial infarction after reperfusion. 1993 , 126, 451-2	11
1667	Acute occlusion of the left anterior descending coronary artery by shotgun pellets. 1993 , 126, 452-3	7
1666	Individual risk assessment for intracranial haemorrhage during thrombolytic therapy. 1993 , 342, 1523-8	268
1665	Systolic left ventricular function after reperfusion therapy for acute myocardial infarction. Analysis of determinants of improvement. The TAMI Study Group. <i>Circulation</i> , 1993 , 87, 1531-41	16.7 52
1664	Design of a linker for trivalent thrombin inhibitors: interaction of the main chain of the linker with thrombin. 1993 , 32, 3396-404	33

1663	Inadvertent administration of rtPA to a patient with type 1 aortic dissection and subsequent cardiac tamponade. 1993 , 11, 613-5	18
1662	Overview of trends in heart disease. Changing prognosis after myocardial infarction. 1993 , 3, 541-6	6
1661	Pharmacodynamics of modified tissue plasminogen activator LY210825 in the conscious dog as evaluated with immunocapture assays. 1993 , 7, 264-274	1
1660	Thrombolytic properties of Desmodus (Vampire Bat) salivary plasminogen activator DSPA β , alteplase and streptokinase following intravenous bolus injection in a rabbit model of carotid artery thrombosis. 1993 , 7, 284-290	21
1659	Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study. 1993 , 22, 381-9	283
1658	Influence of infarct-related artery patency on the indexes of parasympathetic activity and prevalence of late potentials in survivors of acute myocardial infarction. 1993 , 22, 695-706	40
1657	Trickle down thrombolysis. 1993 , 21, 1396-8	15
1656	Intracoronary stenting compared with conventional therapy for abrupt vessel closure complicating coronary angioplasty: a matched case-control study. 1993 , 21, 866-75	117
1655	Excimer laser-assisted coronary angioplasty for lesions containing thrombus. 1993 , 21, 1550-6	48
1654	Culprit lesion morphology and stenosis severity in the prediction of reocclusion after coronary thrombolysis: angiographic results of the APRICOT study. Antithrombotics in the Prevention of Reocclusion in Coronary Thrombolysis. 1993 , 22, 1755-62	74
1653	Thrombolytic therapy for women with myocardial infarction: is there a gender gap? Thrombolysis and Angioplasty in Myocardial Infarction Study Group. 1993 , 22, 1780-7	94
1652	Maintenance of patency after thrombolysis in stenotic coronary arteries requires combined inhibition of thrombin and platelets. 1993 , 22, 296-301	27
1651	The prevalence of myocardial ischemia six months after thrombolytic treatment of acute coronary episodes. A subset of a placebo controlled, randomised trial, the ASSET Study. 1993 , 39, 187-93	1
1650	Prostacyclin analogue, beraprost, sustains recanalization duration after thrombolytic therapy in acute myocardial infarction model. 1993 , 38, 225-33	8
1649	Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative treatment for myocardial infarction. The Mayo Coronary Care Unit and Catheterization Laboratory Groups. 1993 , 328, 685-91	678
1648	Thrombolysis and myocardial salvage. Results of clinical trials and the animal paradigm--paradoxical or predictable?. <i>Circulation</i> , 1993 , 88, 296-306	16.7 126
1647	Enzymatic evidence of impaired reperfusion in diabetic patients after thrombolytic therapy for acute myocardial infarction: a role for plasminogen activator inhibitor?. <i>Heart</i> , 1993 , 70, 530-6	5.1 42
1646	A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. 1993 , 328, 680-4	1031

1645	Clinical and angiographic features of patients with an occluded versus a patent infarct vessel after intravenous streptokinase for acute myocardial infarction. 1993 , 44, 425-31		1
1644	Illusion of reperfusion. Does anyone achieve optimal reperfusion during acute myocardial infarction?. <i>Circulation</i> , 1993 , 88, 1361-74	16.7	222
1643	Gender Differences in the Treatment of Patients With Acute Myocardial Infarction. 1993 , 153, 625		37
1642	The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. 1993 , 329, 1615-22		1505
1641	Thrombin interactions with fibrinogen and fibrin. 1993 , 19, 361-7		10
1640	Lipid peroxidation and antioxidant status following thrombolytic therapy for acute myocardial infarction. 1993 , 14, 1027-33		42
1639	Pharmacoeconomic aspects of treatment of acute myocardial infarction with thrombolytic agents. 1993 , 3, 192-204		7
1638	Relation of plasma lipoprotein(a) to infarct artery patency in survivors of myocardial infarction. <i>Circulation</i> , 1993 , 88, 935-40	16.7	65
1637	Free radical activity and left ventricular function after thrombolysis for acute infarction. <i>Heart</i> , 1993 , 69, 114-20	5.1	16
1636	Quantitative adenosine 201Tl single-photon emission computed tomography for the early assessment of patients surviving acute myocardial infarction. <i>Circulation</i> , 1993 , 87, 1197-210	16.7	70
1635	The search for the ideal thrombolytic agent: maximize the benefit and minimize the risk. 1993 , 21, 190-8		11
1634	Streptokinase induces intravascular release of platelet-activating factor in patients with acute myocardial infarction and stimulates its synthesis by cultured human endothelial cells. <i>Circulation</i> , 1993 , 88, 1476-83	16.7	41
1633	TIMI perfusion grade 3 but not grade 2 results in improved outcome after thrombolysis for myocardial infarction. Ventriculographic, enzymatic, and electrocardiographic evidence from the TEAM-3 Study. <i>Circulation</i> , 1993 , 87, 1829-39	16.7	250
1632	Aspirin versus coumadin in the prevention of reocclusion and recurrent ischemia after successful thrombolysis: a prospective placebo-controlled angiographic study. Results of the APRICOT Study. <i>Circulation</i> , 1993 , 87, 1524-30	16.7	187
1631	Aspirin does not improve early arterial patency after streptokinase treatment for acute myocardial infarction. <i>Heart</i> , 1993 , 69, 492-5	5.1	6
1630	Angiographic monitoring of reperfusion therapy for acute myocardial infarction. TIMI grade 3 perfusion is the goal. <i>Circulation</i> , 1993 , 87, 2055-7	16.7	14
1629	Residual flow to the infarct zone as a determinant of infarct size after direct angioplasty. <i>Circulation</i> , 1993 , 88, 1527-33	16.7	71
1628	Safety and efficacy of recombinant hirudin (CGP 39 393) versus heparin in patients with stable angina undergoing coronary angioplasty. <i>Circulation</i> , 1993 , 88, 2058-66	16.7	108

1627	Tailored thrombolytic therapy. A perspective. <i>Circulation</i> , 1993 , 88, 2556-64	16.7	71
1626	Thrombolysis with intracoronary administration of YM866, a novel modified tissue-type plasminogen activator, in a canine model of coronary artery thrombosis. 1993 , 63, 319-25		4
1625	Thrombolytic activity of a novel modified tissue-type plasminogen activator, YM866, in a canine model of coronary artery thrombosis. 1993 , 63, 9-16		13
1624	Is arrhythmogenicity related to the speed of reperfusion during thrombolysis for myocardial infarction?. 1993 , 14, 516-20		5
1623	Echocardiographic wall motion abnormalities and the signal averaged electrocardiogram in the acute phase of a first myocardial infarction. 1993 , 14, 795-8		2
1622	Thrombolytic Agents in Critical Care. 1993 , 5, 355-366		2
1621	Thrombolytic Therapy: A Comprehensive Review of its Use in Clinical Medicine—Part I. 1993 , 8, 56-72		1
1620	Emergency angioplasty of totally occluded left main coronary artery in acute myocardial infarction and unstable angina pectoris—institutional experience and literature review. 1994 , 15, 602-7		52
1619	Angioplasty versus thrombolysis for acute myocardial infarction. 1994 , 95, 87-91, 95		
1618	Time delays to lytic therapy and outcome in 100 consecutive patients with a history suggestive of acute myocardial infarction in an area with access to a mobile coronary care unit. 1994 , 15, 594-601		4
1617	The use of Gianturco-Roubin flexible metallic coronary stents in old saphenous vein grafts: in-hospital outcome and 7 day angiographic patency. 1994 , 15, 1456-62		5
1616	Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina. European Cooperative Study Group. <i>Circulation</i> , 1994 , 89, 596-603	16.7	220
1615	Earlier diagnosis and treatment of acute myocardial infarction necessitates the need for a 'new diagnostic mind-set'. <i>Circulation</i> , 1994 , 89, 872-81	16.7	95
1614	Prevention of arterial reocclusion after thrombolysis with activated protein C. Comparison with heparin in a canine model of coronary artery thrombosis. <i>Circulation</i> , 1994 , 90, 427-32	16.7	29
1613	Reduction in QT interval dispersion by successful thrombolytic therapy in acute myocardial infarction. TEAM-2 Study Investigators. <i>Circulation</i> , 1994 , 90, 94-100	16.7	193
1612	Long-term prognostic importance of patency of the infarct-related coronary artery after thrombolytic therapy for acute myocardial infarction. <i>Circulation</i> , 1994 , 89, 61-7	16.7	185
1611	Effect of rate of administration of recombinant tissue plasminogen activator on efficacy of coronary thrombolysis. 1994 , 45, 687-94		3
1610	Impact of age on clinical outcome and postlytic management strategies in patients treated with intravenous thrombolytic therapy. Results from the TIMI II Study. TIMI II Investigators. <i>Circulation</i> , 1994 , 90, 78-86	16.7	65

1609	Antiplatelet and antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa receptor antagonist. <i>Circulation</i> , 1994 , 89, 3-12	16.7	90
1608	Quantitative Coronary Angiography in Clinical Practice. 1994 ,		49
1607	Serum Lp(a) lipoprotein concentration and outcome of thrombolytic treatment for myocardial infarction. <i>Heart</i> , 1994 , 71, 316-21	5.1	15
1606	A pilot, early angiographic patency study using a direct thrombin inhibitor as adjunctive therapy to streptokinase in acute myocardial infarction. <i>Circulation</i> , 1994 , 89, 1567-72	16.7	85
1605	Mortality within 24 hours of thrombolysis for myocardial infarction. The importance of early reperfusion. The GUSTO Investigators, Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. <i>Circulation</i> , 1994 , 90, 2658-65	16.7	114
1604	Thrombolytic therapy for myocardial infarction. 1994 , 330, 1089; author reply 1089-90		
1603	Persistent thrombin generation in humans during specific thrombin inhibition with hirudin. <i>Circulation</i> , 1994 , 90, 2671-8	16.7	55
1602	Thrombolysis in thromboembolic diseases. 1994 , 69, S41-57		4
1601	Evaluation of ST segment elevation criteria for the prehospital electrocardiographic diagnosis fo acute myocardial infarction. 1994 , 23, 17-24		91
1600	Value of low-dose echodobutamine in the diagnosis of patency of the infarct related coronary artery. 1994 , 10, 131-6		
1599	Correlation between clinical course and quantitative analysis of the ischemia related artery in patients with unstable angina pectoris, refractory to medical treatment. Results of two randomized trials. The European Cooperative Study Group. 1994 , 10, 177-85		
1598	Time as an Adjunctive Agent to Thrombolytic Therapy. <i>Journal of Thrombosis and Thrombolysis</i> , 1994 , 1, 27-34	5.1	77
1597	Inhibition of pulmonary tumor seeding by antiplatelet and fibrinolytic therapy in an animal experimental model. 1994 , 55, 154-9		10
1596	Alterations in coronary blood flow velocity during intracoronary thrombolysis and rescue coronary angioplasty for acute myocardial infarction. 1994 , 31, 219-24		7
1595	Pros and cons of perfusion balloons in failed angioplasty. 1994 , 31, 264-9		8
1594	Improving results of bailout coronary stenting after failed balloon angioplasty. 1994 , 32, 117-24		12
1593	Bailout techniques for failed coronary angioplasty using 6 French guiding catheters. 1994 , 32, 359-66		9
1592	Thrombolytic retreatment with tissue plasminogen activator for threatened reinfarction and thrombotic coronary reocclusion. 1994 , 17, 3-13		21

1591	Current status of percutaneous transluminal coronary angioplasty. 1994 , 19, 233-283	
1590	Comparison of primary angioplasty versus thrombolytic therapy for acute myocardial infarction. Alabama Registry of Myocardial Ischemia Investigators. 1994 , 74, 111-8	52
1589	Outcome of attempted rescue coronary angioplasty after failed thrombolysis for acute myocardial infarction. 1994 , 74, 172-4	44
1588	Frequency of inclusion of patients with cardiogenic shock in trials of thrombolytic therapy. 1994 , 73, 149-57	25
1587	Time to reperfusion with direct coronary angioplasty and thrombolytic therapy in acute myocardial infarction. 1994 , 73, 231-6	39
1586	Concurrent nitroglycerin therapy impairs tissue-type plasminogen activator-induced thrombolysis in patients with acute myocardial infarction. 1994 , 74, 662-6	15
1585	Effects of low-dose aspirin on in vitro platelet aggregation in the early minutes after ingestion in normal subjects. 1994 , 74, 720-3	41
1584	Predicting ischemic complications after bailout stenting following failed coronary angioplasty. 1994 , 74, 271-4	9
1583	A pooled analysis of coronary arterial patency and left ventricular function after intravenous thrombolysis for acute myocardial infarction. 1994 , 74, 1220-8	56
1582	Relation of reperfusion success with anistreplase or alteplase in acute myocardial infarction to body weight. The TEAM-3 investigators. 1994 , 73, 16-22	6
1581	Benefit of late coronary reperfusion in patients with acute myocardial infarction and persistent ischemic chest pain. 1994 , 74, 538-43	9
1580	Does intravenous heparin or time-to-treatment/reperfusion explain differences between GUSTO and ISIS-3 results?. 1994 , 74, 1057-60	4
1579	Acute angiographic and clinical results of long balloon percutaneous transluminal coronary angioplasty and adjuvant stenting for long narrowings. 1994 , 73, 635-41	21
1578	Laser thrombolysis in acute myocardial infarction: results of a clinical feasibility study. 1994 , 7, 525-34	4
1577	Enhanced thrombolysis, reduced coronary reocclusion and limitation of infarct size with liposomal prostaglandin E1 in a canine thrombolysis model. 1994 , 24, 1382-90	17
1576	Early angiography cannot predict postthrombolytic coronary reocclusion: observations from the GUSTO angiographic study. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries. 1994 , 24, 1439-44	35
1575	Failure of fixed dose intravenous heparin to suppress increases in thrombin activity after coronary thrombolysis with streptokinase. 1994 , 24, 1445-52	33
1574	Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial. 1994 , 24, 1602-10	148

1573	Early assessment of reperfusion therapy using cardiac troponin T. 1994 , 23, 1382-9	40
1572	Frequency of pre-discharge ventricular arrhythmias in postmyocardial infarction patients depends on residual left ventricular pump performance and is independent of the occurrence of acute reperfusion. The GISSI-2 Investigators. 1994 , 23, 290-5	5
1571	A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial. 1994 , 23, 993-1003	230
1570	Rapid diagnosis of coronary reperfusion by measurement of myoglobin level every 15 min in acute myocardial infarction. 1994 , 23, 1009-15	31
1569	Intraaortic balloon counterpulsation enhances coronary thrombolysis induced by intravenous administration of a thrombolytic agent. 1994 , 23, 794-8	59
1568	Antagonism of the platelet 5HT ₂ receptor in the presence of thrombolysis. 1994 , 43, 11-20	5
1567	Experience with the Gianturco-Roubin stent for abrupt vessel closure complicating percutaneous transluminal coronary angioplasty. 1994 , 24, 31-5	2
1566	Thrombosis and restenosis after stenting in failed angioplasty: comparison with elective stenting. 1994 , 128, 12-20	81
1565	Early detection of successful coronary reperfusion based on serum myoglobin concentration: comparison with serum creatine kinase isoenzyme MB activity. 1994 , 128, 641-8	33
1564	Clinical significance of distal embolization after transluminal extraction atherectomy in diffusely diseased saphenous vein grafts. 1994 , 127, 1496-503	43
1563	Factors influencing changes in the signal-averaged electrocardiogram within the first year after a first myocardial infarction. 1994 , 128, 263-70	3
1562	Prostaglandin E ₁ does not accelerate rTPA-induced thrombolysis in acute myocardial infarction. 1994 , 127, 738-43	4
1561	Coronary angioplasty in the patient with acute myocardial infarction. 1994 , 96, 536-43	4
1560	Enhancement of thrombolytic efficacy of tissue-type plasminogen activator by adjuvants in the guinea pig thrombosis model. 1994 , 264, 191-8	15
1559	Meta-analysis of all available published clinical trials (1958-1990) on thrombolytic therapy for AMI: Relative efficacy of different therapeutic strategies. 1994 , 8, 67-86	17
1558	Abciximab (c7E3 Fab). A review of its pharmacology and therapeutic potential in ischaemic heart disease. 1994 , 48, 583-98	85
1557	Design of potent bivalent thrombin inhibitors based on hirudin sequence: incorporation of nonsubstrate-type active site inhibitors. 1994 , 33, 14443-51	29
1556	Ridogrel does not increase the speed and rate of coronary recanalization in patients with myocardial infarction treated with alteplase and heparin. 1994 , 15, 660-4	9

1555	Factors delaying treatment of acute myocardial infarction. 1994 , 15, 1595-8	22
1554	Principles of platelet inhibitor therapy--where we stood in 1993. 1994 , 15, 149-55	8
1553	Toward reliable, noninvasive measurement of myocardial function from 4D images. 1994 , 2168, 149	6
1552	Thrombolytic therapy. Agents, indications, and laboratory monitoring. 1994 , 78, 745-64	4
1551	Acute myocardial infarction. Reperfusion strategies. 1994 , 106, 1851-66	6
1550	Strategies for reestablishing coronary blood flow during the acute phase of myocardial infarction. 1994 , 105, 574-84	1
1549	A comparison of intra-arterial and intravenous tissue-type plasminogen activator on autologous arterial emboli in the cerebral circulation of rabbits. 1994 , 25, 651-5; discussion 656	26
1548	Current status of thrombolysis in acute myocardial infarction. I. Optimal selection and delivery of a thrombolytic drug. 1995 , 107, 225-32	7
1547	Non-invasive assessment of reperfusion of the infarct-related artery during coronary thrombolysis and its relation with left ventricular function. 1995 , 49 Suppl, S59-69	4
1546	Intravenous administration of recombinant tissue plasminogen activator. Optimizing the rate of coronary thrombolysis. 1995 , 107, 1146-51	1
1545	Acute myocardial infarction. Then and now. 1995 , 107, 1732-43	2
1544	Vectorcardiographic monitoring to assess early vessel patency after reperfusion therapy for acute myocardial infarction. 1995 , 16, 21-9	41
1543	Antiplatelet therapy in therapy-resistant unstable angina. A pilot study with REO PRO (c7E3). 1995 , 16 Suppl L, 36-42	7
1542	"Rescue" thrombolysis with intracoronary tissue plasminogen activator for failed intravenous thrombolysis with streptokinase for acute myocardial infarction. 1995 , 75, 172-4	14
1541	In-vitro synergism between t-PA and scu-PA depends on clot retraction. 1995 , 9, 101-105	5
1540	Incomplete recanalization as an important determinant of Thrombolysis in Myocardial Infarction (TIMI) grade 2 flow after thrombolytic therapy for acute myocardial infarction. TEAM Investigators. Thrombolytic Trial of Eminase in Acute Myocardial Infarction. 1995 , 76, 749-52	12
1539	Ability of the no-reflow phenomenon during an acute myocardial infarction to predict left ventricular dysfunction at one-month follow-up. 1995 , 76, 861-8	101
1538	Comparison of mortality from acute myocardial infarction in patients receiving anistreplase with those not receiving thrombolysis. 1995 , 76, 1103-7	11

1537	Value of rescue percutaneous transluminal coronary angioplasty following unsuccessful thrombolytic therapy in patients with acute myocardial infarction. Thrombolysis in Myocardial Infarction Investigators. 1995 , 76, 1108-11			41
1536	Initial experience with hirudin and streptokinase in acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 6 trial. 1995 , 75, 7-13			101
1535	Significance of a coronary artery with thrombolysis in myocardial infarction grade 2 flow "patency" (outcome in the thrombolysis and angioplasty in myocardial infarction trials). Thrombolysis and Angioplasty in Myocardial Infarction Study Group. 1995 , 75, 871-6			72
1534	Electrocardiographic diagnosis of reperfusion during thrombolytic therapy in acute myocardial infarction. 1995 , 75, 1206-10			77
1533	Bailout Palmaz-Schatz coronary stenting in 39 patients with occlusive dissection complicating conventional angioplasty. 1995 , 35, 204-9			10
1532	Hirudin in Acute Myocardial Infarction. <i>Journal of Thrombosis and Thrombolysis</i> , 1995 , 1, 259-267	5.1		4
1531	Achieving Optimal Reperfusion without Adjunctive Antithrombotic Therapy: Novel Thrombolytic Dosing Strategies. <i>Journal of Thrombosis and Thrombolysis</i> , 1995 , 1, 269-277	5.1		1
1530	Thrombolytic Therapy for Acute Myocardial Infarction in Patients with Prior Coronary Bypass Surgery: Results from the Thrombolysis in Myocardial Infarction (TIMI) 4 Trial. <i>Journal of Thrombosis and Thrombolysis</i> , 1995 , 2, 45-50	5.1		2
1529	A Double-Blind Multicenter Comparison of the Efficacy and Safety of Saruplase and Urokinase in the Treatment of Acute Myocardial Infarction: Report of the SUTAMI Study Group. <i>Journal of Thrombosis and Thrombolysis</i> , 1995 , 2, 117-124	5.1		17
1528	Factors influencing myocardial salvage with primary angioplasty. 1995 , 2, 35-41			31
1527	The Thrombolysis in Myocardial Infarction (TIMI) trials: the first decade. 1995 , 8, 117-35			24
1526	An increase in low aortic pressure increases coronary artery flow and coronary thrombolysis induced by intravenous administration of recombinant tissue plasminogen activator. 1995 , 10, 1-6			7
1525	Cardiac complications of cocaine abuse. 1995 , 18, 67-72			58
1524	Myocardial damage after successful thrombolysis is associated with the duration of ST re-elevation at reperfusion. 1995 , 18, 324-8			7
1523	How do smokers differ from nonsmokers in their response to thrombolysis? (the TIMI-4 trial). 1995 , 75, 232-6			50
1522	Platelets and Platelet Inhibitors in Acute Myocardial Infarction. <i>Cardiology Clinics</i> , 1995 , 13, 435-447	2.5		11
1521	Thrombin Inhibitors in Acute Myocardial Infarction. <i>Cardiology Clinics</i> , 1995 , 13, 421-433	2.5		3
1520	Does increased lipoprotein (a) impair the effectiveness of thrombolysis with streptokinase?. 1995 , 46, 727-31			3

1519	Coronary thrombolysis. 1995 , 108, 401S-423S		10
1518	The promiscuous receptor. Prostate cancer comes of age. 1995 , 332, 1440-1		10
1517	Something new out of Africa. 1995 , 332, 1441-2		5
1516	Cost effectiveness of tissue plasminogen activator. 1995 , 332, 1443-4		10
1515	Gusto Hawaii: A Community Hospital's Experience in an International Randomized Study. 1995 , 3, 8-12		
1514	Transient release of lipid peroxidation products as a non-invasive marker of successful reperfusion after thrombolysis for myocardial infarction. <i>Heart</i> , 1995 , 73, 223-6	5.1	5
1513	Efficacy and issues of emergent percutaneous transluminal coronary angioplasty. Comparison of clinical results in younger and elderly patients. 1995 , 46, 1085-95		5
1512	Rescue thrombolysis: alteplase as adjuvant treatment after streptokinase in acute myocardial infarction. <i>Heart</i> , 1995 , 74, 348-53	5.1	33
1511	Ridogrel as an adjunct to thrombolysis in acute myocardial infarction. 1995 , 52, 125-34		13
1510	Transradial artery coronary angioplasty. 1995 , 129, 1-7		214
1509	Concurrent nitroglycerin administration reduces the efficacy of recombinant tissue-type plasminogen activator in patients with acute anterior wall myocardial infarction. 1995 , 130, 692-7		12
1508	Serial changes of plasma plasminogen activator inhibitor activity in acute myocardial infarction: difference between thrombolytic therapy and direct coronary angioplasty. 1995 , 130, 933-9		16
1507	Stratification of the risk of thrombosis after intracoronary stenting for threatened or acute closure complicating coronary balloon angioplasty: a Cook registry study. 1995 , 130, 8-13		27
1506	Myocardial rupture after myocardial infarction is related to the perfusion status of the infarct-related coronary artery. 1995 , 129, 644-50		37
1505	Failure of intravenous metoprolol to limit acute myocardial infarct size in a nonreperfused porcine model. 1995 , 129, 650-5		6
1504	Frequent reocclusion of patent infarct-related arteries between 4 weeks and 1 year: effects of antiplatelet therapy. 1995 , 25, 218-23		67
1503	Noninvasive quantification of regional myocardial flow reserve in patients with coronary atherosclerosis using nitrogen-13 ammonia positron emission tomography. Determination of extent of altered vascular reactivity. 1995 , 26, 1465-75		121
1502	Criteria for drug usage review of thrombolytics in acute myocardial infarction. 1995 , 7, 25-38		3

1501	Another coronary reperfusion regimen. 1995 , 346, 324-5	1
1500	Clinical and economic lessons from studies of coronary thrombolysis. 1995 , 6, 945-1015	5
1499	Reocclusion: the flip side of coronary thrombolysis. 1996 , 27, 766-73	65
1498	Circadian variations of onset of acute myocardial infarction and efficacy of thrombolytic therapy. 1996 , 27, 774-8	75
1497	Primary angioplasty and thrombolysis for acute myocardial infarction: an evidence summary. 1996 , 27, 737-50	25
1496	Coronary stenting with a novel stainless steel balloon-expandable stent: determinants of neointimal formation and changes in arterial geometry after placement in an atherosclerotic model. 1996 , 27, 1270-7	43
1495	Non-Q wave and ST segment depression myocardial infarction: is there a role for thrombolytic therapy?. 1996 , 27, 1333-4	19
1494	Decreased prevalence of late potentials with mechanical versus thrombolysis-induced reperfusion in acute myocardial infarction. 1996 , 27, 1343-8	13
1493	Influence of cigarette smoking on rate of reopening of the infarct-related coronary artery after myocardial infarction: a multivariate analysis. 1996 , 27, 1662-8	42
1492	Prognostic significance of precordial ST segment depression during inferior myocardial infarction in the thrombolytic era: results in 16,521 patients. 1996 , 28, 305-12	63
1491	Management of acute myocardial infarction: evaluating the past, practicing in the present, elaborating the future. 1996 , 132, 465-70; discussion 496-502	6
1490	Vitamin E and coronary heart disease. 1996 , 347, 1689-1691	2
1489	Aortic counterpulsation may improve late patency of the occluded coronary artery in patients with early failure of thrombolytic therapy. 1996 , 28, 876-81	46
1488	Coronary recanalization by elective angioplasty prevents ventricular dilation after anterior myocardial infarction. 1996 , 28, 837-45	68
1487	Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: the GUSTO-I experience. 1996 , 28, 1661-9	234
1486	A chemiluminescent detection of superoxide radical produced by adherent leucocytes to the subendothelium following thrombolysis: studies with a photochemically induced thrombosis model in the guinea pig femoral artery. 1996 , 122, 217-24	3
1485	Intraventricular bleeding after the use of thrombolytics in a cocaine user. 1996 , 14, 663-4	14
1484	CQI: improving the time to thrombolytic therapy for patients with acute myocardial infarction in the emergency department. 1996 , 14, 685-9	13

1483	Role of calcium channel blockers in reducing acute ischaemia and preventing restenosis in PTCA. 1996 , 52 Suppl 4, 9-15; discussion 15-6	1
1482	Ventricular fibrillation following administration of thrombolytic treatment. The EMIP experience. European Myocardial Infarction Project. 1996 , 17, 213-21	15
1481	Late activation of the fibrinolytic system in myocardial infarction treated with thrombolytic therapy. Influence of the coronary anatomical substrate. 1996 , 17, 230-6	8
1480	Streptokinase versus Alteplase in Acute Myocardial Infarction. <i>Journal of the Royal Society of Medicine</i> , 1996 , 89, 427-430	2.3 4
1479	Early myocardial reperfusion: an assessment of current strategies in acute myocardial infarction. 1996 , 17 Suppl E, 42-8	10
1478	Assessment of myocardial injury by serum tumour necrosis factor alpha measurements in acute myocardial infarction. 1996 , 17, 1852-9	39
1477	Management of spinal epidural hematoma after tissue plasminogen activator. A case report. 1996 , 21, 1694-8	46
1476	Thrombolytic therapy. From myocardial to cerebral infarction. The MAST-I Group. Multicentre Acute Stroke Trial. 1996 , 17, 5-21	5
1475	Induction of thrombolysis and prevention of thrombus formation by local drug delivery with a double-occlusion balloon catheter. 1996 , 11, 123-32	3
1474	Usefulness of intracoronary stenting in acute myocardial infarction. 1996 , 78, 148-152	20
1473	Is coronary thrombolysis associated with side effects that significantly compromise clinical benefits?. 1996 , 77, 756-8	4
1472	Angiographically assessed coronary collateral circulation increases vulnerability to myocardial ischemia during vasodilator stress testing. 1996 , 78, 1419-24	23
1471	Stent jail: a minimum-security prison. 1996 , 77, 1226-9	38
1470	Metaanalysis of five reported studies on the relation of early coronary patency grades with mortality and outcomes after acute myocardial infarction. 1996 , 78, 1-8	130
1469	Incidence and importance of thrombolysis in myocardial infarction grade 3 flow after primary percutaneous transluminal coronary angioplasty for acute myocardial infarction. 1996 , 78, 623-6	36
1468	Serial angiographic follow-up after successful direct angioplasty for acute myocardial infarction. 1996 , 78, 980-4	34
1467	Molecular biology of plasminogen activators: what are the clinical implications of drug design?. 1996 , 78, 2-7	64
1466	Thrombolytic therapy for cerebral infarction. 1996 , 3, 881-92	9

1465	Lesion-directed administration of alteplase with intracoronary heparin in patients with unstable angina and coronary thrombus undergoing angioplasty. 1996 , 37, 382-91			14
1464	Immediate hemodynamic effects of thrombolytic therapy on the ischemic myocardium. 1996 , 38, 325-30			
1463	An Angiographic Study of Intracoronary Streptokinase versus Intravenous Tissue Plasminogen Activator After Failed Coronary Thrombolysis with Intravenous Streptokinase. <i>Journal of Thrombosis and Thrombolysis</i> , 1996 , 3, 239-243	5.1		4
1462	Time to Treatment: A Crucial Factor in Thrombolysis and Primary Angioplasty. <i>Journal of Thrombosis and Thrombolysis</i> , 1996 , 3, 249-255	5.1		14
1461	Acute thrombosis in a contralateral kidney after radical nephrectomy: successful treatment by thrombolytic therapy using a tissue-type plasminogen activator. 1996 , 3, 508-10			1
1460	Prehospital Administration of Aspirin in Patients With Unstable Angina and Acute Myocardial Infarction. 1996 , 156, 1506			28
1459	Coronary Palmaz-Schatz stent implantation in acute myocardial infarction. <i>Heart</i> , 1996 , 75, 121-6	5.1		34
1458	Intravascular ultrasound-guided emergency coronary Palmaz-Schatz stent placement without post-procedural systemic anticoagulation. <i>Heart</i> , 1996 , 76, 344-9	5.1		4
1457	Significance of perfusion of the infarct related coronary artery for susceptibility to ventricular tachyarrhythmias in patients with previous myocardial infarction. <i>Heart</i> , 1996 , 75, 17-22	5.1		10
1456	Tissue plasminogen activator, tissue plasminogen activator inhibitor and lipoprotein(a) in patients with coronary, epiaortic and peripheral occlusive artery disease. 1996 , 17, 1329-36			14
1455	Differential effects of tissue plasminogen activator and streptokinase on infarct size and on rate of enzyme release: influence of early infarct related artery patency. The GUSTO Enzyme Substudy. 1996 , 17, 237-46			32
1454	Thrombolytic therapy in acute myocardial infarction. 1996 , 22, 15-26			18
1453	Kaposi's sarcoma--what's human chorionic gonadotropin got to do with it?. 1996 , 335, 1309-10			12
1452	Should thrombolysis or primary angioplasty be the treatment of choice for acute myocardial infarction? Thrombolysis--the preferred treatment. 1996 , 335, 1311-2; discussion 1316-7			52
1451	Thrombolysis, With or Without Heparin, During the First Nine Weeks After Acute Myocardial Infarction. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 1997 , 3, 183-189	3.3		
1450	Prognostic Implication of Creatine Kinase Elevation Following Elective Coronary Artery Interventions. 1997 , 277, 461			185
1449	Patency and reinfarction in late-entry myocardial infarct patients treated with reperfusion therapy. 1997 , 48, 215-22			3
1448	Thrombolysis after acute myocardial infarction. 1997 , 14, 2-9			4

1447	Pharmacological and clinical impact of the unique molecular structure of a new plasminogen activator. 1997 , 18 Suppl F, F11-6		23
1446	Thrombolysis-induced coronary reperfusion causes acute and massive interstitial release of cardiac muscle cell proteins. 1997 , 33, 147-55		11
1445	Impact of early accelerated dose tissue plasminogen activator on in-hospital patency of the infarcted vessel in patients with acute right ventricular infarction. <i>Heart</i> , 1997 , 77, 512-6	5.1	11
1444	Effect of a mechanical vs a pharmacologic increase in aortic pressure on coronary blood flow and thrombolysis induced by IV administration of a thrombolytic agent. 1997 , 111, 449-53		7
1443	Primary angioplasty for acute myocardial infarction. 1997 , 2, 327-34		2
1442	Impact of culprit lesion morphology on prevalence of provoked myocardial ischaemia in patients with old myocardial infarction. A dipyridamole stress echocardiography, exercise electrocardiography and angiographic study. 1997 , 18, 596-602		5
1441	A randomized trial of a fixed high dose vs a weight-adjusted low dose of intravenous heparin during coronary angioplasty. 1997 , 18, 631-5		51
1440	Influence of late reopening of the infarct-related artery on left ventricular remodelling after myocardial infarction. IRIS Study Group. 1997 , 18, 1261-8		14
1439	Targeting new thrombolytic regimens at specific patient groups: implications for research and cost-containment. 1997 , 18 Suppl F, F28-35		3
1438	Chronic total occlusions of coronary arteries--medical versus surgical treatment. 1997 , 31, 297-303		5
1437	Immediate coronary angiography in survivors of out-of-hospital cardiac arrest. 1997 , 336, 1629-33		1245
1436	Long-term prognostic significance of ventricular late potentials after a first acute myocardial infarction. 1997 , 134, 1019-28		13
1435	Early behavior of biochemical markers in patients with thrombolysis in myocardial infarction grade 2 flow in the infarct artery as opposed to other flow grades after intravenous thrombolysis for acute myocardial infarction. PERM Study Group. Prospective Evaluation of Reperfusion Markers. 1997 , 134, 1044-51		5
1434	Significance of the Thrombolysis in Myocardial Infarction scoring system in assessing infarct-related artery reperfusion and mortality rates after acute myocardial infarction. 1997 , 134, 62-8		41
1433	Randomized coronary patency trial of double-bolus recombinant staphylokinase versus front-loaded alteplase in acute myocardial infarction. 1997 , 134, 213-9		52
1432	Clinical characteristics and long-term outcome of patients in whom congestive heart failure develops after thrombolytic therapy for acute myocardial infarction: development of a predictive model. 1997 , 133, 663-73		80
1431	[Pre-hospitalization management of evolving myocardial infarction. 2d conference of south-eastern region emergency medicine experts]. 1997 , 16, 541-8		0
1430	Early detection of successful coronary reperfusion based on serum concentration of human heart-type cytoplasmic fatty acid-binding protein. 1997 , 262, 13-27		26

1429	Early, Complete Infarct Vessel Patency: Arriving at a Gold Standard for Future Clinical Investigation in Myocardial Reperfusion. <i>Journal of Thrombosis and Thrombolysis</i> , 1997 , 4, 259-266	5.1	6
1428	Gender and acute myocardial infarction: is there a different response to thrombolysis?. 1997 , 29, 35-42		124
1427	Coronary revascularization surgery after myocardial infarction: impact of bypass surgery on survival after thrombolysis. GUSTO Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. 1997 , 29, 240-9		13
1426	A prospective, randomized, double-blind multicenter trial of a single bolus injection of the novel modified t-PA E6010 in the treatment of acute myocardial infarction: comparison with native t-PA. E6010 Study Group. 1997 , 29, 1447-53		40
1425	Association of angiotensin I-converting enzyme gene polymorphism with myocardial ischemia and patency of infarct-related artery in patients with acute myocardial infarction. 1997 , 29, 1468-73		25
1424	Can we provide reperfusion therapy to all unselected patients admitted with acute myocardial infarction?. 1997 , 30, 157-64		28
1423	Progression of the culprit lesion in unstable coronary artery disease with warfarin and aspirin versus aspirin alone: preliminary study. 1997 , 30, 364-9		51
1422	Clinical outcome of patients undergoing endoluminal coronary artery reconstruction with three or more stents. 1997 , 30, 676-81		25
1421	Beneficial effect of intracoronary verapamil on microvascular and myocardial salvage in patients with acute myocardial infarction. 1997 , 30, 1193-9		223
1420	Sixty-minute alteplase protocol: a new accelerated recombinant tissue-type plasminogen activator regimen for thrombolysis in acute myocardial infarction. 1997 , 30, 1611-7		27
1419	Changing paradigms in thrombolysis in acute myocardial infarction. 1997 , 59, 227-42		4
1418	Melagatran, hirudin and heparin as adjuncts to tissue-type plasminogen activator in a canine model of coronary artery thrombolysis. 1997 , 11, 121-128		26
1417	Interpretation of results of clinical trials in coronary thrombolysis. 1997 , 11, 17-21		
1416	Thrombolytic therapy of acute myocardial infarction with saruplase, a single-chain urokinase-type plasminogen activator (scu-PA) from recombinant bacteria. 1997 , 11, 45-54		3
1415	Best strategy for reperfusion for acute myocardial infarction: direct PTCA. 1997 , 11, 71-74		
1414	A fresh look at the molecular pharmacology of plasminogen activators: from theory to test tube to clinical outcomes. 1997 , 54 Suppl 1, S17-22		9
1413	Antithrombin III supplementation for patients undergoing PTCA for unstable angina pectoris. A controlled randomized double-blind pilot study. 1997 , 18, 443-9		10
1412	Thrombolysis for Acute Ischemic Stroke. 1997 , 8, 219-226		3

1411	Prehospital Thrombolysis in Acute Myocardial Infarction Salvages Myocardium. 1997 , 10, 315-325		
1410	New Thrombolytic Agents. 1997 , 10, 395-399		2
1409	Removal of thrombus from aortocoronary bypass grafts and coronary arteries using the 6Fr Hydrolyser. 1997 , 79, 1012-6		26
1408	One-week and six-month angiographic controls of stent implantation after occlusive and nonocclusive dissection during primary balloon angioplasty for acute myocardial infarction. 1997 , 79, 1592-5		19
1407	Intravascular therapeutic ultrasound thrombolysis in acute myocardial infarctions. 1997 , 80, 200-4		48
1406	Papillary muscle fractional shortening is a determinant of heart shape in patients with prior myocardial infarction. 1997 , 80, 204-6		2
1405	Accuracy of spiral computed tomography for identifying arterial and venous coronary graft patency. 1997 , 80, 569-74		45
1404	Prognostic value of thrombolysis, coronary artery patency, signal-averaged electrocardiography, left ventricular ejection fraction, and Holter electrocardiographic monitoring for life-threatening ventricular arrhythmias after a first acute myocardial infarction. 1997 , 80, 852-8		23
1403	Effect of platelet glycoprotein IIb/IIIa receptor inhibition on distal embolization during percutaneous revascularization of aortocoronary saphenous vein grafts. EPIC Investigators. Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications. 1997 , 80, 985-8		103
1402	Comparison of peak serum C-reactive protein and hydroxybutyrate dehydrogenase levels in patients with acute myocardial infarction treated with alteplase and streptokinase. 1997 , 80, 1075-7		23
1401	Frequency and predictors of major in-hospital ischemic complications after planned and unplanned new-device angioplasty from the New Approaches to Coronary Intervention (NACI) registry. 1997 , 80, 40K-49K		14
1400	Why does thrombolysis fail? Breaking through the reperfusion ceiling. 1997 , 80, 1588-90		24
1399	Angioscopic coronary macromorphology after thrombolysis in acute myocardial infarction. 1997 , 79, 197-202		5
1398	Evolution of late potential parameters in thrombolysed acute myocardial infarction might predict patency of the infarct-related artery. 1997 , 79, 570-4		4
1397	Is heparin of value in the management of acute myocardial infarction?. 1997 , 11, 111-9		6
1396	Rescue PTCA Following Failed Thrombolysis and Primary PTCA: A Retrospective Study of Angiographic and Clinical Outcome. <i>Journal of Thrombosis and Thrombolysis</i> , 1997 , 4, 281-288	5.1	11
1395	Thrombolytic Therapy: The Treatment of Choice in Acute Myocardial Infarction. <i>Journal of Thrombosis and Thrombolysis</i> , 1997 , 4, 337-343	5.1	1
1394	Coronary Artery Patency and Survival in Clinical Trials. <i>Journal of Thrombosis and Thrombolysis</i> , 1997 , 4, 239-250	5.1	1

1393	Comparison of bailout versus elective stenting: time to reassess our benchmarks of outcome. 1997 , 41, 40-7			3
1392	Primary angioplasty reduces risk of myocardial rupture compared to thrombolysis for acute myocardial infarction. 1997 , 42, 151-7			38
1391	Catheter-induced acute aortic insufficiency with hemodynamic collapse during PTCA: an unreported complication. 1997 , 42, 305-7			6
1390	Use of cardiac markers as assessed by outcomes analysis. 1997 , 30, 339-50			21
1389	Cooling System Permits Effective Transcutaneous Ultrasound Clot Lysis In Vivo Without Skin Damage. <i>Journal of Thrombosis and Thrombolysis</i> , 1998 , 6, 125-131	5.1		10
1388	Impact of a Simple Inexpensive Quality Assurance Effort on Physician's Choice of Thrombolytic Agents and Door-to-Needle Time: Implication for Costs of Management. <i>Journal of Thrombosis and Thrombolysis</i> , 1998 , 5, 151-157	5.1		6
1387	Early deaths with thrombolytic therapy for acute myocardial infarction in corticosteroid-dependent rheumatoid arthritis. 1998 , 21, 853-6			5
1386	Thrombolytic eligibility. 1998 , 28, 518-24			1
1385	Hirudin (desirudin) and Hirulog (bivalirudin) in acute ischaemic syndromes and the rationale for the Hirulog/Early Reperfusion Occlusion (HERO-2) Study. 1998 , 28, 551-4			12
1384	New antiplatelet agents. 1998 , 28, 558-64			2
1383	Detection of reperfusion after thrombolytic therapy by the analysis of released biochemical markers. 1998 , 28, 565-8			
1382	The corrected TIMI frame count. The new gold standard?. 1998 , 28, 569-73			10
1381	Update on Glycoprotein IIb/IIIa Blockade in Endovascular Interventions. 1998 , 11, S18-S28			1
1380	Benefit of early sustained reperfusion in patients with prior myocardial infarction (the GUSTO-I trial). Global Utilization of Streptokinase and TPA for occluded arteries. 1998 , 81, 282-7			22
1379	Comparative early and nine-month results of rotational atherectomy, stents, and the combination of both for calcified lesions in large coronary arteries. 1998 , 81, 552-7			56
1378	Abnormal coronary flow in infarct arteries 1 year after myocardial infarction is predicted at 4 weeks by corrected Thrombolysis in Myocardial Infarction (TIMI) frame count and stenosis severity. 1998 , 81, 665-71			42
1377	Asynergy of the noninfarcted left ventricular inferior wall in anterior wall acute myocardial infarction secondary to isolated occlusion of the left anterior descending artery. 1998 , 81, 828-33			7
1376	Significance of exercise-induced ST-segment elevation and T-wave pseudonormalization for improvement of function in healed Q-wave myocardial infarction. 1998 , 82, 148-53			22

1375	Results of percutaneous coronary angioplasty in patients . 1998 , 82, 135-9	11
1374	Reversible perfusion defects on exercise tomographic thallium imaging in patients with and without collateral flow. 1998 , 82, 234-6	0
1373	Incidence, consequences, and risk factors of early reocclusion after primary and/or rescue percutaneous transluminal coronary angioplasty for acute myocardial infarction. 1998 , 82, 554-8	11
1372	Abciximab administration and outcome after intracoronary stent implantation. 1998 , 82, 705-9	5
1371	Late coronary angioplasty and ventricular late potentials. 1998 , 82, 985-7	10
1370	The clinical implications of no reflow demonstrated with intravenous perfluorocarbon containing microbubbles following restoration of Thrombolysis In Myocardial Infarction (TIMI) 3 flow in patients with acute myocardial infarction. 1998 , 82, 1173-7	101
1369	Direct thrombin inhibition and thrombolytic therapy: rationale for the Hirulog and Early Reperfusion/Occlusion (HERO-2) trial. 1998 , 82, 57P-62P	17
1368	A randomized comparison of bivalirudin and heparin in patients undergoing coronary angioplasty for postinfarction angina. Hirulog Angioplasty Study Investigators. 1998 , 82, 43P-49P	36
1367	Micro stent implantation in patients with acute myocardial infarction without anticoagulation: clinical experience with two different antithrombotic protocols. 1998 , 44, 131-7	1
1366	Pharmacokinetics and pharmacodynamics of recombinant tissue-type plasminogen activator following intravenous administration in rabbits: a comparison of three dosing regimens. 1998 , 19, 31-8	10
1365	[Systemic lysis therapy in retinal vascular occlusions]. 1998 , 95, 568-75	14
1364	Feasibility study of a liquid formulation of recombinant staphylokinase for coronary artery thrombolysis. 1998 , 12, 173-177	1
1363	Clinical outcome of patients undergoing multivessel coronary stent implantation. 1998 , 64, 1-7	7
1362	Primary coronary angioplasty in acute myocardial infarction: clinical correlates of the 'no reflow' phenomenon. 1998 , 65 Suppl 1, S23-8	16
1361	The significance of coronary arterial patency and ventricular function for prognosis after myocardial infarction. 1998 , 65 Suppl 1, S57-60	1
1360	Intravascular ultrasound predictors of angiographic restenosis in lesions treated with Palmaz-Schatz stents. 1998 , 31, 43-9	207
1359	High dose bolus heparin as initial therapy before primary angioplasty for acute myocardial infarction: results of the Heparin in Early Patency (HEAP) pilot study. 1998 , 31, 289-93	34
1358	Systematic direct angioplasty and stent-supported direct angioplasty therapy for cardiogenic shock complicating acute myocardial infarction: in-hospital and long-term survival. 1998 , 31, 294-300	103

1357	Influence of collateral circulation on in-hospital death from anterior acute myocardial infarction. 1998, 31, 512-8		70
1356	Thrombolytic therapy and equivalence trials. 1998, 31, 494-6		3
1355	Critical analysis of coronary artery bypass graft surgery: a 30-year journey. 1998, 31, 1B-63B		82
1354	Efficacy of streptokinase, but not tissue-type plasminogen activator, in achieving 90-minute patency after thrombolysis for acute myocardial infarction decreases with time to treatment. PERM Study Group. Prospective Evaluation of Reperfusion Markers. 1998, 31, 776-9		34
1353	Is time running out on streptokinase?. 1998, 31, 780-2		3
1352	Early noninvasive identification of failed reperfusion after intravenous thrombolytic therapy in acute myocardial infarction. 1998, 31, 1499-505		62
1351	Rescue angioplasty after failed thrombolysis: technical and clinical outcomes in a large thrombolysis trial. GUSTO-1 Angiographic Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. 1998, 31, 1511-7		101
1350	Time dependence of left ventricular recovery after delayed recanalization of an occluded infarct-related coronary artery: findings of a pilot study. 1998, 32, 97-102		28
1349	Clinical predictors of early infarct-related artery patency following thrombolytic therapy: importance of body weight, smoking history, infarct-related artery and choice of thrombolytic regimen: the GUSTO-I experience. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries. 1998, 32, 641-7		52
1348	Importance of time to reperfusion for 30-day and late survival and recovery of left ventricular function after primary angioplasty for acute myocardial infarction. 1998, 32, 1312-9		250
1347	Long-term follow-up after direct percutaneous transluminal coronary angioplasty for acute myocardial infarction. 1998, 32, 1320-5		40
1346	Coronary flow reserve may predict myocardial recovery after myocardial infarction in patients with TIMI grade 3 flow. 1998, 136, 335-44		44
1345	Integrated approach to ischemic heart disease. The one-stop shop. <i>Cardiology Clinics</i> , 1998, 16, 267-76	2.5	27
1344	Thrombolytic therapy: a review of its use in acute myocardial infarction. 1998, 32, 769-84		12
1343	Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. <i>Circulation</i> , 1998, 97, 765-72	16.7	1090
1342	An angiographic assessment of alteplase: double-bolus and front-loaded infusion regimens in myocardial infarction. DouBLE Study Investigators. Double Bolus Lysis Efficacy. 1998, 136, 741-8		16
1341	Multivariate associates of QT dispersion in patients with acute myocardial infarction: primacy of patency status of the infarct-related artery. TEAM-3 Investigators. Third trial of Thrombolysis with Eminase in Acute Myocardial Infarction. 1998, 135, 1027-35		25
1340	Determinants of regional myocardial function in patients with chronic significant coronary stenosis or occlusion. 1998, 136, 169-75		3

1339	Incidence and predictors of restenosis after successful primary coronary angioplasty for acute myocardial infarction: the importance of age and procedural result. 1998 , 136, 518-27		15
1338	ST-segment elevation in right precordial leads implies depressed right ventricular function after acute inferior myocardial infarction. 1998 , 135, 689-95		23
1337	Thrombolysis for acute myocardial infarction. <i>Circulation</i> , 1998 , 97, 1632-46	16.7	149
1336	Thrombolytic Therapy in Acute Myocardial Infarction Part II: 1997 Update. 1998 , 6, 3-10		0
1335	Assessing the myocardium after attempted reperfusion: should we bother?. <i>Circulation</i> , 1998 , 98, 625-7	16.7	30
1334	Non-Q-wave versus Q-wave myocardial infarction after thrombolytic therapy: angiographic and prognostic insights from the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries-I angiographic substudy. GUSTO-I Angiographic Investigators. <i>Circulation</i> , 1998 , 97, 111-50	16.7	63
1333	Low molecular weight heparin as an adjunct to thrombolysis for acute myocardial infarction: the FATIMA study. Fraxiparin Anticoagulant Therapy in Myocardial Infarction Study Amsterdam (FATIMA) Study Group. <i>Heart</i> , 1998 , 80, 35-9	5.1	17
1332	Inhibition of platelet glycoprotein IIb/IIIa with eptifibatid in patients with acute coronary syndromes. 1998 , 339, 436-43		1347
1331	Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. 1998 , 338, 1488-97		1299
1330	Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibraxiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial. Thrombolysis in Myocardial Infarction. <i>Circulation</i> , 1998 , 97, 340-9	16.7	158
1329	A normal electrocardiogram precludes the need for left ventriculography in the assessment of coronary artery disease. <i>Heart</i> , 1998 , 79, 262-7	5.1	9
1328	Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade. Zwolle Myocardial Infarction Study Group. <i>Circulation</i> , 1998 , 97, 2302-6	16.7	1047
1327	Evaluation of a weight-adjusted single-bolus plasminogen activator in patients with myocardial infarction: a double-blind, randomized angiographic trial of lanoteplase versus alteplase. <i>Circulation</i> , 1998 , 98, 2117-25	16.7	76
1326	Coronary thrombolysis. 1998 , 114, 634S-657S		18
1325	Direct percutaneous transluminal coronary angioplasty in acute myocardial infarction. Predictors of short-term outcome and the impact of coronary stenting. Study Group of The Arbeitsgemeinschaft Leitender Kardiologischer KrankenhausÄrzte (ALKK). 1998 , 19, 917-21		16
1324	Exercise-induced T-wave normalization predicts recovery of regional contractile function after anterior myocardial infarction. 1998 , 19, 420-8		15
1323	Clinical presentation and outcome of patients with early, intermediate and late reperfusion therapy by primary coronary angioplasty for acute myocardial infarction. 1998 , 19, 118-23		18
1322	Increase in thrombin generation after coronary thrombolysis with rt-PA or streptokinase with simultaneous heparin versus heparin alone. 1998 , 28, 99-105		1

1321	Rescue coronary angiography after failed thrombolysis: a real-life experience. 1998 , 90, 48-51		4
1320	YM866, a novel modified tissue-type plasminogen activator, affects left ventricular function and myocardial infarct development in dogs with coronary artery thrombi. 1998 , 77, 177-83		6
1319	Applying the open artery theory: use of predictive survival markers. 1998 , 19, 1132-9		36
1318	Angiographic study of mutant tissue-type plasminogen activator versus urokinase for acute myocardial infarction. 1998 , 62, 111-4		5
1317	Myocardial salvage by reperfusion 12 hours after coronary ligation in dogs. 1998 , 62, 294-8		5
1316	Comparison of thrombolytic therapies with mutant tPA (lanoteplase/SUN9216) and recombinant tPA (alteplase) for acute myocardial infarction. 1998 , 62, 801-6		10
1315	Fibrinolytic therapy with low-dose recombinant tissue plasminogen activator in retinal vein occlusion. 1998 , 212, 394-8		39
1314	No Effect of Clot Age or Thrombolysis on Argatroban's Inhibition of Thrombin. 1998 , 92, 2064-2074		34
1313	Effective Use of BCH-2763, a New Potent Injectable Direct Thrombin Inhibitor, in Combination with Tissue Plasminogen Activator (tPA) in a Rat Arterial Thrombolysis Model. 1998 , 80, 186-191		12
1312	Primary Stenting for Acute Myocardial Infarction. 1999 , 82, 160-163		18
1311	A Novel Approach to Arterial Thrombolysis. 1999 , 94, 2735-2743		130
1310	Assessment of coronary angiograms prior to and after treatment with abciximab, and the outcome of angioplasty in refractory unstable angina patients. Angiographic results from the CAPTURE trial. 1999 , 20, 1572-8		40
1309	Decreased no-reflow in patients with anterior myocardial infarction and pre-infarction angina. 1999 , 20, 1724-30		26
1308	The evolving role of platelet glycoprotein IIb/IIIa inhibitors in the management of acute coronary syndromes. 1999 , 33, 712-22		9
1307	Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators. <i>Circulation</i> , 1999 , 99, 2720-32	16.7	559
1306	Acute assessment of microvascular perfusion patterns by myocardial contrast echocardiography during myocardial infarction: relation to timing and extent of functional recovery. <i>Heart</i> , 1999 , 81, 12-6	5.1	31
1305	Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. 1999 , 341, 625-34		1960
1304	Myocardial contrast echocardiography in acute myocardial infarction: time to test for routine clinical use?. <i>Heart</i> , 1999 , 81, 2-5	5.1	8

1303	Recombinant soluble form of PSGL-1 accelerates thrombolysis and prevents reocclusion in a porcine model. <i>Circulation</i> , 1999 , 99, 1363-9	16.7	112
1302	Reteplase, a recombinant plasminogen activator. 1999 , 185-216		1
1301	Eptifibatide: a potent inhibitor of the platelet receptor integrin, glycoprotein IIb/IIIa. 1999 , 8, 1893-1905		9
1300	Alpha-adrenergic blockade improves recovery of myocardial perfusion and function after coronary stenting in patients with acute myocardial infarction. <i>Circulation</i> , 1999 , 99, 482-90	16.7	154
1299	Angiographic frame counts 90 minutes after streptokinase predict left ventricular function at 48 hours following myocardial infarction. <i>Heart</i> , 1999 , 81, 128-133	5.1	21
1298	Biochemical markers of cardiac damage: From traditional enzymes to cardiac-specific proteins. 1999 , 59, 74-82		21
1297	First clinical experience with the R Stent: a new highly flexible stainless steel tube intracoronary stent. 1999 , 2, 163-169		2
1296	Streptokinase antibodies inhibit reperfusion during thrombolytic therapy with streptokinase in acute myocardial infarction. 1999 , 245, 483-8		15
1295	Development and Pathophysiological Basis of Thrombolytic Therapy in Acute Myocardial Infarction: Part IV. 1999 , 12, 3-12		
1294	Volumetric Deformation Analysis Using Mechanics-Based Data Fusion: Applications in Cardiac Motion Recovery. 1999 , 35, 87-107		41
1293	Early detection of the no-reflow phenomenon in reperfused acute myocardial infarction using technetium-99m tetrofosmin imaging. 1999 , 26, 208-14		27
1292	Emergent right coronary artery thrombectomy with a jet aspiration thrombectomy catheter. 1999 , 22, 340-2		4
1291	[The experimental investigation on the preventive effects of API0134 against the re-occlusion of coronary arteries after therapeutic thrombolysis in dogs]. 1999 , 19, 108-11		
1290	Analysis of number needed to treat and cost of platelet glycoprotein IIb/IIIa inhibitors in percutaneous coronary interventions and acute coronary syndromes. 1999 , 19, 1086-93		5
1289	Early infarct artery collateral flow does not improve long-term survival following thrombolytic therapy for acute myocardial infarction. 1999 , 83, 21-6		38
1288	Usefulness of the presenting electrocardiogram in predicting successful reperfusion with streptokinase in acute myocardial infarction. 1999 , 83, 164-8		38
1287	A matched comparison of the combination of prehospital thrombolysis and standby rescue angioplasty with primary angioplasty. 1999 , 83, 305-10		35
1286	Support for the open-artery hypothesis in survivors of acute myocardial infarction: analysis of 11,228 patients treated with thrombolytic therapy. 1999 , 83, 482-7		51

1285	Predictors of long-term outcome after stent implantation in a saphenous vein graft. 1999 , 83, 681-6	33
1284	Robert Roberts, MD: a conversation with the editor. Interview by William Clifford Roberts. 1999 , 83, 1458-75	
1283	Effectiveness of early coronary angioplasty and abciximab for failed thrombolysis (reteplase or alteplase) during acute myocardial infarction (results from the GUSTO-III trial). Global Use of Strategies To Open occluded coronary arteries. 1999 , 84, 779-84	64
1282	Local intramural heparin delivery during primary angioplasty for acute myocardial infarction: results of the Local PAMI Pilot Study. 1999 , 47, 237-42	17
1281	Activation of coagulation factor VII by tissue-type plasminogen activator. 1999 , 61, 34-9	8
1280	Pharmacokinetics of the recombinant thrombolytic agents: what is the clinical significance of their different pharmacokinetic parameters?. 1999 , 11, 115-23	14
1279	The therapeutic use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. 1999 , 8, 555-66	5
1278	Clinical risk factors for ischemic complications after percutaneous coronary interventions: results from the EPIC trial. The EPIC Investigators. 1999 , 137, 264-73	17
1277	Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies: a health system perspective on thrombolytic therapy for acute myocardial infarction. 1999 , 137, S94-6	
1276	Efficacy of intraarterial thrombolysis of basilar artery stroke. 1999 , 8, 22-7	18
1275	Relationship between late infarct artery patency and outcome in the reperfusion era: is there a role for percutaneous revascularisation?. 1999 , 68 Suppl 1, S15-22	
1274	Interventional therapy is the best approach for acute coronary syndromes. 1999 , 68 Suppl 1, S73-8	
1273	The current role of thrombolytic therapy in the treatment of acute myocardial infarction. 1999 , 13, 78-90	4
1272	Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. 1999 , 354, 716-22	629
1271	Intravenous nicorandil can preserve microvascular integrity and myocardial viability in patients with reperfused anterior wall myocardial infarction. 1999 , 33, 654-60	313
1270	Low molecular weight heparin (dalteparin) as adjuvant treatment of thrombolysis in acute myocardial infarction--a pilot study: biochemical markers in acute coronary syndromes (BIOMACS II). 1999 , 33, 627-33	85
1269	Long-term outcome after primary angioplasty: report from the primary angioplasty in myocardial infarction (PAMI-I) trial. 1999 , 33, 640-6	108
1268	[The prognostic factors after an acute myocardial infarct treated with fibrinolytics]. 1999 , 52, 95-102	0

1267	Abciximab in the treatment of acute myocardial infarction eligible for primary percutaneous transluminal coronary angioplasty. Results of the Glycoprotein Receptor Antagonist Patency Evaluation (GRAPE) pilot study. 1999 , 33, 1528-32	104
1266	Survival 12 years after randomization to streptokinase: the influence of thrombolysis in myocardial infarction flow at three to four weeks. 1999 , 34, 62-9	29
1265	The language of lysis: a proposal to standardize the nomenclature. 1999 , 34, 1226-7	6
1264	A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction: the PACT trial. PACT investigators. Plasminogen-activator Angioplasty Compatibility Trial. 1999 , 34, 1954-62	289
1263	Combination therapy for acute myocardial infarction. 1999 , 34, 1963-5	8
1262	Combined intravenous and intra-arterial r-TPA versus intra-arterial therapy of acute ischemic stroke: Emergency Management of Stroke (EMS) Bridging Trial. 1999 , 30, 2598-605	563
1261	Systematic primary angioplasty in octogenarian and older patients. 1999 , 138, 670-4	30
1260	Infarct size: thrombolysis versus PTCA. 1999 , 137, 1007-9	2
1259	Limitation of myocardial infarct size after primary angioplasty: is a higher patency the only mechanism?. 1999 , 137, 1169-72	13
1258	Elevated cardiac troponin I predicts a high-risk angiographic anatomy of the culprit lesion in unstable angina. 1999 , 137, 815-20	76
1257	Timely thrombolysis: synergism to open arteries and reduce mortality rates. 1999 , 137, 1-3	68
1256	Death and nonfatal reinfarction within the first 24 hours after presentation with an acute coronary syndrome: experience from GUSTO-IIb. Global Utilization of Strategies for Total Occlusion. 1999 , 137, 12-23	11
1255	Influence of time to treatment on early infarct-related artery patency after different thrombolytic regimens. ALKK-Study Group. 1999 , 137, 34-8	50
1254	Trends in the use of pharmacotherapies for acute myocardial infarction among physicians who design and/or implement randomized trials versus physicians in routine clinical practice: the MILIS-TIMI experience. Multicenter Investigation on Limitation of Infarct Size. Thrombolysis in Myocardial Infarction. 1999 , 137, 79-92	38
1253	Analysis of the treatment of acute myocardial infarction using ambulance records in Japanese cities. 1999 , 63, 170-6	5
1252	Development and evaluation of a new canine myocardial infarction model using a closed-chest injection of thrombogenic material. 1999 , 63, 900-5	20
1251	Percutaneous transluminal coronary angioplasty, alone or in combination with urokinase therapy, during acute myocardial infarction. 1999 , 63, 91-6	4
1250	Visual outcome after treatment with low-dose recombinant tissue plasminogen activator or hemodilution in ischemic central retinal vein occlusion. 1999 , 213, 360-6	33

1249	Medical treatment for acute coronary syndromes. 2000 , 15, 441-62	8
1248	Debate: Should the elderly receive thrombolytic therapy, or primary angioplasty, for acute myocardial infarction? The case for primary angioplasty. 2000 , 1, 146-149	1
1247	Debate: Should the elderly receive thrombolytic therapy or primary angioplasty?. 2000 , 1, 150-154	5
1246	Ventricular Late Potentials and Degree of Reperfusion of the Infarct-Related Artery. 2000 , 5, 229-233	
1245	ST-segment elevation in leads I and aVL predicts short-term prognosis in acute anterior wall myocardial infarction. 2000 , 85, 101-4, A8	7
1244	Frequency of collateral blood flow in the infarct-related coronary artery in rupture of the ventricular septum after acute myocardial infarction. 2000 , 85, 497-9, A10	41
1243	Microvascular dysfunction in acute myocardial infarction: focus on the roles of platelet and inflammatory mediators in the no-reflow phenomenon. 2000 , 85, 50B-60B	90
1242	Angiographic and clinical characteristics associated with increased in-hospital mortality in elderly patients with acute myocardial infarction undergoing percutaneous intervention (a pooled analysis of the primary angioplasty in myocardial infarction trials). 2000 , 86, 30-4	118
1241	Effectiveness of rotational atherectomy in narrowed left internal mammary artery grafts to the left anterior descending coronary artery. 2000 , 86, 86-8	6
1240	Effectiveness of rotational atherectomy in aortocoronary saphenous vein grafts. 2000 , 86, 88-91	8
1239	Polytetrafluoroethylene-covered stent for the treatment of narrowings in aortocoronary saphenous vein grafts. 2000 , 86, 343-6	34
1238	Inhibition of platelet aggregation with a glycoprotein IIb/IIIa antagonist does not prevent thrombin generation in patients undergoing thrombolysis for acute myocardial infarction. <i>Journal of Thrombosis and Thrombolysis</i> , 2000 , 9, 5-12	5.1 13
1237	Antiplatelet therapy in interventional cardiology: II. Glycoprotein IIb/IIIa inhibitors. <i>Journal of Thrombosis and Thrombolysis</i> , 2000 , 9, 163-74	5.1 2
1236	Effects of early captopril therapy after myocardial infarction on the incidence of late potentials. 2000 , 23, 96-102	5
1235	Severity of residual stenosis of infarct-related lesion and left ventricular function after single-vessel anterior wall myocardial infarction: implication of ST-segment elevation in lead aVL of the admission electrocardiograms. 2000 , 23, 175-80	6
1234	Sudden onset of EDTA-dependent pseudothrombocytopenia after therapy with the glycoprotein IIb/IIIa antagonist c7E3 Fab. 2000 , 79, 161-4	16
1233	Streptokinase-induced platelet activation involves antistreptokinase antibodies and cleavage of protease-activated receptor-1. 2000 , 95, 1301-1308	20
1232	A role of angiotensin-converting enzyme gene polymorphism in left ventricular remodeling after myocardial infarction. 2000 , 67, 96-104	4

1231	Early reperfusion assessment and repeated thrombolysis in acute myocardial infarction estimated by repeated standard electrocardiography. A randomised, double-blind, placebo-controlled pilot study. 2000 , 94, 58-65		6
1230	Improvement of Principles of Nature: t-PA. 2000 , 157-202		
1229	. 2000 ,		
1228	Relationship of infarct artery patency and left ventricular ejection fraction to health-related quality of life after myocardial infarction: the GUSTO-I Angiographic Study experience. <i>Circulation</i> , 2000 , 102, 1245-51	16.7	27
1227	ST-Segment recovery adds to the assessment of TIMI 2 and 3 flow in predicting infarct wall motion after thrombolytic therapy. <i>Circulation</i> , 2000 , 101, 2138-43	16.7	57
1226	Optimizing percutaneous coronary revascularization in diabetic women: analysis from the EPISTENT trial. 2000 , 9, 741-6		12
1225	Relation of phasic coronary flow velocity characteristics with TIMI perfusion grade and myocardial recovery after primary percutaneous transluminal coronary angioplasty and rescue stenting. <i>Circulation</i> , 2000 , 101, 2361-7	16.7	82
1224	Acute interventions for ischemic stroke: present status and future directions. 2000 , 7, 423-8		25
1223	Cardiogenic shock: a more aggressive approach is now warranted. 2000 , 21, 1897-901		7
1222	Combination reperfusion therapy with abciximab and reduced dose reteplase: results from TIMI 14. The Thrombolysis in Myocardial Infarction (TIMI) 14 Investigators. 2000 , 21, 1944-53		68
1221	New Q waves on the presenting electrocardiogram independently predict increased cardiac mortality following a first ST-elevation myocardial infarction. 2000 , 21, 647-53		20
1220	Patient comprehension and reaction to participating in a double-blind randomized clinical trial (ISIS-4) in acute myocardial infarction. 2000 , 160, 1142-6		63
1219	Low rates of clinical restenosis with the new flexible stainless steel tube intracoronary stent: the R Stent. A six-month safety and feasibility study. 2000 , 3, 91-95		2
1218	Enhanced efficacy of eptifibatide administration in patients with acute coronary syndrome requiring in-hospital coronary artery bypass grafting. PURSUIT Investigators. <i>Circulation</i> , 2000 , 102, 2952-8	16.7	51
1217	Basic principles of angiogenesis for the interventional cardiologist. 2000 , 3, 13-19		
1216	Glycoprotein IIb/IIIa receptor blockade improves outcomes in diabetic patients presenting with unstable angina/non-ST-elevation myocardial infarction: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) study. <i>Circulation</i> , 2000 , 102, 2466-72	16.7	63
1215	Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Strategies for Patency Enhancement in the Emergency Department (SPEED) Group. <i>Circulation</i> , 2000 , 101, 2788-94	16.7	228
1214	Antiarrhythmic efficacy of dipyridamole in treatment of reperfusion arrhythmias: evidence for cAMP-mediated triggered activity as a mechanism responsible for reperfusion arrhythmias. <i>Circulation</i> , 2000 , 101, 624-30	16.7	37

1213	Elevated troponin I level on admission is associated with adverse outcome of primary angioplasty in acute myocardial infarction. <i>Circulation</i> , 2000 , 102, 1611-6	16.7	72
1212	Reduced thrombus burden with abciximab delivered locally before percutaneous intervention in saphenous vein grafts. 2000 , 139, 824-9		42
1211	A comparison of electrocardiographic changes during reperfusion of acute myocardial infarction by thrombolysis or percutaneous transluminal coronary angioplasty. 2000 , 139, 430-6		43
1210	Primary percutaneous intervention in octogenarians with acute myocardial infarction: the treatment of choice. 2000 , 108, 257-8		1
1209	Non-invasive coronary bypass graft imaging after multivessel revascularisation. 2000 , 76, 65-74		47
1208	Prehospital delay with myocardial infarction: the interactive effect of clinical symptoms and race. 2000 , 13, 125-33		25
1207	Design and methodology of the ESPRIT trial: evaluating a novel dosing regimen of eptifibatide in percutaneous coronary intervention. 2000 , 140, 834-9		29
1206	Long-term effects of bisoprolol compared with imidapril on left ventricular remodeling after reperfusion in acute myocardial infarction: an angiographic study in patients with maintained vessel patency. 2000 , 140, E27		7
1205	Point-tracked quantitative analysis of left ventricular surface motion from 3-D image sequences. 2000 , 19, 36-50		74
1204	Relationship between corrected TIMI frame counts at three weeks and late survival after myocardial infarction. 2000 , 35, 1516-24		27
1203	Clinical benefit of glycoprotein IIb/IIIa blockade with Abciximab is independent of gender: pooled analysis from EPIC, EPILOG and EPISTENT trials. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation in Percutaneous Transluminal Coronary Angioplasty to Improve		115
1202	Long-Term Outcome with Abciximab, GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Cardiopulmonary cerebral resuscitation using emergency cardiopulmonary bypass, coronary reperfusion therapy and mild hypothermia in patients with cardiac arrest outside the hospital. 2000 , 36, 776-83		239
1201	Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction: results from the SPEED (GUSTO-4 Pilot) Trial. 2000 , 36, 1489-96		140
1200	Out-of-hospital ventricular fibrillation in patients with acute myocardial infarction: coronary angiographic determinants. 2000 , 35, 144-50		49
1199	Increased leukocyte activity as a predictor for flow-limiting coronary lesions in patients with angina pectoris. 2001 , 158, 477-81		4
1198	Therapeutic value of eptifibatide at community hospitals transferring patients to tertiary referral centers early after admission for acute coronary syndromes. PURSUIT Investigators. 2001 , 37, 492-8		27
1197	New diagnostic criteria for diabetes and coronary artery disease: insights from an angiographic study. 2001 , 37, 1543-50		136
1196	TIMI frame count immediately after primary coronary angioplasty as a predictor of functional recovery in patients with TIMI 3 reperfused acute myocardial infarction. 2001 , 38, 666-71		84

1195	Pressure-derived collateral flow index as a parameter of microvascular dysfunction in acute myocardial infarction. 2001 , 38, 1383-9	42
1194	Accuracy of technetium-99m tetrofosmin myocardial perfusion imaging in the detection of spontaneous recanalization in patients with acute anterior myocardial infarction. 2001 , 28, 327-33	5
1193	New heparin dosing recommendations for patients with acute coronary syndromes. 2001 , 110, 641-50	25
1192	Transcardiac 8-iso-prostaglandin F(2 alpha) generation from acute myocardial infarction heart: insight into abrupt reperfusion and oxidant stress. 2001 , 64, 161-6	17
1191	Effect of the stenosis location and severity on left ventricular function after single-vessel anterior wall myocardial infarction. 2001 , 141, 55-64	4
1190	A nonischemic electrocardiogram does not always predict a small myocardial infarction: results with acute myocardial perfusion imaging. 2001 , 141, 360-6	23
1189	Corrected TIMI frame counts correlate with stenosis severity and infarct zone wall motion after thrombolytic therapy. 2001 , 141, 586-91	9
1188	Effect of smoking status and abciximab use on outcome after percutaneous coronary revascularization: Pooled analysis from EPIC, EPILOG, and EPISTENT. 2001 , 141, 599-602	9
1187	Predictors of left ventricular function after acute myocardial infarction: effects of time to treatment, patency, and body mass index: the GUSTO-I angiographic experience. 2001 , 142, 43-50	14
1186	Predictors of improvement in left ventricular function after percutaneous revascularization of occluded coronary arteries: a report from the Total Occlusion Study of Canada (TOSCA). 2001 , 142, 301-8	56
1185	A randomized trial confirming the efficacy of reduced dose recombinant tissue plasminogen activator in a Chinese myocardial infarction population and demonstrating superiority to usual dose urokinase: the TUCC trial. 2001 , 142, 244-7	34
1184	Decade-long trends (1986 to 1997) in the medical treatment of patients with acute myocardial infarction: A community-wide perspective. 2001 , 142, 594-603	54
1183	Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. 2001 , 358, 1855-63	269
1182	[Elective primary angioplasty in cardiogenic shock: results from a single center]. 2001 , 54, 1048-54	1
1181	Prognosis of acute myocardial infarction in the thrombolytic era: medical evaluation is still valuable. 2001 , 3, 569-76	5
1180	Comparison of eptifibatide and abciximab with decision analysis. 2001 , 58, 1432-6	9
1179	Dependency on Infarct Size Limits the Clinical Applicability of Non-Invasive Reperfusion Assessment by Biochemical Markers in Acute Myocardial Infarction. 2001 , 1, 197-206	1
1178	Long-term clinical outcome of rescue balloon angioplasty compared with rescue stenting after failed thrombolysis. 2001 , 3, 217-20	1

1177	Possible reasons for the prognostic value of troponin-T on admission in patients with ST-elevation myocardial infarction. 2001 , 12, 227-37	9
1176	Clinical significance of coronary flow to the infarct zone before successful primary percutaneous transluminal coronary angioplasty in acute myocardial infarction. 2001 , 120, 1959-63	7
1175	Correlates of bundle-branch block in patients undergoing primary angioplasty for acute myocardial infarction. 2001 , 24, 770-4	2
1174	Thrombolytic therapy: 2001. 2001 , 15, 143-57	27
1173	Upstream use of tirofiban in patients admitted for an acute coronary syndrome in hospitals with or without facilities for invasive management. PRISM-PLUS Investigators. 2001 , 87, 375-80	19
1172	Results and significance of Holter monitoring after direct percutaneous transluminal coronary angioplasty for acute myocardial infarction. 2001 , 87, 466-9, A7	3
1171	Predictors and prognosis of suboptimal coronary blood flow after primary coronary angioplasty in patients with acute myocardial infarction. 2001 , 88, 124-8	69
1170	Usefulness of the rescue PT catheter to remove fresh thrombus from coronary arteries and bypass grafts in acute myocardial infarction. 2001 , 88, 306-8	27
1169	Relation of pathologic Q waves at presentation and time to streptokinase therapy with early changes in infarct-related artery flow and ventricular wall motion. 2001 , 88, 558-61	8
1168	Importance of time to reperfusion on outcomes with primary coronary angioplasty for acute myocardial infarction (results from the Stent Primary Angioplasty in Myocardial Infarction Trial). 2001 , 88, 1085-90	110
1167	Predictors of long-term outcomes following direct percutaneous coronary intervention for acute myocardial infarction. 2001 , 88, 1103-7	17
1166	Interventions in acute myocardial infarction. 2001 , 26, 619-72	3
1165	Blood transfusion in elderly patients with acute myocardial infarction. 2001 , 345, 1230-6	813
1164	A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE study. 2001 , 22, 1716-24	121
1163	Outcome after combined reperfusion therapy for acute myocardial infarction, combining pre-hospital thrombolysis with immediate percutaneous coronary intervention and stent. 2001 , 22, 1128-35	21
1162	The impact of high pressure vs low pressure stent implantation on intimal hyperplasia and follow-up lumen dimensions; results of a randomized trial. 2001 , 22, 2015-24	15
1161	Intravenous thrombolysis in acute myocardial infarction. 2001 , 119, 253S-277S	49
1160	Platelet glycoprotein IIb/IIIa receptor inhibition in primary angioplasty for acute myocardial infarction: The new paradigm of direct revascularization. 2001 , 4, 7-14	

1159	Pharmacodynamics and safety of lefradafiban, an oral platelet glycoprotein IIb/IIIa receptor antagonist, in patients with stable coronary artery disease undergoing elective angioplasty. 2001 , 85, 444-50		5
1158	Arterial thrombus dissolution in vivo using a transducer-tipped, high-frequency ultrasound catheter and local low-dose urokinase delivery. 2001 , 8, 282-90		24
1157	Quantitative assessment of the ischemic brain by means of perfusion-related parameters derived from perfusion CT. 2001 , 32, 431-7		208
1156	New aspects of pharmacological reperfusion: from macro- to microlysis. 2001 , 3, C62-C68		
1155	Benefits and safety of tirofiban among acute coronary syndrome patients with mild to moderate renal insufficiency: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial. <i>Circulation</i> , 2002 , 105, 2361-6	16.7	81
1154	Time Is Muscle—Only in Experienced Hands and High-Volume Centers. 2002 , 17, 199-201		
1153	Facilitated thrombolysis: dethrombosis?. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2002 , 8, 133-8	3.3	2
1152	Determinants of improvement in epicardial flow and myocardial perfusion for ST elevation myocardial infarction; insights from TIMI 14 and InTIME-II. 2002 , 23, 928-33		26
1151	C-reactive protein levels on admission are associated with response to thrombolysis and prognosis after ST-segment elevation acute myocardial infarction. 2002 , 144, 782-9		49
1150	Usefulness of the presenting electrocardiogram in predicting myocardial salvage with thrombolytic therapy in patients with a first acute myocardial infarction. 2002 , 23, 399-404		20
1149	New-device angioplasty in women: outcomes of planned and unplanned use. 2002 , 13 Suppl 3, S40-5		0
1148	Slowed ST segment recovery despite early infarct artery patency in patients with Q waves at presentation with a first acute myocardial infarction. Implications of initial Q waves on myocyte reperfusion. 2002 , 23, 1449-55		19
1147	The coronary slow flow phenomenon—a new coronary microvascular disorder. 2002 , 97, 197-202		167
1146	Coronary flow velocity pattern immediately after percutaneous coronary intervention as a predictor of complications and in-hospital survival after acute myocardial infarction. <i>Circulation</i> , 2002 , 106, 3051-6	16.7	78
1145	Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial. <i>Circulation</i> , 2002 , 105, 1642-9	16.7	190
1144	Thrombolytic therapy. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2002 , 8, 291-314	3.3	9
1143	What's the point of ST elevation?. 2002 , 19, 126-8		18
1142	First experience with direct factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamic evaluation. <i>Circulation</i> , 2002 , 105, 2385-91	16.7	62

1141	Platelet glycoprotein IIb/IIIa inhibitors: overview and implications for the anesthesiologist. 2002 , 95, 879-88		5
1140	Continuous vectorcardiography is superior to standard electrocardiography in the prediction of long-term outcome after thrombolysis in patients with acute myocardial infarction. 2002 , 13, 169-75		5
1139	Platelet Glycoprotein IIb/IIIa Inhibitors: Overview and Implications for the Anesthesiologist. 2002 , 95, 879-888		19
1138	New grading system for angiographic evaluation of arterial occlusions and recanalization response to intra-arterial thrombolysis in acute ischemic stroke. 2002 , 50, 1405-14; discussion 1414-5		106
1137	The value of the TIMI frame count method in the diagnosis of coronary no-reflow: a comparison with myocardial perfusion SPECT in patients with acute myocardial infarction. 2002 , 23, 1205-10		11
1136	An early and complete reperfusion strategy for acute myocardial infarction using fibrinolysis and subsequent transluminal therapy--The FAST trial. <i>Circulation Journal</i> , 2002 , 66, 576-82	2.9	19
1135	New Grading System for Angiographic Evaluation of Arterial Occlusions and Recanalization Response to Intra-arterial Thrombolysis in Acute Ischemic Stroke. 2002 , 50, 1405-1415		75
1134	Eptifibatide and low-dose tissue plasminogen activator in acute myocardial infarction: the integrilin and low-dose thrombolysis in acute myocardial infarction (INTRO AMI) trial. 2002 , 39, 377-86		74
1133	Revisiting the culprit lesion in non-Q-wave myocardial infarction. Results from the VANQWISH trial angiographic core laboratory. 2002 , 39, 1456-63		104
1132	Angiographic plaque complexity: the tip of the unstable plaque iceberg. 2002 , 39, 1464-7		21
1131	A randomized trial of transfer for primary angioplasty versus on-site thrombolysis in patients with high-risk myocardial infarction: the Air Primary Angioplasty in Myocardial Infarction study. 2002 , 39, 1713-9		281
1130	Reperfusion therapy in elderly patients with acute myocardial infarction: a randomized comparison of primary angioplasty and thrombolytic therapy. 2002 , 39, 1723-8		203
1129	Late intervention after anterior myocardial infarction: effects on left ventricular size, function, quality of life, and exercise tolerance: results of the Open Artery Trial (TOAT Study). 2002 , 40, 869-76		101
1128	Coronary recanalization in anterior myocardial infarction: the open perforator hypothesis. 2002 , 40, 1205-13		32
1127	Bivalirudin: an anticoagulant for acute coronary syndromes and coronary interventions. 2002 , 3, 777-88		12
1126	Early ST-segment recovery, infarct artery blood flow, and long-term outcome after acute myocardial infarction. 2002 , 143, 265-71		29
1125	How long is too long? Association of time delay to successful reperfusion and ventricular function outcome in acute myocardial infarction: the case for thrombolytic therapy before planned angioplasty for acute myocardial infarction. 2002 , 144, 456-62		22
1124	The reperfusion era. Strategies for establishing or maintaining coronary patency. <i>Cardiology Clinics</i> , 2002 , 20, 137-57, ix	2.5	1

1123	[Prognostic value of persistent ST-segment elevation after successful primary angioplasty]. 2002 , 55, 816-22	9
1122	The electrocardiographs signs of reperfusion. 2002 , 99-115	
1121	Gender differences in clinical outcome after coronary artery stenting with use of glycoprotein IIb/IIIa inhibitors. 2002 , 89, 976-9	24
1120	Effect of treatment delay on outcomes in patients with acute myocardial infarction transferred from community hospitals for primary percutaneous coronary intervention. 2002 , 89, 1243-7	25
1119	Relation of initial platelet counts to Thrombolysis In Myocardial Infarction-3 flow rates at 90 minutes after commencing fibrinolytic therapy in patients with acute myocardial infarction. 2002 , 90, 54-7	14
1118	Comparison of short- and long-term benefits of reperfusion in single-vessel inferior wall acute myocardial infarction with and without right ventricular wall infarction. 2002 , 90, 144-7	7
1117	Prevalence of coronary occlusion and outcome of an immediate invasive strategy in suspected acute myocardial infarction with and without ST-segment elevation. 2002 , 90, 579-84	39
1116	A case of acute myocardial infarction treated with a new thrombectomy system. 2002 , 55, 239-43	5
1115	Safety of coronary stenting early after thrombolysis in patients with acute myocardial infarction: one- and six-month clinical and angiographic evolution. 2002 , 55, 467-76	4
1114	Percutaneous reperfusion of left main coronary disease complicated by acute myocardial infarction. 2002 , 56, 31-4	28
1113	Relation of troponin T release kinetics to long-term clinical outcome in patients with acute ST segment elevation myocardial infarction treated with a percutaneous intervention. 2002 , 56, 312-9	2
1112	Export aspiration catheter thrombosuction before actual angioplasty in primary coronary intervention for acute myocardial infarction. 2002 , 57, 332-9	36
1111	Effects of microvascular dysfunction on myocardial fractional flow reserve after percutaneous coronary intervention in patients with acute myocardial infarction. 2002 , 57, 452-9	57
1110	Early prediction of regional functional recovery in reperfused myocardium using single-injection resting quantitative electrocardiographic gated SPET. 2002 , 29, 458-64	9
1109	The multicenter research group. 2002 , 7, 271-7	2
1108	Limitation of infarct size and ventricular remodeling in patients with completely reperfused anterior acute myocardial infarction--the potential role of ischemia time. 2002 , 25, 566-71	1
1107	Pharmacologic reperfusion therapy for acute myocardial infarction. <i>Journal of Thrombosis and Thrombolysis</i> , 2002 , 14, 179-96	5.1 9
1106	QT-interval dispersion in acute myocardial infarction is only shortened by thrombolysis in myocardial infarction grade 2/3 reperfusion. 2003 , 26, 291-5	15

1105	Effects of glycoprotein IIb/IIIa inhibition on clinical stabilization parameters in patients with unstable angina and non-Q-wave myocardial infarction. 2003 , 18, 117-22	2
1104	Comparison of effect of glycoprotein IIb/IIIa inhibitors during percutaneous coronary interventions on risk of hemorrhagic stroke in patients ≥ 75 years of age versus those . 2003 , 92, 1083-6	5
1103	Relation of mortality of primary angioplasty during acute myocardial infarction to door-to-Thrombolysis In Myocardial Infarction (TIMI) time. 2003 , 91, 1401-5	45
1102	The long-term clinical outcomes after rescue percutaneous coronary intervention in patients with acute myocardial infarction. 2003 , 16, 209-16	14
1101	Residual Flow Signals Predict Complete Recanalization in Stroke Patients Treated With TPA. 2003 , 13, 28-33	52
1100	Thrombolytic therapy: clinical applications. 2003 , 17, 283-311	17
1099	Short- and long-term oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention. 2003 , 41, 79S-88S	70
1098	Detection of myocardial viability by contrast echocardiography in acute infarction predicts recovery of resting function and contractile reserve. 2003 , 41, 827-33	86
1097	Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction: results of the integrilin and tenecteplase in acute myocardial infarction (INTEGRITI) Phase II Angiographic Trial. 2003 , 41, 1251-60	80
1096	Coronary hemodynamic and metabolic studies of the coronary slow flow phenomenon. 2003 , 146, 84-90	121
1095	Effect of platelet glycoprotein IIb/IIIa receptor blockade with tirofiban on adverse cardiac events in women with unstable angina/non-ST-elevation myocardial infarction (PRISM-PLUS Study). 2003 , 146, 668-73	8
1094	Collaborative Angiographic Patency Trial Of Recombinant Staphylokinase (CAPTORS II). 2003 , 146, 484-8	21
1093	Current perspectives on reperfusion therapy for acute ST-segment elevation myocardial infarction: integrating pharmacologic and mechanical reperfusion strategies. 2003 , 146, 958-68	19
1092	Noninvasive transcutaneous ultrasound augments thrombolysis in the left circumflex coronary artery--an in vivo canine study. 2003 , 110, 149-58	11
1091	C-reactive protein on admission and the success of thrombolytic therapy with streptokinase: is there any relation?. 2003 , 92, 27-33	7
1090	A score predicts failure of reperfusion after fibrinolytic therapy for acute myocardial infarction. 2003 , 145, 508-14	16
1089	Relationship between initial white blood cell counts, stage of acute myocardial infarction evolution at presentation, and incidence of Thrombolysis In Myocardial Infarction-3 flow after streptokinase. 2003 , 145, 95-102	27
1088	Importance of time-to-reperfusion in patients with acute myocardial infarction with and without cardiogenic shock treated with primary percutaneous coronary intervention. 2003 , 145, 708-15	78

1087	Clinical potential of intra-arterial thrombolytic therapy in patients with acute ischaemic stroke. 2003 , 17, 213-24		5
1086	Primary stenting produces earlier and more efficient myocardial reperfusion than primary PTCA alone in patients with acute ST segment elevation MI. 2003 , 54, 195-203		
1085	Therapy-dependent influence of time-to-treatment interval on myocardial salvage in patients with acute myocardial infarction treated with coronary artery stenting or thrombolysis. <i>Circulation</i> , 2003 , 108, 1084-8	16.7	110
1084	Thrombolytics: prospects for new agents. 2003 , 4, 41-54		
1083	Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: data from the CAPTIM randomized clinical trial. <i>Circulation</i> , 2003 , 108, 2851-6	16.7	390
1082	Coronary flow velocity analysis during short term follow up after coronary reperfusion: use of transthoracic Doppler echocardiography to predict regional wall motion recovery in patients with acute myocardial infarction. 2003 , 89, 1163-8		30
1081	Comparative efficacy of thrombolytics in acute myocardial infarction: a systematic review. 2003 , 96, 103-13		47
1080	[Percutaneous carotid angioplasty with stent implantation and protection device against embolism--a prospective study of 100 consecutive cases]. 2003 , 128, 790-6		16
1079	Spontaneous intracerebral hemorrhage due to coagulation disorders. 2003 , 15, E3		81
1078	Intravenous nicorandil in conjunction with coronary reperfusion therapy is associated with better clinical and functional outcomes in patients with acute myocardial infarction. <i>Circulation Journal</i> , 2003 , 67, 295-300	2.9	58
1077	Predictors of adverse long-term outcome in acute myocardial infarction patients undergoing primary percutaneous transluminal coronary angioplasty: with special reference to the admission concentration of lipoprotein (a). <i>Circulation Journal</i> , 2003 , 67, 605-11	2.9	13
1076	Administration of atrial natriuretic peptide attenuates reperfusion phenomena and preserves left ventricular regional wall motion after direct coronary angioplasty for acute myocardial infarction. <i>Circulation Journal</i> , 2003 , 67, 443-8	2.9	50
1075	Prediction of no-reflow phenomenon after successful percutaneous coronary intervention in patients with acute myocardial infarction: intravascular ultrasound findings. <i>Circulation Journal</i> , 2003 , 67, 667-71	2.9	41
1074	Effectiveness of thrombectomy before stent implantation in acute myocardial infarction. <i>Circulation Journal</i> , 2003 , 67, 951-4	2.9	10
1073	Relationship between collateral blood flow and microvascular perfusion after reperfused acute myocardial infarction. 2003 , 44, 855-63		8
1072	Recommended and actual lepirudin doses in patients with renal insufficiency. 2003 , 60, 2588-93		2
1071	The safety and feasibility of transradial cutting balloon angioplasty: immediate results, benefits, and limitations. 2003 , 44, 51-60		6
1070	Coronary Artery Flow Velocity Pattern Predicting Myocardial Recovery after Acute Anterior Myocardial Infarction. 2003 , 33, 259		3

1069	Enhancement of endogenous fibrinolysis does not reduce local fibrin deposition, but modulates inflammation upon intestinal ischemia and reperfusion. 2004 , 91, 497-505		13
1068	Relation between serum lipoprotein (a) and residual lesion stenosis of coronary artery after myocardial Infarction without reperfusion therapy. 2004 , 45, 397-407		7
1067	Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. 2004 , 292, 1555-62		725
1066	Evidence for "lumen sealing" with sirolimus eluting stents in the treatment of complex coronary artery dissection. <i>Heart</i> , 2004 , 90, e13	5.1	2
1065	Lack of association between baseline plasma homocysteine concentrations and restenosis rates after a first elective percutaneous coronary intervention without stenting. <i>Heart</i> , 2004 , 90, 1299-302	5.1	6
1064	Combined membrane covered and uncovered stents for coronary arteriovenous fistula associated with atherosclerotic plaque in a patient with acute myocardial infarction. 2004 , 90, 150		8
1063	Role of collateral circulation in the acute phase of ST-segment-elevation myocardial infarction treated with primary coronary intervention. 2004 , 25, 854-8		88
1062	New support for clarifying the relation between ST segment resolution and microvascular function: degree of ST segment resolution correlates with the pressure derived collateral flow index. 2004 , 90, 146-50		16
1061	The predictive value of cumulative lactate dehydrogenase release within the first 72 h of acute myocardial infarction in patients treated with primary angioplasty. 2004 , 41, 142-8		11
1060	ST-depression with negative T waves in leads V4-V5--a marker of severe coronary artery disease in non-ST elevation acute coronary syndrome: a prospective study of Angina at rest, with troponin, clinical, electrocardiographic, and angiographic correlation. 2004 , 9, 207-14		35
1059	Qureshi Grading Scheme for Angiographic Occlusions Strongly Correlates With the Initial Severity and In-Hospital Outcome of Acute Ischemic Stroke. 2004 , 14, 235-241		23
1058	Comparison of frequency of hemorrhagic stroke in patients or =75 years of age among patients receiving glycoprotein IIb/IIIa inhibitors during percutaneous coronary interventions. 2004 , 93, 346-9		5
1057	Tirofiban therapy for patients with acute coronary syndromes and prior coronary artery bypass grafting in the PRISM-PLUS trial. 2004 , 93, 843-7		22
1056	Quantitative myocardial contrast echocardiography for prediction of thrombolysis in myocardial infarction flow in acute myocardial infarction. 2004 , 93, 1212-7		9
1055	Combined assessment of thrombolysis in myocardial infarction flow grade, myocardial perfusion grade, and ST-segment resolution to evaluate epicardial and myocardial reperfusion. 2004 , 93, 1362-7, A5-6		36
1054	Relation of left ventricular sphericity to 10-year survival after acute myocardial infarction. 2004 , 94, 1270-5		61
1053	Myocardial salvage after reduced-dose thrombolysis combined with glycoprotein IIb/IIIa blockade versus thrombolysis alone in patients with acute myocardial infarction. <i>Journal of Thrombosis and Thrombolysis</i> , 2004 , 17, 191-7	5.1	2
1052	Tirofiban and eptifibatide treatment of patients presenting with acute coronary syndrome with non-ST segment elevation. 2004 , 26, 38-43		1

1051	Utilization of low-profile intra-aortic balloon catheters inserted by the sheathless technique in acute cardiac patients: clinical efficacy with a very low complication rate. 2004 , 27, 600-4	13
1050	Usefulness of predischarge exercise electrocardiographic testing in detecting the late patency status of the infarct-related artery. 2004 , 19, 111-5	1
1049	Acute Myocardial Infarction: Fibrinolytic Therapy. 2004 , 6, 15-28	2
1048	Evaluation of heart perfusion in patients with acute myocardial infarction using dynamic contrast-enhanced magnetic resonance imaging. 2004 , 20, 403-10	19
1047	Treatment of slow/no-reflow phenomenon with intracoronary nitroprusside injection in primary coronary intervention for acute myocardial infarction. 2004 , 63, 171-6	50
1046	Relationship of metabolic syndrome with quantum of coronary artery disease in Indian patients with chronic stable angina. 2004 , 2, 187-91	3
1045	Therapeutic use of intravenous eptifibatid in patients undergoing percutaneous coronary intervention: acute coronary syndromes and elective stenting. 2004 , 4, 31-41	9
1044	Adjunctive use of direct thrombin inhibitors in patients receiving fibrinolytic therapy for acute myocardial infarction. 2004 , 4, 107-15	3
1043	A randomized comparison of radial-artery and saphenous-vein coronary bypass grafts. 2004 , 351, 2302-9	406
1042	Real Time Myocardial Contrast Echocardiography to Predict Left Ventricular Wall Motion Recovery After Reperfused Acute Myocardial Infarction. 2004 , 57, 815-825	0
1041	Association of a pulsatile blood flow pattern on coronary arteriography and short-term clinical outcomes in acute myocardial infarction. 2004 , 43, 1170-6	6
1040	The angiographic and clinical benefits of mibefradil in the coronary slow flow phenomenon. 2004 , 44, 57-62	88
1039	Hemodynamic effects of inhaled nitric oxide in right ventricular myocardial infarction and cardiogenic shock. 2004 , 44, 793-8	76
1038	Association of duration of symptoms at presentation with angiographic and clinical outcomes after fibrinolytic therapy in patients with ST-segment elevation myocardial infarction. 2004 , 44, 980-7	38
1037	Achieved platelet aggregation inhibition after different antiplatelet regimens during percutaneous coronary intervention for ST-segment elevation myocardial infarction. 2004 , 44, 1187-93	80
1036	Ecocardiografía de perfusión miocárdica en tiempo real para la predicción de la recuperación de la función ventricular después del infarto agudo de miocardio reperfundido. 2004 , 57, 815-825	0
1035	Bleeding events with abciximab in acute coronary syndromes without early revascularization: An analysis of GUSTO IV-ACS. 2004 , 147, 865-73	35
1034	Bivalirudin versus heparin and protamine in off-pump coronary artery bypass surgery. 2004 , 77, 925-31; discussion 931	94

1033	Risk stratification and survival in post myocardial infarction patients: a large prospective and multicenter study in Japan. 2004 , 93, 263-8		11
1032	How Much do we Know about ST Elevation?: Case Report of a Patient with Acute Coronary Syndrome in the Observation Ward. 2004 , 11, 230-235		1
1031	Thrombolysis and adjunctive therapy in acute myocardial infarction: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. 2004 , 126, 549S-575S		72
1030	Medical and surgical management of central retinal vein occlusion. 2004 , 44, 1-16		12
1029	Do collaterals affect heart rate variability in patients with acute myocardial infarction?. 2004 , 15, 405-11		3
1028	Invasive Management of Patients With ST Elevation Myocardial Infarction With > 12-h Delay in Presentation. 2004 , 126, 2-4		2
1027	B-type natriuretic peptide as a marker of resuscitation in patients with cardiac arrest outside the hospital. <i>Circulation Journal</i> , 2004 , 68, 477-82	2.9	22
1026	Intracoronary verapamil rapidly terminates reperfusion tachyarrhythmias in acute myocardial infarction. 2004 , 126, 702-8		19
1025	Scintigraphic prediction of left ventricular functional recovery early after primary coronary angioplasty using single-injection quantitative electrocardiographic gated SPECT. 2005 , 26, 505-11		4
1024	Preinfarction Angina Limits Myocardial Infarction Size in Nondiabetic Patients Treated With Primary Coronary Angioplasty. 2005 , 127, 1116-1121		1
1023	Clinical implications of intermediate QRS prolongation in the absence of bundle-branch block in patients with ST-segment-elevation acute myocardial infarction. <i>Circulation Journal</i> , 2005 , 69, 29-34	2.9	14
1022	Comparison of the effects of a distal embolic protection device and an aspiration catheter during percutaneous coronary intervention in patients with acute myocardial infarction. <i>Circulation Journal</i> , 2005 , 69, 49-54	2.9	16
1021	Effect of reperfusion on P-wave duration and P-wave dispersion in acute myocardial infarction: primary angioplasty versus thrombolytic therapy. 2005 , 10, 35-40		23
1020	Safety of coronary stenting with eptifibatide and ultra-low-dose heparin. 2005 , 95, 630-2		6
1019	Follow-up of coronary artery bypass graft patency by multislice computed tomography. 2005 , 95, 1094-7		90
1018	Impact of failed mechanical reperfusion in patients with acute myocardial infarction treated with primary angioplasty. 2005 , 96, 332-4		6
1017	Effects of reperfusion obtained two to six months after acute myocardial infarction on myocardial electrical stabilization in patients with an occluded infarct-related coronary artery. 2005 , 96, 769-72		11
1016	Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. 2005 , 96, 1200-6		517

1015	The role of thrombolytic therapy in surgical practice. 1989 , 76, 298-304		18
1014	Prevention of distal embolization and no-reflow in patients with acute myocardial infarction and total occlusion in the infarct-related vessel: a subgroup analysis of the cohort of acute revascularization in myocardial infarction with excimer laser-CARMEL multicenter study. 2005 , 64, 67-74		23
1013	Plasma fibrinolysis inhibitor levels in acute stroke patients with thrombolysis failure. 2005 , 1, 142-7		13
1012	Acute Coronary Syndromes: Acute Myocardial Infarction and Ischemia. 2005 , 151-172		2
1011	Comparison of pre-hospital combination-fibrinolysis plus conventional care with pre-hospital combination-fibrinolysis plus facilitated percutaneous coronary intervention in acute myocardial infarction. 2005 , 26, 1956-63		69
1010	Late reopening of an occluded infarct related artery improves left ventricular function and long term clinical outcome. <i>Heart</i> , 2005 , 91, 646-51	5.1	24
1009	Images in cardiology: Inappropriate pacemaker therapy in congestive heart failure. <i>Heart</i> , 2005 , 91, 1140-1		
1008	Clopidogrel in non-ST segment elevation acute coronary syndromes: an overview of the submission by the British Cardiac Society and the Royal College of Physicians of London to the National Institute for Clinical Excellence, and beyond. <i>Heart</i> , 2005 , 91, 1135-40	5.1	6
1007	Compartment syndrome after thrombolysis for acute myocardial infarction. 2005 , 22, 77		10
1006	Differentiating pharmacologic agents used in catheter-directed thrombolysis. 2005 , 22, 121-9		6
1005	Association of hemoglobin levels with clinical outcomes in acute coronary syndromes. <i>Circulation</i> , 2005 , 111, 2042-9	16.7	487
1004	Postconditioning the human heart. <i>Circulation</i> , 2005 , 112, 2143-8	16.7	831
1003	Brugada syndrome precipitated by a tricyclic antidepressant. <i>Heart</i> , 2005 , 91, 651	5.1	23
1002	Thrombolytic therapy: current clinical practice. 2005 , 19, 147-81, vii		7
1001	Endovascular treatment of acute stroke. 2005 , 16, 433-44, xi		4
1000	Normal angiogram in acute coronary syndrome-preangiographic risk stratification, angiographic findings and follow-up. 2005 , 99, 19-23		34
999	Impact of vessel calcification on outcomes after coronary stenting. 2005 , 6, 147-53		85
998	Balancing the benefit and risk of oral antiplatelet agents in coronary artery bypass surgery. 2005 , 80, 768-79		54

997	Tenecteplase and tirofiban in ST-segment elevation acute myocardial infarction: results of a randomized trial. 2005 , 150, 79-88		8
996	Facilitated percutaneous coronary intervention for acute ST-segment elevation myocardial infarction: results from the prematurely terminated ADDRESSING the Value of facilitated ANgioplasty after Combination therapy or Eptifibatide monotherapy in acute Myocardial Infarction (ADVANCE MI) trial. 2005 , 150, 116-22		67
995	Left ventricular remodeling after primary coronary angioplasty in patients treated with abciximab or intracoronary adenosine. 2005 , 150, 1015		60
994	Improving the quality of coronary bypass surgery with intraoperative angiography: validation of a new technique. 2005 , 46, 1521-5		77
993	Clopidogrel use in coronary artery disease. 2006 , 4, 7-15		4
992	Clopidogrel in the treatment of ischaemic heart disease. 2006 , 7, 1109-20		3
991	Initial Q waves accompanying ST-segment elevation at presentation of acute myocardial infarction and 30-day mortality in patients given streptokinase therapy: an analysis from HERO-2. 2006 , 367, 2061-7		60
990	Coronary flow velocity pattern assessed noninvasively by transthoracic color Doppler echocardiography serves as a predictor of adverse cardiac events and left ventricular remodeling in patients with acute myocardial infarction. 2006 , 19, 335-40		13
989	Acute coronary syndromes. <i>Emergency Medicine Clinics of North America</i> , 2006 , 24, 53-89, vi	1.9	17
988	Effects of primary angioplasty for acute myocardial infarction on early and late infarct size and left ventricular wall characteristics. 2006 , 47, 40-4		148
987	A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes. 2006 , 47, 809-16		254
986	Thoracic spinal cord ischemia following acute myocardial infarction and cardiac arrest in a young male. <i>Heart Lung and Circulation</i> , 2006 , 15, 53-5	1.8	4
985	Successful reperfusion for acute ST elevation myocardial infarction is associated with a decrease in WBC count. 2006 , 147, 321-6		4
984	Implantable defibrillator early after primary percutaneous intervention for ST-elevation myocardial infarction: rationale and design of the Defibrillator After Primary Angioplasty (DAPA) trial. 2006 , 152, 636-40		9
983	Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial. 2006 , 152, 1042-50		71
982	Platelet microaggregation inhibition in patients with acute myocardial infarction pretreated with tirofiban and relationship with angiographic and clinical outcome. 2006 , 151, 1102-7		8
981	Comparison of very early treatment with either fibrinolysis or percutaneous coronary intervention facilitated with abciximab with respect to ST recovery and infarct-related artery epicardial flow in patients with acute ST-segment elevation myocardial infarction: the Swedish Early Decision (SWEDES) reperfusion trial. 2006 , 151, 798.e1-7		27
980	Impact of infarct location on left ventricular ejection fraction after correction for enzymatic infarct size in acute myocardial infarction treated with primary coronary intervention. 2006 , 151, 1239.e9-14		15

979	Level of Selvester QRS score is predictive of ST-segment resolution and 30-day outcomes in patients with acute myocardial infarction undergoing primary coronary intervention. 2006 , 151, 1239.e1-7	26
978	Role of fibrinolytic therapy in the current era of ST-segment elevation myocardial infarction management. 2006 , 151, S17-23	4
977	THROMBOLYTIC THERAPY IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION. 2006 , 2, 58-62	
976	Prognostic value of blood glucose in patients with cardiogenic shock. <i>Circulation Journal</i> , 2006 , 70, 1064-9	4
975	Traitements fibrinolytiques. 2006 , 1, 1-8	
974	Pressure-derived collateral flow index: a strong predictor of late left ventricular remodeling after thrombolysis for acute myocardial infarction. 2006 , 17, 139-44	9
973	Intra-arterial reteplase and intravenous abciximab in patients with acute ischemic stroke: an open-label, dose-ranging, phase I study. 2006 , 59, 789-96; discussion 796-7	75
972	Direct and rapid inhibition of factor Xa by otamixaban: a pharmacokinetic and pharmacodynamic investigation in patients with coronary artery disease. 2006 , 80, 691-702	20
971	Effect of coronary occlusion site on angiographic and clinical outcome in acute myocardial infarction patients treated with early coronary intervention. 2006 , 97, 1137-41	49
970	Usefulness of plasma brain natriuretic peptide concentration for predicting subsequent left ventricular remodeling after coronary angioplasty in patients with acute myocardial infarction. 2006 , 98, 453-7	24
969	ST-segment recovery and prognosis in patients with ST-elevation myocardial infarction reperfused by prehospital combination fibrinolysis, prehospital initiated facilitated percutaneous coronary intervention, or primary percutaneous coronary intervention. 2006 , 98, 1132-9	27
968	Rescue percutaneous coronary intervention for failed thrombolysis. 2006 , 67, 214-20	8
967	Failure of transradial approach during coronary interventions: anatomic considerations. 2006 , 67, 870-8	140
966	Day case transradial coronary angioplasty: a four-year single-center experience. 2006 , 68, 549-53	41
965	Bleeding and management of bleeding. 2006 , 8, G38-G45	50
964	Effect of tirofiban therapy on ST segment resolution and clinical outcomes in patients with ST segment elevated acute myocardial infarction undergoing primary angioplasty. 2006 , 105, 168-75	8
963	Late myocardial salvage: time to recognize its reality in the reperfusion therapy of acute myocardial infarction. 2006 , 27, 1900-7	46
962	Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. 2006 , 355, 1006-17	266

961	Randomized trial of percutaneous coronary intervention for subacute infarct-related coronary artery occlusion to achieve long-term patency and improve ventricular function: the Total Occlusion Study of Canada (TOSCA)-2 trial. <i>Circulation</i> , 2006 , 114, 2449-57	16.7	118
960	Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes. 2007 , 28, 1193-204		216
959	Long-term nicorandil therapy improves cardiac sympathetic nerve activity after reperfusion therapy in patients with first acute myocardial infarction. 2007 , 48, 1676-82		21
958	Development of systems of care for ST-elevation myocardial infarction patients: the emergency medical services and emergency department perspective. <i>Circulation</i> , 2007 , 116, e43-8	16.7	51
957	Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial. 2007 , 297, 591-602		226
956	Initial and mid-term results of a 4F compatible self-expanding low strut profile nitinol stent in the superficial femoral artery. 2007 , 179, 733-8		3
955	Intracoronary streptokinase after primary percutaneous coronary intervention. 2007 , 356, 1823-34		132
954	Time to treatment in primary percutaneous coronary intervention. 2007 , 357, 1631-8		212
953	Frequent change of procedure during coronary artery bypass surgery suggests insufficient preoperative diagnostic strategy. 2007 , 6, 298-302		3
952	Non-invasive treatment of ST elevation myocardial infarction. 2007 , 83, 725-30		1
951	Outcomes of primary percutaneous coronary intervention in acute myocardial infarction at Tehran Heart Center. 2007 , 16, 333-8		8
950	Middle cerebral artery stenting for acute ischemic stroke after unsuccessful Merci retrieval. 2007 , 60, 701-6; discussion 706		52
949	Effects of the early administration of heparin in patients with ST-elevation myocardial infarction treated by primary angioplasty. <i>Circulation Journal</i> , 2007 , 71, 862-7	2.9	9
948	Myocardial protection via the coronary sinus. <i>Circulation Journal</i> , 2008 , 72, 526-33	2.9	16
947	Quantitative evaluation of myocardial blush to assess tissue level reperfusion in patients with acute ST-elevation myocardial infarction: incremental prognostic value compared with visual assessment. 2007 , 153, 612-20		28
946	Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. 2007 , 369, 907-19		322
945	Atrial fibrillation after percutaneous coronary intervention: predictive importance of clinical, angiographic features and P-wave dispersion. 2007 , 107, 203-8		7
944	Revascularization in the acute coronary syndromes. 2007 , 38, 259-268		

943	Combined intravenous and intra-arterial approach in acute stroke treatment. 2007 , 8, 1837-49		1
942	Endovascular management of acute ischemic stroke: advances in patient and treatment selection. 2007 , 7, 143-53		3
941	Effects of intravenous atrial natriuretic peptide on cardiac sympathetic nerve activity and left ventricular remodeling in patients with first anterior acute myocardial infarction. 2007 , 49, 667-74		63
940	Surgical bleeding after pre-operative unfractionated heparin and low molecular weight heparin for coronary bypass surgery. 2007 , 92, 366-73		17
939	A novel inhibitor of activated thrombin activatable fibrinolysis inhibitor (TAFIa) âPart II: Enhancement of both exogenous and endogenous fibrinolysis in animal models of thrombosis. 2007 , 97, 54-61		40
938	The endocardial extent of reperfused first-time myocardial infarction is more predictive of pathologic Q waves than is infarct transmural: a magnetic resonance imaging study. 2007 , 27, 101-8		21
937	Predictors and outcomes of emergency department visits within 30 days following percutaneous coronary intervention. 2007 , 99, 197-201		1
936	The challenge of defining bleeding among patients with acute coronary syndromes. 2007 , 30, 116-23		7
935	Issues in management of acute coronary syndromes: effects of bleeding. 2007 , 30, 111-3		
934	Routine upstream versus selective down stream use of tirofiban in non-ST elevation myocardial infarction patients scheduled for early invasive therapy; a randomized comparison. <i>Journal of Thrombosis and Thrombolysis</i> , 2007 , 24, 241-6	5.1	2
933	Tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel (3T/2R). Rationale for the study and protocol design. 2008 , 22, 313-20		17
932	Bleeding after antithrombotic therapy in patients with acute ischemic heart disease: is it the drugs or how we use them?. <i>Journal of Thrombosis and Thrombolysis</i> , 2008 , 26, 175-82	5.1	7
931	A new ischemic model using a radiofrequency wire electrode in a rabbit hindlimb. 2008 , 31, 790-8		3
930	Effect of statin therapy on reperfusion arrhythmia in patients who underwent successful primary angioplasty. 2008 , 97, 147-51		5
929	Feasibility of primary clot extraction prior to percutaneous coronary intervention in acute myocardial infarction. 2008 , 71, 870-6		2
928	Efficacy and safety of argatroban in patients with heparin induced thrombocytopenia undergoing endovascular intervention for peripheral arterial disease. 2008 , 72, 116-20		7
927	Qureshi grading scheme predicts subsequent volume of brain infarction following intra-arterial thrombolysis in patients with acute anterior circulation ischemic stroke. 2008 , 18, 262-7		24
926	Major adverse noncardiac events after PCI as predictors of long-term mortality. 2008 , 21, 395-402		3

925	Comparison of usefulness of C-reactive protein versus white blood cell count to predict outcome after primary percutaneous coronary intervention for ST elevation myocardial infarction. 2008 , 101, 446-51	32
924	Incidence of bleeding and compliance on prolonged dual antiplatelet therapy (aspirin + thienopyridine) following drug-eluting stent implantation. 2008 , 102, 1477-81	20
923	Anemia. Infarto de miocardio. Influence of Hemoglobin Level on In-Hospital Prognosis in Patients With Acute Coronary Syndrome. 2008 , 61, 945-52	5
922	Major bleeding: management and risk reduction in acute coronary syndromes. 2008 , 9, 1869-83	8
921	Influence of Hemoglobin Level on In-Hospital Prognosis in Patients With Acute Coronary Syndrome. 2008 , 61, 945-952	4
920	Effects of Ile164 polymorphism of beta2-adrenergic receptor gene on coronary artery disease. 2008 , 52, 1381-8	29
919	Impact of clopidogrel in patients with acute coronary syndromes requiring coronary artery bypass surgery: a multicenter analysis. 2008 , 52, 1693-701	160
918	Effect of cyclosporine on reperfusion injury in acute myocardial infarction. 2008 , 359, 473-81	1026
917	Shock: Classification, Pathophysiology, and Approach to Management. 2008 , 379-422	2
916	Abciximab in elderly with acute coronary syndrome invasively treated: effect on outcome. 2008 , 130, 380-5	5
915	Antiplatelet therapy in acute coronary syndromes: the emergency physician's perspective. 2008 , 35, 5-13	10
914	Decreased activated protein C levels as a clinical predictor in patients with ST-elevation myocardial infarction. 2008 , 156, 931-8	5
913	Metabolic syndrome is a predictor for an ECG sign of no-reflow after primary PCI in patients with acute ST-elevation myocardial infarction. 2008 , 18, 441-7	13
912	Oral Crohn's disease: a favorable clinical response with delayed-release triamcinolone acetonide intralesional injections. 2008 , 103, 2954-5	11
911	Antiplatelet therapy use after discharge among acute myocardial infarction patients with in-hospital bleeding. <i>Circulation</i> , 2008 , 118, 2139-45	16.7 86
910	Staged escalation therapy in acute basilar artery occlusion: intravenous thrombolysis and on-demand consecutive endovascular mechanical thrombectomy: preliminary experience in 16 patients. 2008 , 39, 1496-500	60
909	Improving the adequacy of the rectal examination in gastroenterology. 2008 , 103, 2940; author reply 2940	
908	Rectal examination. 2008 , 103, 2940; author reply 2940-1	

- 907 Bleeding colonic ulcers due to invasive mold infection. **2008**, 103, 2960-1 1
- 906 Toll-like receptor-4 signaling: a possible candidate pathway to support tobacco smoking effects in ulcerative colitis. **2008**, 103, 2947-8 7
- 905 Response to Hart and Marshall. **2008**, 103, 2943-2944
- 904 Impaired inactivation of digestive proteases: a factor that may have confounded the efficacy of antibiotics aimed at reducing the exposure to luminal bacteria and their components. **2008**, 103, 2955-6 1
- 903 Do the two ends reflect the full picture?. **2008**, 103, 2941-2; author reply 2942-3 20
- 902 Farnesoid X receptors and their role in the etiopathogenesis of systemic malignancies. **2008**, 103, 2958
- 901 Author's Response: A Significant Decrease in the American Domination of Research in Gastroenterology Between 1980 and 2005: Did This Happen Mostly Between 1980 and 1995 or Between 1995 and 2005?. **2008**, 103, 2942-2943
- 900 Reply to Dr. Kittisupamongkol. **2008**, 103, 2940-2941
- 899 Cautionary note on using rectosigmoid biopsies to diagnose graft-versus-host disease: necessity of ruling out cytomegalovirus colitis. **2008**, 103, 2959-60 1
- 898 Barrett's esophagus: still much to learn, but "Yes, we can!". **2008**, 103, 2944-6; author reply 2946-7 5
- 897 Globalization of gastroenterology research. **2008**, 103, 2943; author reply 2943-4
- 896 Sickle cell trait-related ischemic colitis in a patient with Sjögren's syndrome. **2008**, 103, 2952-4 1
- 895 Endoscopic diagnosis of adenocarcinoma of the common bile duct using an ultra-slim upper endoscope. **2008**, 103, 2956-7 1
- 894 Gastric necrosis due to rapidly growing pancreatic pseudocyst. **2008**, 103, 2949-51 3
- 893 Response to the Letter by Dr. Marshall. **2008**, 103, 2940-2940
- 892 Optimizing Surveillance in Barrett's Esophagus: Response to Ruggeet al.. **2008**, 103, 2946-2947
- 891 Bleeding complications as predictor for mortality. **2008**, 103, 2948-9
- 890 Endoscopic celiac plexus blockade via direct intraneuronal injection versus perineuronal injection: results of a pilot study. **2008**, 103, 2958-9 1

889	Response to infliximab in atypical pyoderma gangrenosum associated with ulcerative colitis. 2008 , 103, 2951-2		7
888	Long-term benefit of postconditioning. <i>Circulation</i> , 2008 , 117, 1037-44	16.7	347
887	Radial artery versus saphenous vein patency randomized trial: five-year angiographic follow-up. <i>Circulation</i> , 2008 , 117, 2859-64	16.7	223
886	Intra-arterial thrombolysis of occluded middle cerebral artery by use of collateral pathways in patients with tandem cervical carotid artery/middle cerebral artery occlusion. <i>American Journal of Neuroradiology</i> , 2008 , 29, 1596-600	4.4	37
885	Assessment of acute myocardial infarction using MDCT after percutaneous coronary intervention: comparison with MRI. 2008 , 191, 441-7		22
884	Effectiveness and safety of routine primary angioplasty in patients aged > or =85 years with acute myocardial infarction. <i>Circulation Journal</i> , 2008 , 72, 67-70	2.9	37
883	The risk of iatrogenic bleeding in acute coronary syndromes and long-term mortality. 2008 , 23, 327-34		14
882	Preservation of myocardial viability within the risk area by intravenous nicorandil before primary coronary intervention in patients with acute myocardial infarction. 2008 , 29, 956-62		2
881	Glycoprotein IIb/IIIa inhibitors in patients with renal insufficiency undergoing percutaneous coronary intervention. 2008 , 16, 213-8		3
880	Acute Coronary Syndromes and Acute Myocardial Infarction. 2008 , 589-646		
879	. 2009 ,		0
878	Percutaneous coronary intervention following thrombolysis: for whom and when?. 2009 , 11, 195-203		1
877	Platelet inhibition with cangrelor in patients undergoing PCI. 2009 , 361, 2318-29		454
876	Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. <i>Circulation</i> , 2009 , 119, 2877-85	16.7	371
875	The success of primary angioplasty: beyond TIMI flow summary of a presentation held at acute cardiac care meeting in Paris, October 2008. 2009 , 11, 66-8		1
874	Presence and extent of cardiac magnetic resonance microvascular obstruction in reperfused non-ST-elevated myocardial infarction and correlation with infarct size and myocardial enzyme release. 2009 , 113, 50-8		24
873	The penumbra pivotal stroke trial: safety and effectiveness of a new generation of mechanical devices for clot removal in intracranial large vessel occlusive disease. 2009 , 40, 2761-8		795
872	Fragmentation of the classical magnetic resonance mismatch "penumbral" pattern with time. 2009 , 40, 3752-7		19

871	Acute coronary syndromes: Diagnosis and management, part II. 2009 , 84, 1021-36		29
870	Antiplatelet agents in the perioperative period. 2009 , 144, 69-76; discussion 76		63
869	Endovascular intervention for acute thromboembolic stroke in young patients: an ideal population for aggressive intervention?. 2009 , 110, 30-4		12
868	Comparison of two visual angiographic perfusion grades in acute myocardial infarction. 2009 , 114, 149-53		3
867	Antithrombotic prophylaxis in elderly patients with atrial fibrillation. 2009 , 35, 548-53		8
866	Glycaemic control and restenosis after percutaneous coronary interventions in patients with diabetes mellitus: a report from the Insulin Diabetes Angioplasty study. 2009 , 6, 71-9		14
865	Duration of symptoms is the key modulator of the choice of reperfusion for ST-elevation myocardial infarction. <i>Circulation</i> , 2009 , 119, 1293-303	16.7	32
864	Response to Letter Regarding Article, "The Impact of Diabetic Status on Coronary Artery Bypass Graft Patency: Insights From the Radial Artery Patency Study" <i>Circulation</i> , 2009 , 119,	16.7	
863	Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) Bleeding Score. <i>Circulation</i> , 2009 , 119, 1873-82	16.7	701
862	Late endovascular revascularization in acute ischemic stroke based on clinical-diffusion mismatch. <i>American Journal of Neuroradiology</i> , 2009 , 30, 1024-7	4.4	32
861	Avoiding and managing bleeding complications in patients with non-ST-segment elevation acute coronary syndromes. 2009 , 60, 148-58		1
860	Impact of acute and chronic risk factors on use of evidence-based treatments in patients in Australia with acute coronary syndromes. <i>Heart</i> , 2009 , 95, 1442-8	5.1	21
859	Duration of symptoms is not always the key modulator of the choice of reperfusion for ST-elevation myocardial infarction. <i>Circulation</i> , 2009 , 119, 1304-10	16.7	4
858	Primary percutaneous coronary angioplasty with and without eptifibatide in ST-segment elevation myocardial infarction: a safety and efficacy study of integrilin-facilitated versus primary percutaneous coronary intervention in ST-segment elevation myocardial infarction (ASSIST). 2009 ,		40
857	Intravenous administration of adenosine triphosphate disodium during primary percutaneous coronary intervention attenuates the transient rapid improvement of myocardial wall motion, not myocardial stunning, shortly after recanalization in acute anterior myocardial infarction. 2009 , 54, 289-96		6
856	Coronary Thrombolysis. 2009 , 224, 413-424		1
855	Intravenous thrombolytic treatment for acute myocardial infarction. Effects of early intervention and early examination. 1988 , 224, 523-9		1
854	Comparison of outcomes and safety of "facilitated" versus primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction. 2009 , 103, 316-21		14

853	Prognostic impact of Q waves on presentation and ST resolution in patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention. 2009 , 104, 780-5		12
852	Five-year experience with transradial coronary angioplasty in ST-segment-elevation myocardial infarction. 2009 , 10, 73-9		16
851	Perioperative red blood cell transfusion and outcome in stable patients after elective major vascular surgery. 2009 , 37, 311-8		69
850	Rheolytic thrombectomy in patients with massive and submassive acute pulmonary embolism. 2009 , 73, 506-13		44
849	Angiographic and clinical outcomes of drug-eluting versus bare metal stent deployment in the Occluded Artery Trial. 2009 , 73, 771-9		8
848	Effectiveness of the transradial approach to reduce bleedings in patients undergoing urgent coronary angioplasty with GPIIb/IIIa inhibitors for acute coronary syndromes. 2009 , 74, 408-15		40
847	Multicenter randomized trial of facilitated percutaneous coronary intervention with low-dose tenecteplase in patients with acute myocardial infarction: the Athens PCI trial. 2009 , 74, 398-405		7
846	Impact of day versus night as intervention time on the outcomes of primary angioplasty for acute myocardial infarction. 2009 , 74, 826-34		17
845	Transfusion associated microchimerism: a heretofore little-recognized complication following transfusion. <i>Journal of Thrombosis and Thrombolysis</i> , 2009 , 27, 57-67	5:1	7
844	Factors associated with myocardial salvage immediately after emergent percutaneous coronary intervention in patients with ST-elevation acute myocardial infarction. 2009 , 23, 383-90		2
843	Infarct size in primary angioplasty without on-site cardiac surgical backup versus transferal to a tertiary center: a single photon emission computed tomography study. 2009 , 36, 237-43		1
842	Impact of bivalirudin use on outcomes in nonagenarians undergoing percutaneous coronary intervention. 2009 , 22, 61-7		7
841	Occurrence, predictors, and outcomes of post-percutaneous coronary intervention thrombocytopenia in an unselected population. 2009 , 22, 156-62		9
840	Safety of angioplasty and stenting without thrombolysis for the treatment of early ischemic stroke. 2009 , 19, 139-43		7
839	The clinical manifestation of myocardial infarction in elderly patients. 2009 , 32, E46-51		33
838	The influence of anemia after percutaneous coronary intervention on clinical outcomes. 2009 , 32, 373-9		24
837	Percutaneous coronary interventions in nonagenarians: in-hospital mortality and outcome at one year follow-up. 2009 , 32, E16-21		10
836	N-terminal pro-B-type natriuretic peptide is associated with adverse short-term clinical outcomes in patients with acute ST-elevation myocardial infarction underwent primary percutaneous coronary intervention. 2009 , 133, 173-8		25

835	Glycoprotein IIb-IIIa inhibitors in the emergency department for patients with non-ST-elevation acute coronary syndromes: principles and practices. 2009 , 36, 162-70	1
834	Acute coronary angiographic findings in survivors of out-of-hospital cardiac arrest. 2009 , 157, 312-8	134
833	Design and rationale of the WOEST trial: What is the Optimal antiplatelet and anticoagulant therapy in patients with oral anticoagulation and coronary Stenting (WOEST). 2009 , 158, 713-8	48
832	The clinical significance of hematocrit values before and after percutaneous coronary intervention. 2009 , 158, 1024-30	21
831	Standardized reporting of bleeding complications for clinical investigations in acute coronary syndromes: a proposal from the academic bleeding consensus (ABC) multidisciplinary working group. 2009 , 158, 881-886.e1	27
830	Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the Early Rapid ReversAL of platelet thromboSis trial. 2009 , 158, 1024-30	79
829	Long-term prognostic value of ST-segment resolution in patients treated with fibrinolysis or primary percutaneous coronary intervention results from the DANAMI-2 (DANish trial in acute myocardial infarction-2). 2009 , 54, 1763-9	20
828	Prediction of long-term outcome by percent improvement after the first day of thrombolytic treatment in stroke patients. 2009 , 281, 69-73	50
827	Post-treatment platelet reactivity predicts long-term adverse events better than the response to clopidogrel in patients with non-ST-segment elevation acute coronary syndrome. 2009 , 62, 126-35	2
826	Cost-effectiveness analysis of anticoagulation strategies in non-ST-elevation acute coronary syndromes. 2009 , 43, 586-95	11
825	Non-invasive coronary flow reserve after successful primary angioplasty for acute anterior myocardial infarction is an independent predictor of left ventricular recovery and in-hospital cardiac events. 2009 , 22, 1071-9	13
824	The effect of statins on the no-reflow phenomenon: an observational study in patients with hyperglycemia before primary angioplasty. 2009 , 9, 81-9	15
823	Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. 2009 , 374, 1967-74	422
822	La reactividad plaquetaria post-tratamiento predice los eventos adversos a largo plazo mejor que la respuesta al clopidogrel en pacientes con sñdrome coronario agudo sin elevaciñ del ST. 2009 , 62, 126-135	20
821	Bridging of chronic oral anticoagulation with enoxaparin in patients with atrial fibrillation: results from the prospective BRAVE registry. 2009 , 27, 230-8	22
820	Acute Coronary Syndromes: Diagnosis and Management, Part II. 2009 , 84, 1021-1036	29
819	Clinical implications and management of bleeding events in patients with acute coronary syndromes. 2009 , 10, 677-86	7
818	Antiplatelet intervention in acute coronary syndrome. 2009 , 16, e29-40	20

817 ST-Segment-Elevation Myocardial Infarction. **2009**, 79-121

816 Impact of bleeding complications on outcomes after percutaneous coronary interventions. **2009**, 1, 51-62 10

815 Bivalirudin in patients with coronary artery disease. **2010**, 8, 199-203

814 Prediction of cardiovascular mortality in patients with ST-elevation myocardial infarction after primary percutaneous coronary intervention. **2010**, 21, 207-11 9

813 Comparison of outcomes in young versus nonyoung patients with ST elevation myocardial infarction treated by primary angioplasty. **2010**, 21, 72-7 18

812 Assessment of coronary artery flow velocity pattern as a long-term predictor of left ventricular function and cardiac events after percutaneous coronary intervention in anterior acute myocardial infarction. **2010**, 49, 1693-701 3

811 Early induction of hypothermia during cardiac arrest improves neurological outcomes in patients with out-of-hospital cardiac arrest who undergo emergency cardiopulmonary bypass and percutaneous coronary intervention. *Circulation Journal*, **2010**, 74, 77-85 2.9 148

810 Drug Reactions. **2010**, 1-177 24

809 [Efficacy and safety of concomitant use of rabeprazole during dual-antiplatelet therapy with clopidogrel and aspirin after drug-eluting stent implantation: a retrospective cohort study]. **2010**, 130, 1743-50 10

808 Ventricular function and cardiac hypertrophy after coronary thrombolysis with tissue-type plasminogen activator (t-PA) in dogs with coronary artery thrombi. **2000**, 52, 969-76 1

807 'Ins' and 'outs' of triple therapy: Optimal antiplatelet therapy in patients on chronic oral anticoagulation who need coronary stenting. *Netherlands Heart Journal*, **2010**, 18, 444-50 2.2 5

806 A comparison between upfront high-dose tirofiban versus provisional use in the real-world of non-selected STEMI patients undergoing primary PCI: Insights from the Zwolle acute myocardial infarction registry. *Netherlands Heart Journal*, **2010**, 18, 592-7 2.2 9

805 Economic consequences of severe bleeding in patients with acute coronary syndrome in the USA. **2010**, 27, 564-79 7

804 Safety of immediate reversal of anticoagulation by protamine to reduce bleeding complications after infarct artery stenting for acute myocardial infarction and adjunctive abciximab therapy. *Journal of Thrombosis and Thrombolysis*, **2010**, 30, 446-51 5.1 11

803 Estratificaci3n del riesgo hemorr3gico en el s3ndrome coronario agudo. **2010**, 10, 49-58

802 [Prognosis value of thrombin activatable fibrinolysis inhibitor concentration and C1040T polymorphism in acute myocardial infarction treated with fibrinolysis]. **2010**, 34, 513-22 3

801 The GPIIIA P1A2 polymorphism is associated with an increased risk of cardiovascular adverse events. **2010**, 10, 41 43

800 Safety and in-hospital outcomes of bivalirudin use in dialysis patients undergoing percutaneous coronary intervention. **2010**, 105, 297-301 12

799	Predictive value of ST resolution analysis performed immediately versus at ninety minutes after primary percutaneous coronary intervention. 2010 , 105, 467-74		7
798	Effect of anemia in high-risk groups of patients with acute myocardial infarction treated with percutaneous coronary intervention. 2010 , 105, 611-8		38
797	Intracoronary compared to intravenous Abciximab and high-dose bolus compared to standard dose in patients with ST-segment elevation myocardial infarction undergoing transradial primary percutaneous coronary intervention: a two-by-two factorial placebo-controlled randomized study. 2010 , 105, 1520-7		43
796	Incidence, range, and clinical effect of hemoglobin changes within 24 hours after transradial coronary stenting. 2010 , 106, 155-61		11
795	Antiplatelet therapy after placement of a drug-eluting stent: a review of efficacy and safety studies. 2010 , 32, 2265-81		19
794	Impact of abciximab on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction treated with primary stenting. 2010 , 75, 895-902		9
793	Early assessment of infarct size and prediction of functional recovery by quantitative myocardial blush grade in patients with acute coronary syndromes treated according to current guidelines. 2010 , 76, 502-10		9
792	Study design and rationale of 'Influence of Cilostazol-based triple anti-platelet therapy on ischemic complication after drug-eluting stent implantation (CILON-T)' study: A multicenter randomized trial evaluating the efficacy of Cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease. 2010 , 11, 87		11
791	Safety and efficacy of bivalirudin for percutaneous coronary intervention with rotational atherectomy. 2010 , 23, 223-9		5
790	Management of myocardial infarction in children with Kawasaki disease. 2010 , 21, 620-31		20
789	Reperfusion Therapies for Acute ST Segment Elevation Myocardial Infarction. 2010 , 110-144		
788	Recurrent Ischemia after Reperfusion Therapy for Acute Myocardial Infarction. 2010 , 203-211		
787	Incidence, correlates, and outcomes of acute, hospital-acquired anemia in patients with acute myocardial infarction. 2010 , 3, 337-46		64
786	Effect of postconditioning on infarct size in patients with ST elevation myocardial infarction. <i>Heart</i> , 2010 , 96, 1710-5	5.1	137
785	Intracoronary eptifibatide bolus administration during percutaneous coronary revascularization for acute coronary syndromes with evaluation of platelet glycoprotein IIb/IIIa receptor occupancy and platelet function: the Intracoronary Eptifibatide (ICE) Trial. <i>Circulation</i> , 2010 , 121, 784-91	16.7	83
784	Minimizing the risks of anticoagulants and platelet inhibitors. <i>Circulation</i> , 2010 , 121, 1960-70	16.7	26
783	Management strategies in posterior circulation intracranial atherosclerotic disease. 2010 , 17, 308-13		4
782	Bringing forward reperfusion with oxygenated blood perfusion beyond arterial occlusion during endovascular procedures in patients with acute ischemic stroke. <i>American Journal of Neuroradiology</i> , 2010 , 31, 1899-902	4.4	12

781	Mehran contrast-induced nephropathy risk score predicts short- and long-term clinical outcomes in patients with ST-elevation-myocardial infarction. 2010 , 3, 491-8		86
780	The POST trial: initial post-market experience of the Penumbra system: revascularization of large vessel occlusion in acute ischemic stroke in the United States and Europe. 2010 , 2, 341-4		105
779	Is the myocardial blush grade scored by the operator during primary percutaneous coronary intervention of prognostic value in patients with ST-elevation myocardial infarction in routine clinical practice?. 2010 , 3, 216-23		15
778	Non-culprit coronary artery percutaneous coronary intervention during acute ST-segment elevation myocardial infarction: insights from the APEX-AMI trial. 2010 , 31, 1701-7		170
777	Relation of homocysteine levels with patency and flow rate of infarct-related artery in patients receiving fibrinolytic therapy. 2010 , 10, 410-5		1
776	Impact of a well-organized collaborative team approach on mortality in patients with ST-segment elevation myocardial infarction. 2010 , 10, 508-13		1
775	Cytochrome P450 2C19 polymorphism, suboptimal reperfusion and all-cause mortality in patients with acute myocardial infarction. 2010 , 117, 81-7		19
774	Myocardial beta-adrenoceptor down-regulation early after infarction is associated with long-term incidence of congestive heart failure. 2010 , 31, 1722-9		24
773	Drip, ship, and retrieve: cooperative recanalization therapy in acute basilar artery occlusion. 2010 , 41, 722-6		74
772	New P2Y12 inhibitors versus clopidogrel in percutaneous coronary intervention: a meta-analysis. 2010 , 56, 1542-51		86
771	Hybrid revascularization, comprising coronary artery bypass graft with exclusive arterial conduits followed by early drug-eluting stent implantation, in multivessel coronary artery disease. 2010 , 103, 502-11		24
770	Successful reperfusion therapy: from epicardial to myocardial salvage. 2010 , 63, 757-9		1
769	Early stent thrombosis in patients undergoing primary coronary stenting for acute myocardial infarction: incidence, a simple risk score, and prognosis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2010 , 16, 33-41	3,3	8
768	Coronary slow flow phenomenon: a local or systemic disease?. 2010 , 75, 334-7		26
767	Use of Impella Recover LP 2.5 in elective high risk percutaneous coronary intervention. 2010 , 145, 235-237		19
766	Recurrent form of neurogenic stunned myocardium: is myocardial adrenergic receptor distribution a dynamic process?. 2010 , 145, 237-239		7
765	Effects of distal embolization on the timing of platelet and inflammatory cell activation in interventional coronary no-reflow. 2010 , 126, 50-5		24
764	Temporal trend of in-hospital major bleeding among patients with non ST-elevation acute coronary syndromes. 2010 , 160, 420-7		22

763	The role of the electrocardiogram as a prognostic tool in ST-segment elevation myocardial infarction. 2010 , 160, 574-6		
762	Angiographic assessment of microvascular perfusion--myocardial blush in clinical practice. 2010 , 160, 1015-22		30
761	Thrombus Aspiration in ST-Elevation myocardial infarction in Scandinavia (TASTE trial). A multicenter, prospective, randomized, controlled clinical registry trial based on the Swedish angiography and angioplasty registry (SCAAR) platform. Study design and rationale. 2010 , 160, 1042-8		111
760	[Not Available]. 2010 , 63, 757-9		1
759	Evaluation of a new heparin agent in percutaneous coronary intervention: results of the phase 2 evaluation of M118 IN pErcutaNeous Coronary intErvention (EMINENCE) Trial. <i>Circulation</i> , 2010 , 121, 1713-21	16.7	18
758	Utilizaci3n de recursos en el manejo del sangrado en pacientes ingresados por s3ndrome coronario agudo. 2010 , 7, 176-186		2
757	Medium on-treatment platelet reactivity to ADP is favorable in patients with acute coronary syndromes undergoing coronary stenting. 2011 , 22, 521-9		4
756	Medication errors in patients with severe chronic kidney disease and acute coronary syndrome: the impact of computer-assisted decision support. 2011 , 86, 1161-4		15
755	Safety of clopidogrel in older patients: a nonrandomized, parallel-group, controlled, two-centre study. 2011 , 28, 119-29		6
754	Apixaban with antiplatelet therapy after acute coronary syndrome. 2011 , 365, 699-708		765
753	Incidence and clinical consequences of acquired thrombocytopenia after antithrombotic therapies in patients with acute coronary syndromes: results from the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial. 2011 , 161, 298-306.e1		35
752	Clopidogrel loading dose and bleeding outcomes in patients undergoing urgent coronary artery bypass grafting. 2011 , 161, 404-10		20
751	The kinetics of integrilin limited by obesity: a multicenter randomized pharmacokinetic and pharmacodynamic clinical trial. 2011 , 162, 996-1002		3
750	Dynamic Changes in ST Segment Resolution After Myocardial Infarction and the Association with Microvascular Injury on Cardiac Magnetic Resonance Imaging. <i>Heart Lung and Circulation</i> , 2011 , 20, 111-8 ^{1.8}		20
749	Argatroban for elective percutaneous coronary intervention: the ARG-E04 multi-center study. 2011 , 148, 214-9		21
748	[Reduction of haemorrhagic risk in acute coronary syndromes]. 2011 , 137, 650-5		
747	[Minimum salvaged myocardium after rescue percutaneous coronary intervention: quantification by cardiac magnetic resonance]. 2011 , 64, 965-71		12
746	Value of post-resuscitation electrocardiogram in the diagnosis of acute myocardial infarction in out-of-hospital cardiac arrest patients. 2011 , 82, 1148-53		88

745	Minimum Salvaged Myocardium After Rescue Percutaneous Coronary Intervention: Quantification by Cardiac Magnetic Resonance. 2011 , 64, 965-971	
744	Stents farmacológicos liberadores de Everolimus Xience™ V no tratamento de pacientes com lesões coronárias complexas na prática diária: resultados iniciais do registro brasileiro BRAVO. 2011 , 19, 357-366	2
743	Implications of bleeding in acute coronary syndrome and percutaneous coronary intervention. 2011 , 7, 551-67	12
742	Bleeding risk assessment and management in atrial fibrillation patients. Executive Summary of a Position Document from the European Heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] Working Group on Thrombosis. 2011 , 106, 997-1011	184
741	Hemoglobin A1c as a prognostic marker in patients undergoing primary angioplasty for acute myocardial infarction. 2011 , 22, 131-7	31
740	Red cell distribution width as a novel prognostic marker in patients undergoing primary angioplasty for acute myocardial infarction. 2011 , 22, 138-44	113
739	Bleeding and acute coronary syndromes: defining, predicting, and managing risk and outcomes. 2011 , 12, 1831-5	7
738	Contrast-induced nephropathy after percutaneous coronary intervention in simple lesions: risk factors and incidence are affected by the definition utilized. 2011 , 50, 983-9	19
737	Primary percutaneous coronary intervention in 'early' latecomers with ST-segment elevation acute myocardial infarction: the role of the infarct-related artery status. 2011 , 12, 13-8	9
736	Failure of complete recanalization is associated with poor outcome after cardioembolic stroke. 2011 , 18, 1171-8	16
735	Grade 3 ischemia on the admission electrocardiogram is associated with severe microvascular injury on cardiac magnetic resonance imaging after ST elevation myocardial infarction. 2011 , 44, 49-57	25
734	Prominent precordial T waves as a sign of acute anterior myocardial infarction: electrocardiographic and angiographic correlations. 2011 , 44, 533-7	12
733	New and emerging anticoagulant therapy for atrial fibrillation and acute coronary syndrome. 2011 , 31, 975-1016	28
732	Striking a balance between the risks and benefits of anticoagulation bridge therapy in patients with atrial fibrillation: clinical updates and remaining controversies. 2011 , 31, 1208-20	8
731	Effect of clopidogrel pretreatment on ischemic complications of percutaneous coronary intervention among bivalirudin-treated patients (from the EVENT registry). 2011 , 107, 1751-6	4
730	Recovery from hospital-acquired anemia after acute myocardial infarction and effect on outcomes. 2011 , 108, 949-54	17
729	Outcome and treatment quality of transfer primary percutaneous intervention in older patients with acute ST-elevation myocardial infarction (STEMI). 2011 , 53, e259-62	6
728	STEMI patients--the more you bleed, the more you die: a comparison between classifications. 2011 , 34, 90-6	7

727	The frequency of vascular complications associated with the use of vascular closure devices varies by indication for cardiac catheterization. 2011 , 100, 789-95		18
726	How serious a problem is bleeding in patients with acute coronary syndromes?. 2011 , 13, 312-9		10
725	Effect of haemoglobin concentration on the clinical outcomes in patients with acute myocardial infarction and the factors related to haemoglobin. 2011 , 4, 142		3
724	Long-term outcome of provisional side-branch T-stenting for the treatment of unprotected distal left main coronary artery disease. 2011 , 77, 765-72		4
723	Mechanical thrombectomy with the Penumbra recanalization device in acute ischemic stroke. 2011 , 38, 47-52		19
722	Extending the time window for endovascular procedures according to collateral pial circulation. 2011 , 42, 3465-9		75
721	Target vessel reopening by guidewire insertion in ST-elevation myocardial infarction is a predictor of final TIMI flow and survival. 2011 , 105, 52-8		3
720	Impact of a Pharmacist-Directed Anticoagulation Service on the Quality and Safety of Heparin-Induced Thrombocytopenia Management. 2011 , 45, 195-200		14
719	Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. <i>Circulation</i> , 2011 , 123, 2736-47	16.7	2467
718	Clinical outcome after mechanical recanalization as mono- or adjunctive therapy in acute stroke: importance of time to recanalization. 2011 , 32, 211-8		22
717	Clinical outcomes in patients with the concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention: an analysis from the Guthrie Health Off-Label Stent (GHOST) investigators. 2011 , 4, 162-70		41
716	Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin—Acute Coronary Syndromes Trial. <i>Circulation</i> , 2011 , 123, 1843-53	16.7	130
715	Effect of baseline CT scan appearance and time to recanalization on clinical outcomes in endovascular thrombectomy of acute ischemic strokes. 2011 , 42, 93-7		118
714	Bridging intravenous-intra-arterial rescue strategy increases recanalization and the likelihood of a good outcome in nonresponder intravenous tissue plasminogen activator-treated patients: a case-control study. 2011 , 42, 993-7		62
713	Perioperative bridging of chronic oral anticoagulation in patients undergoing pacemaker implantation—a study in 200 patients. 2011 , 13, 1304-10		10
712	Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis. 2011 , 13, 723-46		166
711	Evaluation of the Implementation of an Anticoagulation Management Protocol at a Community Hospital. 2011 ,		1
710	Inference on treatment effects from a randomized clinical trial in the presence of premature treatment discontinuation: the SYNERGY trial. 2011 , 12, 258-69		13

709	The safety of clopidogrel. 2011 , 10, 85-95	10
708	Clinical outcomes of primary angioplasty in ST elevation myocardial infarction patients with antecedent hypertension during hospital stay and follow-up. 2012 , 34, 357-62	
707	Prognostic impact of red blood cell transfusion in patients undergoing primary angioplasty for ST elevation myocardial infarction. 2012 , 23, 517-22	10
706	Impact of clopidogrel resistance on ST-segment resolution and no-reflow in acute myocardial infarction with ST-elevation patients treated with a primary percutaneous coronary intervention. 2012 , 23, 523-7	4
705	Risk of renal dysfunction after less invasive multivessel coronary artery bypass grafting. 2012 , 7, 180-6	2
704	High SYNTAX score predicts worse in-hospital clinical outcomes in patients undergoing primary angioplasty for acute myocardial infarction. 2012 , 23, 542-8	16
703	Coronary slow flow phenomenon: more than just an angiographic curiosity. 2012 , 4, 337-347	4
702	Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials. 2012 , 172, 209-16	199
701	Effect of ischaemic postconditioning on recovery of left ventricular contractile function after acute myocardial infarction. 2012 , 40, 1082-8	20
700	Risk of bleeding related to antithrombotic treatment in cardiovascular disease. 2012 , 18, 5362-78	5
699	Management of tandem occlusion stroke with endovascular therapy. 2012 , 32, E16	12
698	Direct thrombin inhibitors for management of heparin-induced thrombocytopenia in patients receiving renal replacement therapy: comparison of clinical outcomes. 2012 , 69, 1559-67	11
697	Survival of patients after ST-elevation myocardial infarction: external validation of a predictive biomarker model. 2012 , 58, 1063-4	2
696	Gender-related difference in ST-elevation myocardial infarction treated with primary angioplasty: a single-centre 6-year registry. 2012 , 19, 233-40	38
695	Re-establishing Blood Flow After Intravascular Thrombosis. 2012 , 285-298	1
694	Revascularization grading in endovascular acute ischemic stroke therapy. 2012 , 79, S110-6	47
693	Clinical outcome, and survival between primary percutaneous coronary intervention versus fibrinolysis in patients older than 60 years with acute myocardial infarction. 2012 , 13, 129-31	2
692	Suboptimal coronary blood flow after primary percutaneous coronary intervention for acute myocardial infarction: incidence, a simple risk score, and prognosis. 2012 , 23, 98-104	4

691	Prediction of thrombus resolution after intravenous thrombolysis assessed by CT-based thrombus imaging. 2012 , 107, 786-94		19
690	Impact of Side Branch Predilation on Percutaneous Coronary Intervention in Complex Coronary Bifurcation Lesions. 2012 , 20, 125-132		
689	Examining the appropriateness of radial or femoral access: evidence from the RIVAL trial and clinical practice. 2012 , 4, 675-687		1
688	Prognostic value of venous blood ammonia in patients with out-of-hospital cardiac arrest. <i>Circulation Journal</i> , 2012 , 76, 891-9	2.9	13
687	Patients with tombstoning pattern on the admission electrocardiography who have undergone primary percutaneous coronary intervention for anterior wall ST-elevation myocardial infarction: in-hospital and midterm clinical outcomes. 2012 , 17, 315-22		2
686	Bleeding and the use of antiplatelet agents in the management of acute coronary syndromes and atrial fibrillation. 2012 , 47, 125-40		
685	Thrombolytics and myocardial infarction. 2012 , 30, e81-8		28
684	Tranexamic acid: less bleeding and less thrombosis?. 2012 , 16, 135		55
683	Acute gastrointestinal bleeding after percutaneous coronary intervention. 2012 , 6, 211-21		3
682	Anemia and prognosis in acute coronary syndromes. 2012 , 31, 133-134		2
681	Can the presence of anemia on admission improve the predictive value of the GRACE risk score for short- and medium-term mortality after acute coronary syndrome?. 2012 , 31, 279-285		3
680	Implementation of a pre-hospital network favoring primary angioplasty in STEMI to reduce mortality: The Algarve Project. 2012 , 31, 193-201		8
679	Primary PCI in ST-elevation myocardial infarction: Mode of referral and time to PCI. 2012 , 31, 641-646		4
678	Ultrasound enhanced prehospital thrombolysis using microbubbles infusion in patients with acute ST elevation myocardial infarction: pilot of the Sonolysis study. 2012 , 38, 247-52		34
677	Implementation of a pre-hospital network favoring primary angioplasty in STEMI to reduce mortality: the Algarve Project. 2012 , 31, 193-201		8
676	[Anemia and prognosis in acute coronary syndromes]. 2012 , 31, 133-4		3
675	[Primary PCI in ST-elevation myocardial infarction: mode of referral and time to PCI]. 2012 , 31, 641-6		6
674	Attributable Cost and Length of Stay for Patients with Enoxaparin-Associated Bleeding. 2012 , 1, 41-45		2

673	[Can the presence of anemia on admission improve the predictive value of the GRACE risk score for short- and medium-term mortality after acute coronary syndrome?]. 2012 , 31, 279-85		2
672	Role of cardiac troponin in the diagnosis of acute myocardial infarction in comatose patients resuscitated from out-of-hospital cardiac arrest. 2012 , 83, 452-8		38
671	Chronic oral anticoagulant therapy in carotid artery stenting: the un-necessity of perioperative bridging heparin therapy. 2012 , 130, 12-5		18
670	Newest-generation drug-eluting and bare-metal stents combined with prasugrel-based antiplatelet therapy in large coronary arteries: the BASel Stent Kosten Effektivit�s Trial PROspective Validation Examination part II (BASKET-PROVE II) trial design. 2012 , 163, 136-41.e1		11
669	Reduced immediate ischemic events with cangrelor in PCI: a pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction. 2012 , 163, 182-90.e4		83
668	Incidence, predictors and outcome of upper gastrointestinal bleeding in patients with acute coronary syndromes. 2012 , 157, 386-90		23
667	Oral factor Xa inhibitors for the long-term management of ACS. 2012 , 9, 392-401		5
666	Renal insufficiency is an independent predictor of in-hospital mortality for patients with acute myocardial infarction receiving primary percutaneous coronary intervention. 2012 , 13, 638-44		7
665	Bleeding risk and safety profile related to the use of eptifibatide: a current review. 2012 , 11, 315-24		7
664	Post-conditioning reduces infarct size and edema in patients with ST-segment elevation myocardial infarction. 2012 , 59, 2175-81		171
663	Transradial versus transfemoral artery approach for coronary angiography and percutaneous coronary intervention in the extremely obese. <i>JACC: Cardiovascular Interventions</i> , 2012 , 5, 819-26	5	58
662	Superior outcome with direct catheter laboratory access vs ED-activated primary percutaneous coronary intervention. 2012 , 30, 1118-24		6
661	The use of a 4-step algorithm in the electrocardiographic diagnosis of ST-segment elevation myocardial infarction by novice interpreters. 2012 , 30, 1282-95		4
660	Comparison of abciximab versus eptifibatide during percutaneous coronary intervention in ST-segment elevation myocardial infarction (from the HORIZONS-AMI trial). 2012 , 110, 940-7		8
659	[Non-invasive coronary flow reserve is an independent predictor of exercise capacity after acute anterior myocardial infarction]. 2012 , 61, 323-30		0
658	Endovascular recanalization of central venous access to allow for pacemaker implantation or upgrade. 2012 , 13, 215-8		6
657	Safety profile and bleeding risk of ticagrelor compared with clopidogrel. 2012 , 11, 959-67		5
656	Modeling of the fibrin agarose plate assay and its application for thrombolytic analysis. 2012 , 57, 3233-3238		3

655	Glycoprotein IIb/IIIa inhibitor associated severe thrombocytopenia in patients with coronary artery disease: Clinical course and outcomes. 2012 , 23, 224-8	6
654	A single center, open, randomized study investigating the clinical safety and the endothelial modulating effects of a prostacyclin analog in combination with eptifibatide in patients having undergone primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction. 2012 , 99, 87-95	12
653	Tutorials in Endovascular Neurosurgery and Interventional Neuroradiology. 2012 ,	9
652	Comparison of short- and long-term haemostatic compression after transradial procedures. 2012 , 7, 178-183	
651	Transradial Approach for Coronary Interventions: The New Gold Standard for Vascular Access?. 2012 ,	1
650	Emerging antiplatelet therapy for coronary artery disease and acute coronary syndrome. 2012 , 32, 244-73	9
649	Frequency and impact of bleeding in elective coronary stent clinical trials--utility of three commonly used definitions. 2012 , 80, E23-9	3
648	Outcomes of primary percutaneous coronary intervention for acute myocardial infarction with unprotected left main coronary artery occlusion. 2012 , 79, 1111-6	18
647	Novel oral anticoagulants after acute coronary syndromes. 2012 , 26, 265-71	
646	Apixaban: an oral direct factor-xa inhibitor. 2012 , 29, 187-201	12
645	Preceding intravenous thrombolysis facilitates endovascular mechanical recanalization in large intracranial artery occlusion. 2012 , 7, 14-8	44
644	Bridging therapy after recent stent implantation: case report and review of data. 2012 , 13, 30-8	9
643	Impact of vascular approach (transradial vs. transfemoral) on the efficacy of thrombus aspiration in acute myocardial infarction patients. 2012 , 13, 79-83	5
642	Relation between red blood cell omega-3 fatty acid index and bleeding during acute myocardial infarction. 2012 , 109, 13-8	24
641	Association between bleeding severity and long-term mortality in patients experiencing vascular complications after percutaneous coronary intervention. 2012 , 109, 75-81	28
640	Prognostic value of uric acid in patients with ST-elevated myocardial infarction undergoing primary coronary intervention. 2012 , 109, 486-91	83
639	Low risk of intracranial and systemic hemorrhages in patients on dual antiplatelet treatment beyond 1 month following neuroendovascular angioplasty and/or stent placement. 2012 , 22, 67-73	6
638	Arterial blood gas analysis of samples directly obtained beyond cerebral arterial occlusion during endovascular procedures predicts clinical outcome. 2013 , 23, 180-4	5

637	Comparison of prasugrel and clopidogrel reloading on high platelet reactivity in clopidogrel-loaded patients undergoing percutaneous coronary intervention (PRAISE-HPR): a study protocol for a prospective randomized controlled clinical trial. 2013 , 14, 62		1
636	Prognostic role of heart rate variability in patients with ST-segment elevation acute myocardial infarction treated by primary angioplasty. 2013 , 124, 63-70		23
635	Periprocedural aspects in mechanical recanalization for acute stroke: data from the ENDOSTROKE registry. 2013 , 55, 1143-51		25
634	Prognostic significance of bleeding location and severity among patients with acute coronary syndromes. <i>JACC: Cardiovascular Interventions</i> , 2013 , 6, 709-17	5	13
633	The Coronary Slow Flow Phenomenon. 2013 , 101-117		2
632	Chest Pain with Normal Coronary Arteries. 2013 ,		2
631	Verapamil reverses myocardial no-reflow after primary percutaneous coronary intervention in patients with acute myocardial infarction. 2013 , 67, 911-4		8
630	Acute myocardial infarction: early CT aspects of myocardial microcirculation obstruction after percutaneous coronary intervention. 2013 , 23, 2405-12		8
629	Invasive versus non-invasive cooling after in- and out-of-hospital cardiac arrest: a randomized trial. 2013 , 102, 607-14		52
628	Impact of an immunoglobulin G-specific enzyme-linked immunosorbent assay on the management of heparin-induced thrombocytopenia. 2013 , 33, 1191-8		6
627	Thrombin receptor antagonism in antiplatelet therapy. 2013 , 2, 57-68		10
626	Prognostic value of total bilirubin in patients with ST-segment elevation acute myocardial infarction undergoing primary coronary intervention. 2013 , 111, 166-71		48
625	A guideline based approach of percutaneous coronary intervention in acute myocardial infarction: Single center experience. <i>Egyptian Heart Journal</i> , 2013 , 65, 163-173	1.3	
624	Excellent rates of recanalization and good functional outcome after stent-based thrombectomy for acute middle cerebral artery occlusion. Is it time for a paradigm shift?. 2013 , 20, 1219-23		15
623	Dual antiplatelet therapy versus oral anticoagulation plus dual antiplatelet therapy in patients with atrial fibrillation and low-to-moderate thromboembolic risk undergoing coronary stenting: design of the MUSICA-2 randomized trial. 2013 , 166, 669-75		18
622	Management of vascular access in transcatheter aortic valve replacement: part 2: Vascular complications. <i>JACC: Cardiovascular Interventions</i> , 2013 , 6, 767-76	5	89
621	Predictive value of elevated cystatin C in patients undergoing primary angioplasty for ST-elevation myocardial infarction. 2013 , 28, 882.e13-20		10
620	The first year of the Venlo percutaneous coronary intervention program: procedural and 6-month clinical outcomes. <i>Netherlands Heart Journal</i> , 2013 , 21, 449-55	2.2	5

619	Ethnic differences in the occurrence of acute coronary syndrome: results of the Malaysian National Cardiovascular Disease (NCVD) Database Registry (March 2006 - February 2010). 2013 , 13, 97		26
618	Acute management of bleeding in patients on novel oral anticoagulants. 2013 , 34, 489-498b		138
617	Efficacy of a new accelerated streptokinase regime in acute myocardial infarction: a double blind randomized clinical trial. 2013 , 31, 53-9		3
616	Prognostic significance of T-wave amplitude in lead aVR on the admission electrocardiography in patients with anterior wall ST-elevation myocardial infarction treated by primary percutaneous intervention. 2013 , 18, 51-7		15
615	Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. 2013 , 381, 1107-15		1191
614	Balance of Ischemia and Bleeding in Selecting an Antithrombotic Regimen. 2013 , 2, 515-525		
613	Chronic kidney disease and percutaneous coronary interventions with drug-eluting stents: does the K/DOQI classification matter?. 2013 , 166, 530-3		1
612	Risk score, causes, and clinical impact of failure of transradial approach for percutaneous coronary interventions. <i>JACC: Cardiovascular Interventions</i> , 2013 , 6, 1129-37	5	80
611	STEMI - The importance of balance between antithrombotic treatment and bleeding risk. 2013 , 55, e135-e146		1
610	Closed versus open cell stent for high-risk percutaneous coronary interventions in ST-elevation acute myocardial infarction: the Closed versus Open Cells stent for High risk percutaneous coronary Interventions in ST-Elevation acute myocardial infarction (COHISE) pilot study. 2013 , 165, 115-20		4
609	Embedding a randomized clinical trial into an ongoing registry infrastructure: unique opportunities for efficiency in design of the Study of Access site For Enhancement of Percutaneous Coronary Intervention for Women (SAFE-PCI for Women). 2013 , 166, 421-8		59
608	Platelet inhibition by abciximab bolus-only administration and oral ADP receptor antagonist loading in acute coronary syndrome patients: the blocking and bridging strategy. 2013 , 132, e36-41		15
607	Relation of body mass index to bleeding events among patients with percutaneous coronary intervention: a meta-analysis. 2013 , 168, 4831-5		3
606	Early- and late-term clinical outcome and their predictors in patients with ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction. 2013 , 169, 254-61		75
605	Impact of postoperative nadir hemoglobin and blood transfusion on outcomes after operations for atherosclerotic vascular disease. 2013 , 57, 1331-7; discussion		10
604	Contrast-induced nephropathy in patients undergoing primary percutaneous coronary intervention without acute left ventricular ejection fraction impairment. 2013 , 111, 684-8		31
603	Incorporation of bleeding as an element of the composite end point in clinical trials of antithrombotic therapies in patients with non-ST-segment elevation acute coronary syndrome: validity, pitfalls, and future approaches. 2013 , 165, 644-54, 654.e1		8
602	New guidelines on tPA in stroke: putting out fires with gasoline?. 2013 , 62, A13-8		5

601	'Mother-in-child' thrombectomy technique: a novel and effective approach to decrease intracoronary thrombus burden in acute myocardial infarction. 2013 , 14, 14-7			6
600	Treatment of Acute Ischaemic Stroke. 2013 , 343-398			
599	Recommendations on angiographic revascularization grading standards for acute ischemic stroke: a consensus statement. 2013 , 44, 2650-63			884
598	Incidence and outcome of procedural distal emboli using the Penumbra thrombectomy for acute stroke. 2013 , 5, 135-8			24
597	Hemoglobin A1c and short-term outcomes in patients with acute myocardial infarction undergoing primary angioplasty: an observational multicenter study. 2013 , 24, 16-22			26
596	The relationship between Eglutamyl transferase levels and the clinical outcomes in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. 2013 , 24, 272-8			12
595	Difficult catheter access to the occluded vessel during endovascular treatment of acute ischemic stroke is associated with worse clinical outcome. 2013 , 5 Suppl 1, i70-3			94
594	High incidence of acute coronary occlusion in patients without protocol positive ST segment elevation referred to an open access primary angioplasty programme. 2013 , 89, 376-81			4
593	Impact of altitude on predicting midterm outcome in patients with ST elevation myocardial infarction. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2013 , 19, 382-8	3-3		2
592	Circadian, weekly, and seasonal variation in early stent thrombosis patients who previously underwent primary percutaneous intervention with ST elevation myocardial infarction. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2013 , 19, 679-84	3-3		3
591	Invasive mechanical ventilation in acute coronary syndromes in the era of percutaneous coronary intervention. 2013 , 2, 109-17			15
590	Age dependency of successful recanalization in anterior circulation stroke: the ENDOSTROKE study. 2013 , 36, 437-45			66
589	Timing of mortality after severe bleeding and recurrent myocardial infarction in patients with ST-segment-elevation myocardial infarction. 2013 , 6, 391-8			23
588	Predictive value of elevated D-dimer in patients undergoing primary angioplasty for ST elevation myocardial infarction. 2013 , 24, 704-10			32
587	Risk of long-term dual antiplatelet therapy following drug-eluting stent implantation in octogenarians. 2013 , 26, 114-22			3
586	Model building in nonproportional hazard regression. 2013 , 32, 5301-14			9
585	Synergistic effect of thrombus aspiration and abciximab in primary percutaneous coronary intervention. 2013 , 82, 604-11			10
584	The SPEED study: initial clinical evaluation of the Penumbra novel 054 Reperfusion Catheter. 2013 , 5 Suppl 1, i74-6			34

583	Solitaire Flow Restoration thrombectomy for acute ischemic stroke: retrospective multicenter analysis of early postmarket experience after FDA approval. 2013 , 73, 19-25; discussion 25-6		52
582	Lytic failure in the current pharmacointensive ST-elevated acute myocardial infarction care: insights from a pilot real-world study. 2013 , 14, 35-42		0
581	The clinical utility of bivalirudin in patients with coronary artery disease. 2013 , 11, 44-8		3
580	Effects of clopidogrel on mortality, cardiovascular and bleeding outcomes in patients with chronic kidney disease - data from Taiwan acute coronary syndrome full spectrum registry. <i>PLoS ONE</i> , 2013 , 8, e71917	3.7	8
579	Left ventricular thrombus and subsequent thromboembolism, comparison of anticoagulation, surgical removal, and antiplatelet agents. 2013 , 20, 73-93		58
578	Prognostic value of elevated mean platelet volume in patients undergoing primary angioplasty for ST-elevation myocardial infarction. 2013 , 68, 307-14		12
577	Clinical Coronary In-Stent Restenosis Follow-Up after Treatment and Analyses of Clinical Outcomes. <i>Arquivos Brasileiros De Cardiologia</i> , 2015 , 104, 375-86	1.2	4
576	Phase 2 study of TAK-442, an oral factor Xa inhibitor, in patients following acute coronary syndrome. 2014 , 111, 1141-52		23
575	Aspirin for primary prevention of cardiovascular events: meta-analysis of randomized controlled trials and subgroup analysis by sex and diabetes status. <i>PLoS ONE</i> , 2014 , 9, e90286	3.7	50
574	Effect of clinical and RBC hemorheological parameters on myocardial perfusion in patients with type 2 diabetes mellitus. 2014 , 51, 215-26		4
573	Long-term prognostic value of admission haemoglobin A1c (HbA1c) levels in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. 2014 , 10, 166-74		5
572	Efficacy of combination treatment with intracoronary abciximab and aspiration thrombectomy on myocardial perfusion in patients with ST-segment elevation myocardial infarction undergoing primary coronary stenting. 2014 , 55, 606-16		18
571	Comparação dos Resultados da Intervenção Coronária Percutânea por Via Radial na Síndrome Coronariana Aguda Entre Mulheres e Homens. 2014 , 22, 16-22		1
570	Prognostic implications of bleeding measured by Bleeding Academic Research Consortium (BARC) categorisation in patients undergoing primary percutaneous coronary intervention. <i>Heart</i> , 2014 , 100, 146-52	5.1	23
569	Admission hyperglycemia predicts inhospital mortality and major adverse cardiac events after primary percutaneous coronary intervention in patients without diabetes mellitus. 2014 , 65, 154-9		21
568	The relation between hypointense core, microvascular obstruction and intramyocardial haemorrhage in acute reperfused myocardial infarction assessed by cardiac magnetic resonance imaging. 2014 , 24, 3277-88		45
567	Efficacy of two different self-expanding nitinol stents for atherosclerotic femoropopliteal arterial disease (SENS-FP trial): study protocol for a randomized controlled trial. 2014 , 15, 355		3
566	A high ratio of ADP-TRAP induced platelet aggregation is associated more strongly with increased mortality after coronary stent implantation than high conventional ADP induced aggregation alone. 2014 , 103, 968-75		7

565	Comparison of Percutaneous Coronary Intervention Outcomes in Men and Women Using the Transradial Approach in Acute Coronary Syndrome. 2014 , 22, 16-22		
564	Late Outcomes of Patients Undergoing Drug-Eluting Stent Implantation âThe SAFIRA Registry. 2014 , 22, 23-31		
563	Case report: Severe hypercalcemia mimicking ST-segment elevation myocardial infarction. 2014 , 10, 193-7		5
562	Admission hyperglycemia predicts poorer short- and long-term outcomes after primary percutaneous coronary intervention for ST-elevation myocardial infarction. 2014 , 5, 80-6		24
561	Risk of hemorrhage in patients with chronic liver disease and coagulopathy receiving pharmacologic venous thromboembolism prophylaxis. 2014 , 34, 1043-9		21
560	The use of vascular closure devices and impact on major bleeding and net adverse clinical events (NACEs) in balloon aortic valvuloplasty: a sub-analysis of the BRAVO study. 2014 , 83, 148-53		14
559	Cangrelor: a novel intravenous antiplatelet agent with a questionable future. 2014 , 34, 1061-76		15
558	Prognostic impact of atrial fibrillation in acute coronary syndromes: results from the ARIAM registry. 2014 , 3, 141-8		31
557	Â¿Por quÂ¿debemos estratificar el riesgo hemorrÃ¡gico junto con el isquÃ©mico en el sÃ­ndrome coronario agudo?. 2014 , 14, 10-17		
556	Individualising dual antiplatelet therapy after percutaneous coronary intervention: the IDEAL-PCI registry. <i>BMJ Open</i> , 2014 , 4, e005781	3	20
555	Sequential evaluation of coronary flow patterns after primary angioplasty in acute anterior ST-elevation myocardial infarction predicts recovery of left ventricular systolic function. 2014 , 31, 644-653		1
554	Left anterior descending coronary artery flow after primary angioplasty in acute anterior ST-elevation myocardial infarction: how much flow is needed for left ventricular functional recovery?. 2014 , 3, 223-8		1
553	Predictive value of elevated soluble CD40 ligand in patients undergoing primary angioplasty for ST-segment elevation myocardial infarction. 2014 , 25, 558-64		15
552	Predictive value of elevated neutrophil to lymphocyte ratio in patients undergoing primary angioplasty for ST-segment elevation myocardial infarction. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2014 , 20, 427-32	3.3	22
551	Bleeding complications in patients undergoing percutaneous coronary interventions: current status and perspective. 2014 , 25, 247-57		15
550	Elevated plasma level of pentraxin-3 predicts in-hospital and 30-day clinical outcomes in patients with non-ST-segment elevation myocardial infarction who have undergone percutaneous coronary intervention. 2014 , 129, 178-88		17
549	Risks and Benefits of Thrombolytic, Antiplatelet, and Anticoagulant Therapies for ST Segment Elevation Myocardial Infarction: Systematic Review. 2014 , 2014, 416253		3
548	Comparison of Cockcroft-Gault and modification of diet in renal disease formulas as predictors of cardiovascular outcomes in patients with myocardial infarction treated with primary percutaneous coronary intervention. 2014 , 65, 838-43		10

547	Mid-term patency of the inverted left internal thoracic artery conduit. 2014 , 29, 790-3		1
546	Posttreatment platelet reactivity on clopidogrel is associated with the risk of adverse events after off-pump coronary artery bypass. 2014 , 167, 818-25		6
545	High BNP level as risk factor for acute kidney injury and predictor of all-cause mortality in STEMI patients. 2014 , 39, 507-14		20
544	Chronic metformin treatment is associated with reduced myocardial infarct size in diabetic patients with ST-segment elevation myocardial infarction. 2014 , 28, 163-71		41
543	The prognostic value of bleeding academic research consortium (BARC)-defined bleeding complications in ST-segment elevation myocardial infarction: a comparison with the TIMI (Thrombolysis In Myocardial Infarction), GUSTO (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries), and ISTH (International Society on Thrombosis and Hemostasis) bleeding classifications. 2014 , 11, 1046-53		69
542	Prognostic value of access site and nonaccess site bleeding after percutaneous coronary intervention: a cohort study in ST-segment elevation myocardial infarction and comprehensive meta-analysis. <i>JACC: Cardiovascular Interventions</i> , 2014 , 7, 622-30	5	23
541	Impact of runoff grade after endovascular therapy for femoropopliteal lesions. 2014 , 59, 720-7		19
540	Bivalirudin versus heparin for percutaneous coronary intervention: an updated meta-analysis of randomized controlled trials. 2014 , 15, 315-22		9
539	Inter- and intraobserver agreement in scoring angiographic results of intra-arterial stroke therapy. <i>American Journal of Neuroradiology</i> , 2014 , 35, 1163-9	4.4	10
538	The age, creatinine, and ejection fraction score to risk stratify patients who underwent percutaneous coronary intervention of coronary chronic total occlusion. 2014 , 114, 1158-64		22
537	Myocardial tissue perfusion predicts the evolution of fragmented QRS in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. 2014 , 19, 454-61		13
536	Disease-specific guidelines for reporting adverse events for peripheral vascular medical devices. 2014 , 60, 212-25		9
535	Bleeding Definitions. 2014 , 259-265		
534	Triple therapy for atrial fibrillation and percutaneous coronary intervention: a contemporary review. 2014 , 64, 1270-80		46
533	Microvascular obstruction in patients with non-ST-elevation myocardial infarction: a contrast-enhanced cardiac magnetic resonance study. 2014 , 30, 1087-95		12
532	The effects of a low international normalized ratio on thromboembolic and bleeding complications in patients with mechanical mitral valve replacement. 2014 , 9, 79		5
531	A registry-based randomized trial comparing radial and femoral approaches in women undergoing percutaneous coronary intervention: the SAFE-PCI for Women (Study of Access Site for Enhancement of PCI for Women) trial. <i>JACC: Cardiovascular Interventions</i> , 2014 , 7, 857-67	5	168
530	Presence of sigma shaped right coronary artery is an indicator of poor prognosis in patients with inferior myocardial infarction treated with primary percutaneous coronary intervention. 2014 , 84, 965-72		1

529	Relation between coronary calcium and major bleeding after percutaneous coronary intervention in acute coronary syndromes (from the Acute Catheterization and Urgent Intervention Triage Strategy and Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction Trials). 2014 , 113, 930-5	18
528	Deconstructing the language of bleeding. 2014 , 63, 1876-8	0
527	A role for pericytes in coronary no-reflow. 2014 , 11, 427-32	69
526	Bleeding risk stratification in an era of aggressive management of acute coronary syndromes. 2014 , 6, 1140-8	12
525	Predictors and clinical implications of minimal ST-segment elevation in patients with ST-segment elevation myocardial infarction. 2014 , 128, 273-81	2
524	Remedial hydration reduces the incidence of contrast-induced nephropathy and short-term adverse events in patients with ST-segment elevation myocardial infarction: a single-center, randomized trial. 2014 , 53, 2265-72	32
523	Mean platelet volume at admission is a determinant of left ventricular thrombus formation after primary percutaneous coronary intervention for first anterior wall myocardial infarction. 2014 , 69, 603-609	3
522	Long-term dual antiplatelet treatment and bleeding complications in diabetic patients treated with drug eluting stent implantation. <i>IJC Heart and Vasculature</i> , 2014 , 5, 57-62	2.4
521	Seguimento de 12 meses de pacientes complexos tratados com stents farmacológicos liberadores de everolimus XIENCE V na prática diária - resultados do registro brasileiro BRAVO. 2015 , 23, 22-27	
520	The 'MAP strategy' (Maximum aspiration of atherothrombus and adjunctive glycoprotein IIb/IIIa inhibitor utilization combined with prolonged inflation of balloon/stent) for preventing no-reflow in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: A retrospective analysis of seventy-one cases. 2015 , 67 Suppl 3, S43-6	4
519	Increased risk for vascular complications due to GP IIb/IIIa-antagonists in patients with cardiogenic shock supported by intraaortic balloon pump (IABP). 2015 , 8, 1-3	
518	Stents farmacológicos de segunda geração para tratamento de lesões proximais isoladas da artéria descendente anterior. Dados do Registro SAFIRA. 2015 , 23, 256-260	
517	Second-generation drug-eluting stent treatment for isolated proximal left anterior descending artery stenoses. The SAFIRA Registry data. 2015 , 23, 256-260	
516	Twelve-month follow-up of complex patients treated with the Xience VTM everolimus drug-eluting stents in daily practice - results of the BRAVO Brazilian Registry. 2015 , 23, 22-27	
515	Cardiovascular magnetic resonance imaging of myocardial oedema following acute myocardial infarction: Is whole heart coverage necessary?. 2016 , 18, 7	8
514	Femoral vascular closure device use, bivalirudin anticoagulation, and bleeding after primary angioplasty for STEMI: results from the HORIZONS-AMI trial. 2015 , 85, 371-9	12
513	Application of Intravascular Ultrasound in the Emergency Diagnosis and Treatment of Patients with ST-Segment Elevation Myocardial Infarction. 2015 , 32, 1003-8	0
512	The impact of initial and residual thrombus burden on the no-reflow phenomenon in patients with ST-segment elevation myocardial infarction. 2015 , 26, 245-53	9

511	Long-term prognostic value of elevated pentraxin 3 in patients undergoing primary angioplasty for ST-elevation myocardial infarction. 2015 , 26, 592-7		17
510	Impact of in-hospital bleeding according to the Bleeding Academic Research Consortium classification on the long-term adverse outcomes in patients undergoing percutaneous coronary intervention. 2015 , 85, 63-71		5
509	Interpretation of fractional flow reserve in ST-elevation myocardial infarction culprit lesions. 2015 , 26, 495-502		3
508	Endovascular treatment of vasculogenic erectile dysfunction. 2015 , 17, 40-3		12
507	Re-evaluation of Bleeding Events in the Japanese PRASFIT-Elective and PRASFIT-ACS Clinical Trials using the Bleeding Academic Research Consortium Criteria. 2015 , 04,		3
506	Mechanical Recanalization following i.v. Thrombolysis: A Retrospective Analysis regarding Secondary Hemorrhagic Infarctions and Parenchymal Hematomas. 2015 , 2015, 159815		1
505	Short-Term Effects of Verapamil and Diltiazem in the Treatment of No Reflow Phenomenon: A Meta-Analysis of Randomized Controlled Trials. 2015 , 2015, 382086		21
504	The effects of tirofiban infusion on clinical and angiographic outcomes of patients with STEMI undergoing primary PCI. 2015 , 15, 899-906		8
503	Combined ECG, Echocardiographic, and Biomarker Criteria for Diagnosing Acute Myocardial Infarction in Out-of-Hospital Cardiac Arrest Patients. 2015 , 56, 887-94		13
502	ST-segment elevation of right precordial lead (V4 R) is associated with multivessel disease and increased in-hospital mortality in acute anterior myocardial infarction patients. 2015 , 20, 362-7		2
501	Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran. 2015 , 114, 198-205		119
500	Why so little progress in therapeutic thrombolysis? The current state of the art and prospects for improvement. <i>Journal of Thrombosis and Thrombolysis</i> , 2015 , 40, 480-7	5.1	1
499	Performance of CMR Methods for Differentiating Acute From Chronic MI. 2015 , 8, 669-79		16
498	Optical coherence tomography assessment of efficacy of thrombus aspiration in patients undergoing a primary percutaneous coronary intervention for acute ST-elevation myocardial infarction. 2015 , 26, 567-72		7
497	Serial assessment of the index of microcirculatory resistance during primary percutaneous coronary intervention comparing manual aspiration catheter thrombectomy with balloon angioplasty (IMPACT study): a randomised controlled pilot study. 2015 , 2, e000238		27
496	Association Between Contrast Media Volume-Glomerular Filtration Rate Ratio and Contrast-Induced Acute Kidney Injury After Primary Percutaneous Coronary Intervention. 2015 , 66, 519-24		29
495	Platelet reactivity following high loading doses of clopidogrel in patients undergoing primary percutaneous coronary angioplasty: A pilot study. 2015 , 10, 7-12		1
494	Acceso radial frente a femoral en angioplastia por infarto agudo de miocardio con elevaci3n del segmento ST con stent farmacoactivo de segunda generaci3n. 2015 , 68, 47-53		9

493	Predictors and prognostic consequence of gastrointestinal bleeding in patients with ST-segment elevation myocardial infarction. 2015 , 184, 128-134		12
492	The assessment of relationship between fragmented QRS complex and left ventricular wall motion score index in patients with ST elevation myocardial infarction who underwent primary percutaneous coronary intervention. 2015 , 20, 148-57		18
491	Anticoagulant therapy and outcomes in patients with prior or acute heart failure and acute coronary syndromes: Insights from the APixaban for PRevention of Acute ISchemic Events 2 trial. 2015 , 169, 531-8		6
490	Prognostic impact of clopidogrel pretreatment in patients with acute coronary syndrome managed invasively. 2015 , 115, 1019-26		13
489	Impact of transient or persistent slow flow and adjunctive distal protection on mortality in ST-segment elevation myocardial infarction. <i>Cardiovascular Intervention and Therapeutics</i> , 2015 , 30, 121-30		4
488	Large early variation of residual platelet reactivity in Acute Coronary Syndrome patients treated with clopidogrel: results from Assessing Platelet Activity in Coronary Heart Disease (APACHE). 2015 , 136, 335-40		4
487	Characterising and predicting bleeding in high-risk patients with an acute coronary syndrome. <i>Heart</i> , 2015 , 101, 1475-84	5.1	10
486	Incidence and Clinical Significance of Poststent Optical Coherence Tomography Findings: One-Year Follow-Up Study From a Multicenter Registry. <i>Circulation</i> , 2015 , 132, 1020-9	16.7	154
485	A Combined Optical Coherence Tomography and Intravascular Ultrasound Study on Plaque Rupture, Plaque Erosion, and Calcified Nodule in Patients With ST-Segment Elevation Myocardial Infarction: Incidence, Morphologic Characteristics, and Outcomes After Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2015 , 8, 1166-1176	5	150
484	Effect of patient age on blood product transfusion after cardiac surgery. 2015 , 150, 209-14		19
483	Evaluation of a structured training program for arterial femoral sheath removal after percutaneous arterial catheter procedures by assistant personnel. 2015 , 115, 879-83		3
482	Major bleeding complications related to combined antithrombotic therapy in atrial fibrillation patients 12 months after coronary artery stenting. 2015 , 65, 197-202		16
481	Post-infectious group A streptococcal autoimmune syndromes and the heart. 2015 , 14, 710-25		66
480	Nicorandil improves myocardial function by regulating plasma nitric oxide and endothelin-1 in coronary slow flow. 2015 , 26, 114-20		21
479	Safety profile of prasugrel and clopidogrel in patients with acute coronary syndromes in Switzerland. <i>Heart</i> , 2015 , 101, 854-63	5.1	34
478	Mechanical recanalization in basilar artery occlusion: the ENDOSTROKE study. 2015 , 77, 415-24		212
477	Door to Balloon Time: Is There a Point That Is Too Short?. 2015 , 58, 230-40		10
476	Post-Resuscitation ECG for Selection of Patients for Immediate Coronary Angiography in Out-of-Hospital Cardiac Arrest. 2015 , 8,		43

475	Final 3-Year Outcome of a Randomized Trial Comparing Second-Generation Drug-Eluting Stents Using Either Biodegradable Polymer or Durable Polymer: NOBORI Biolimus-Eluting Versus XIENCE/PROMUS Everolimus-Eluting Stent Trial. 2015 , 8,		49
474	Effect of Diltiazem on Coronary Artery Flow and Myocardial Perfusion in Patients With Isolated Coronary Artery Ectasia and Either Stable Angina Pectoris or Positive Myocardial Ischemic Stress Test. 2015 , 116, 1199-203		4
473	Comprehensive meta-analysis of safety and efficacy of bivalirudin versus heparin with or without routine glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndrome. <i>JACC: Cardiovascular Interventions</i> , 2015 , 8, 201-213	5	50
472	Acute coronary syndrome. 2015 , 30, 186-200		60
471	The relationship between epicardial adipose tissue and ST-segment resolution in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. 2015 , 30, 147-53		10
470	Safety and efficacy of in-hospital clopidogrel-to-prasugrel switching in patients with acute coronary syndrome. An analysis from the 'real world'. <i>Journal of Thrombosis and Thrombolysis</i> , 2015 , 39, 499-507	5.1	17
469	Coronary microvascular dysfunction: mechanisms and functional assessment. 2015 , 12, 48-62		262
468	Predictive value of a fragmented QRS complex in patients undergoing primary angioplasty for ST elevation myocardial infarction. 2015 , 20, 263-72		26
467	Radial versus femoral access for angioplasty of ST-segment elevation acute myocardial infarction with second-generation drug-eluting stents. 2015 , 68, 47-53		1
466	Zwolle risk score predicts contrast-induced acute kidney injury in STEMI patients undergoing PCI. 2015 , 40, 109-15		1
465	Additive effect of in-hospital TIMI bleeding and chronic kidney disease on 1-year cardiovascular events in patients with acute coronary syndrome: Data from Taiwan Acute Coronary Syndrome Full Spectrum Registry. 2015 , 30, 441-50		14
464	Efficacy and Safety of High-Dose Subcutaneous Unfractionated Heparin Prophylaxis for the Prevention of Venous Thromboembolism in Obese Hospitalized Patients. 2016 , 51, 376-81		8
463	Impact of Triple Therapy in Elderly Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. <i>PLoS ONE</i> , 2016 , 11, e0147245	3.7	20
462	Favorable outcomes in octogenarians treated with bioresorbable polymer drug-eluting stent. 2016 , 16, 1246-1253		
461	BleeMACS: rationale and design of the study. 2016 , 17, 744-9		19
460	Magnesium as a predictor of acute stent thrombosis in patients with ST-segment elevation myocardial infarction who underwent primary angioplasty. 2016 , 27, 47-51		8
459	Gender differences in risk factors and clinical outcomes in young patients with acute myocardial infarction. 2016 , 70, 1057-1064		9
458	Balance of Ischemia and Bleeding in Selecting Antithrombotic Regimens. 2016 , 389-396		

457	Prediction and impact of failure of transradial approach for primary percutaneous coronary intervention. <i>Heart</i> , 2016 , 102, 919-25	5.1	18
456	The association of the coronary thrombus burden with all-cause mortality and major cardiac events in ST-segment elevation myocardial infarction patients treated with tirofiban. 2016 , 27, 543-50		4
455	Outcomes of 6-month versus 12-month dual antiplatelet therapy after drug-eluting stent implantation: A meta-analysis and meta-regression. 2016 , 95, e5819		9
454	Combination of the Thrombolysis-Myocardial Perfusion Score and Coronary Flow Reserve Is Highly Predictive of Microvascular Obstruction on Cardiac Magnetic Resonance Imaging After ST-Segment Elevation Myocardial Infarction. <i>JACC: Cardiovascular Interventions</i> , 2016 , 9, 793-801	5	25
453	Variation in Arterial Access for Invasive Coronary Procedures in New Zealand: A National Analysis (ANZACS-QI 5). <i>Heart Lung and Circulation</i> , 2016 , 25, 451-8	1.8	3
452	Impact of the origin of the collateral feeding donor artery on short-term mortality in ST-elevation myocardial infarction with comorbid chronic total occlusion. 2016 , 218, 158-163		11
451	Safety of Early Discharge After Primary Percutaneous Coronary Intervention. 2016 , 117, 1911-6		10
450	One-year outcome of a prospective trial stopping dual antiplatelet therapy at 3 months after everolimus-eluting cobalt-chromium stent implantation: ShortT and OPTimal duration of Dual AntiPlatelet Therapy after everolimus-eluting cobalt-chromium stent (STOPDAPT) trial. <i>Cardiovascular Intervention and Therapeutics</i> , 2016 , 31, 196-203	2.5	39
449	Efficacy and Safety of Local Intracoronary Drug Delivery in Treatment of No-Reflow Phenomenon: A Pilot Study. 2016 , 29, 496-504		7
448	Effect of remote ischemic conditioning on infarct size in patients with anterior ST-elevation myocardial infarction. 2016 , 181, 66-73		46
447	Does Residual Thrombus After Aspiration Thrombectomy Affect the Outcome of Primary PCI in Patients With ST-Segment Elevation Myocardial Infarction?: An Optical Coherence Tomography Study. <i>JACC: Cardiovascular Interventions</i> , 2016 , 9, 2002-2011	5	33
446	The ADAPTABLE Trial and Aspirin Dosing in Secondary Prevention for Patients with Coronary Artery Disease. 2016 , 18, 81		49
445	Treatment of heparin-induced thrombocytopenia before and after the implementation of a hemostatic and antithrombotic stewardship program. <i>Journal of Thrombosis and Thrombolysis</i> , 2016 , 42, 616-22	5.1	8
444	A systematic review of the prevalence and incidence of prescribing errors with high-risk medicines in hospitals. 2016 , 41, 239-45		23
443	Relation Between Neutrophil-to-Lymphocyte Ratio and Index of Microcirculatory Resistance in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. 2016 , 118, 1323-1328		12
442	A comparison of infarct mass by cardiac magnetic resonance and real time myocardial perfusion echocardiography as predictors of major adverse cardiac events following reperfusion for ST elevation myocardial infarction. 2016 , 33, 1539-1545		2
441	Serious infections among unselected patients with ST-elevation myocardial infarction treated with contemporary primary percutaneous coronary intervention. 2016 , 181, 52-59		17
440	Association Between Duration of Dual Antiplatelet Therapy and Angiographic Multivessel Disease on Outcomes in Patients Treated With Newer-Generation Drug-Eluting Stents. 2016 , 9,		10

439	Effects of Triple Therapy in Patients With Non-Valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention Regarding Thromboembolic Risk Stratification. <i>Circulation Journal</i> , 2016 , 80, 354-62	29	17
438	Coronary Plaque Characteristics Associated With Reduced TIMI (Thrombolysis in Myocardial Infarction) Flow Grade in Patients With ST-Segment-Elevation Myocardial Infarction: A Combined Optical Coherence Tomography and Intravascular Ultrasound Study. 2016 , 9,		10
437	ECG evaluation in patients with pacemaker and suspected acute coronary syndrome: Which score should we apply?. 2016 , 49, 744-8		7
436	High platelet reactivity after P2Y12-inhibition in patients with atrial fibrillation and coronary stenting. <i>Journal of Thrombosis and Thrombolysis</i> , 2016 , 42, 558-65	5.1	1
435	Estudo SAVEME (Salvamento Miocárdico Após Angioplastia de Resgate: Avaliação por Ressonância Magnética). Racional e desenho do estudo. 2016 , 24, 9-13		
434	SAVEME (Myocardial Salvage After Rescue Angioplasty: Evaluation by Magnetic Resonance) Study: Rationale and Study Design. 2016 , 24, 9-13		
433	Prognostic value of CHA2DS2-VASc score in patients with ST-segment elevation myocardial infarction who underwent primary percutaneous coronary intervention. 2016 , 71, 663-669		4
432	Impact of coronary collaterals on in-hospital and 5-year mortality after ST-elevation myocardial infarction in the contemporary percutaneous coronary intervention era: a prospective observational study. <i>BMJ Open</i> , 2016 , 6, e011105	3	25
431	Safety of the primary percutaneous coronary intervention strategy combining pre-hospital prasugrel, enoxaparin and in-hospital bivalirudin in acute ST-segment elevation myocardial infarction. 2016 , 16, 154		2
430	Two-year prognosis of admission hemoglobin A1c following a primary percutaneous coronary intervention. 2016 , 27, 673-681		1
429	Which long-term antiplatelet regimen for patients with acute coronary syndromes?. 2016 , 30, 333-8		
428	Validity of standard gamble utilities in patients referred for aortic valve replacement. 2016 , 25, 1703-12		7
427	Clinical management and outcome of major bleeding in patients on treatment with vitamin K antagonists. 2016 , 33, 47-54		2
426	New Therapeutic Agents in Thrombosis and Thrombolysis. 2016 ,		6
425	Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention: Insights From the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION PHOENIX) Trial. <i>Circulation</i> , 2016 , 133, 248-55	16.7	23
424	Fibrinolytic PLGA nanoparticles for slow clot lysis within abdominal aortic aneurysms attenuate proteolytic loss of vascular elastic matrix. 2016 , 59, 145-156		6
423	Predicting ischemic mitral regurgitation in patients with acute ST-elevation myocardial infarction: Does time to reperfusion really matter and what is the role of collateral circulation?. 2016 , 203, 667-71		8
422	Women With Early Menopause Have Higher Rates of Target Lesion Revascularization After Percutaneous Coronary Intervention. 2016 , 67, 311-6		1

421	Changes in Coronary Blood Flow After Acute Myocardial Infarction: Insights From a Patient Study and an Experimental Porcine Model. <i>JACC: Cardiovascular Interventions</i> , 2016 , 9, 602-13	5	31
420	Intra-arterial revascularization therapy for basilar artery occlusion-a systematic review and analysis. 2016 , 39, 575-80		22
419	Editor's Choice- Gender difference in prognostic impact of in-hospital bleeding after myocardial infarction - data from the SWEDEHEART registry. 2016 , 5, 463-472		8
418	Utility of the Logistic Clinical Syntax Score in the Prediction of Contrast-Induced Nephropathy After Primary Percutaneous Coronary Intervention. 2016 , 32, 240-6		15
417	Unfavorable neurological outcome in diabetic patients with acute ischemic stroke is associated with incomplete recanalization after intravenous thrombolysis. 2016 , 8, 342-6		15
416	Morphological predictors for no reflow phenomenon after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction caused by plaque rupture. 2017 , 18, 103-110		31
415	CHADS-VASc Score Predicts In-Hospital and Long-Term Clinical Outcomes in Patients With ST-Segment Elevation Myocardial Infarction Who Were Undergoing Primary Percutaneous Coronary Intervention. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017 , 23, 132-138	3.3	24
414	Coronary flow improvement following unsuccessful primary percutaneous coronary intervention in ST-elevation myocardial infarction with diffuse ectatic coronary artery. 2017 , 6, 623-631		7
413	Reduction of in-stent thrombus immediately after percutaneous coronary intervention by pretreatment with prasugrel compared with clopidogrel: An optical coherence tomography study. 2017 , 69, 436-441		9
412	Bleeding complications of triple antithrombotic therapy after percutaneous coronary interventions. 2017 , 89, E64-E74		10
411	Fractional flow reserve-guided coronary angioplasty using paclitaxel-coated balloons without stent implantation: feasibility, safety and 6-month results by angiography and optical coherence tomography. 2017 , 106, 18-27		25
410	Association of Lymphocyte-to-Monocyte Ratio With the Mortality in Patients With ST-Elevation Myocardial Infarction Who Underwent Primary Percutaneous Coronary Intervention. 2017 , 68, 707-715		21
409	Defining optimal activated clotting time for percutaneous coronary intervention: A systematic review and Bayesian meta-regression. 2017 , 89, 351-366		12
408	A prospective, randomized, open-label trial of 6-month versus 12-month dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction: Rationale and design of the "DAPT-STEMI trial". 2017 , 188, 11-17		12
407	Bleeding associated with the management of acute coronary syndromes. <i>Heart</i> , 2017 , 103, 546-562	5.1	5
406	A review of strategies for infarct size reduction during acute myocardial infarction. 2017 , 18, 374-383		7
405	Interactions between iodinated contrast media and tissue plasminogen activator: In vitro comparison study. 2017 , 66, 167-174		1
404	Preemptive warfarin dose reduction after initiation of sulfamethoxazole-trimethoprim or metronidazole. <i>Journal of Thrombosis and Thrombolysis</i> , 2017 , 44, 88-93	5.1	5

403	Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study. 2017 , 38, 3070-3078	215
402	Safety and Efficacy of Prasugrel and Ticagrelor in Acute Coronary Syndrome. Results of a "Real World" Multicenter Registry. 2017 , 70, 952-959	4
401	Prognostic Impact of Age and Hemoglobin in Acute ST-Segment Elevation Myocardial Infarction Treated With Reperfusion Therapy. 2017 , 119, 1909-1916	12
400	Seguridad y eficacia clínica con prasugrel y ticagrelor en síndrome coronario agudo. Resultados de un registro multicéntrico en el mundo real. 2017 , 70, 952-959	18
399	Safety and efficacy of drug eluting stents in patients with spontaneous coronary artery dissection. 2017 , 238, 105-109	15
398	Out-of-hospital cardiac arrest survivors sent for emergency angiography: a clinical score for predicting acute myocardial infarction. 2017 , 6, 103-111	13
397	Collateral filling efficiency of comorbid chronic total occlusion segment on short-term mortality in ST-elevation myocardial infarction. 2017 , 230, 346-352	2
396	The design and rationale of the primary angioplasty registry of Kerala. 2017 , 69, 777-783	3
395	Role of coronary angiography for out-of-hospital cardiac arrest survivors according to postreturn of spontaneous circulation on an electrocardiogram. 2017 , 96, e6123	6
394	Prognostic Impact of in-Hospital-Bleeding in Patients With ST-Elevation Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention. 2017 , 120, 1734-1741	10
393	Head-to-head comparison of prasugrel versus ticagrelor in patients undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials. 2017 , 30, 457-464	6
392	Comparative efficacy and safety of reperfusion therapy with fibrinolytic agents in patients with ST-segment elevation myocardial infarction: a systematic review and network meta-analysis. 2017 , 390, 747-759	35
391	Magnetic targeting to enhance microbubble delivery in an occluded microarterial bifurcation. 2017 , 62, 7451-7470	13
390	[Acute pulmonary embolism: still a diagnostic and therapeutic challenge?]. 2017 , 112, 499-509	1
389	The Prognostic Value of ADP-Induced Platelet Aggregation for Bleeding Complications in Low - Intermediate Risk Patients with Acute Coronary Syndrome Taking Clopidogrel After Percutaneous Coronary Intervention. <i>Heart Lung and Circulation</i> , 2017 , 26, 49-57	1.8 2
388	Prognostic Implications of Newly Developed T-Wave Inversion After Primary Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction. 2017 , 119, 515-519	3
387	Gender differences in the association between discharge hemoglobin and 12-month mortality after acute myocardial infarction. 2017 , 40, 1279-1284	3
386	Single Derivation Fragmented QRS Can Predict Poor Prognosis in Successfully Revascularized Acute STEMI Patients. <i>Arquivos Brasileiros De Cardiologia</i> , 2017 , 109, 213-221	1.2 9

367	Utility of a Power Aspiration-Based Extraction Technique as an Initial and Secondary Approach in the Treatment of Peripheral Arterial Thromboembolism: Results of the Multicenter PRISM Trial. 2018 , 29, 92-100			21
366	Prasugrel versus clopidogrel for residual thrombus burden in patients with ST-segment elevation myocardial infarction: an optical coherence tomography study. 2018 , 29, 663-669			3
365	The POST trial: initial post-market experience of the Penumbra system: revascularization of large vessel occlusion in acute ischemic stroke in the United States and Europe. 2018 , 10, i35-i38			3
364	Unfractionated Heparin with Sequential Enoxaparin in Patients with Complex Coronary Artery Lesions during Percutaneous Coronary Intervention. 2018 , 131, 2417-2423			2
363	Effects of Coronary Artery Revascularization with a Polymer-Free Biolimus A9-Coated BioFreedom Stent Versus Bypass Surgery before Noncardiac Surgery. 2018 , 59, 480-488			
362	Six months versus 12 months dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction (DAPT-STEMI): randomised, multicentre, non-inferiority trial. 2018 , 363, k3793			83
361	Pathology of Arterial Thrombosis. 2018 , 15-30			2
360	Practical issues in clinical scenarios involving CKD patients requiring antithrombotic therapy in light of the 2017 ESC guideline recommendations. 2018 , 16, 158			12
359	Safety and effectiveness of direct oral anticoagulants following ultrasound-assisted catheter directed thrombolysis for venous thromboembolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2018 , 46, 58-61	5.1		2
358	Multisociety Consensus Quality Improvement Revised Consensus Statement for Endovascular Therapy of Acute Ischemic Stroke. <i>American Journal of Neuroradiology</i> , 2018 , 39, E61-E76	4.4		22
357	Increased Cystatin C Level in ST-Elevation Myocardial Infarction Predisposes the Prognosis of Angioplasty. 2018 , 355, 530-536			2
356	Bleeding complications after myocardial infarction in a real world population - An observational retrospective study with a sex perspective. 2018 , 167, 156-163			6
355	Bleeding by the numbers: The utility and the limitations of bleeding scores, bleeding prediction tools, and bleeding case definitions. 2018 , 57, 458-462			3
354	Evaluation of neuregulin-1's neuroprotection against ischemic injury in rats using diffusion tensor imaging. 2018 , 53, 63-70			4
353	Impact of percutaneous coronary intervention extent, complexity and platelet reactivity on outcomes after drug-eluting stent implantation. 2018 , 268, 61-67			18
352	Impact of smoking on stroke outcome after endovascular treatment. <i>PLoS ONE</i> , 2018 , 13, e0194652	3.7		9
351	Serious hemorrhages after ischemic stroke or TIA - Incidence, mortality, and predictors. <i>PLoS ONE</i> , 2018 , 13, e0195324	3.7		1
350	Angiography and Electrocardiography (ECG) for the Assessment of Coronary Microvascular Obstruction. 2018 , 109-126			

349	Primary Angioplasty. 2018 ,		3
348	Perioperative management of antiplatelet therapy in patients undergoing non-cardiac surgery following coronary stent placement: a systematic review. 2018 , 7, 4		19
347	Predictive value of the age, creatinine, and ejection fraction (ACEF) score in patients with acute coronary syndromes. 2018 , 270, 7-13		23
346	Sex differences in the outcome after percutaneous coronary intervention - A propensity matching analysis. 2019 , 20, 101-107		12
345	Early versus delayed invasive strategy in patients with non-ST-elevation acute coronary syndrome and concomitant congestive heart failure. 2019 , 74, 320-327		1
344	Pathophysiology, Diagnosis, and Management of the No-Reflow Phenomenon. 2019 , 33, 589-597		19
343	Antiplatelet treatment in acute coronary syndrome patients: Real-world data from the START-Antiplatelet Italian Registry. <i>PLoS ONE</i> , 2019 , 14, e0219676	3-7	7
342	Clinical consequences of bleeding among individuals with a recent acute coronary syndrome: Insights from the APPRAISE-2 trial. 2019 , 215, 106-113		5
341	The Relationship Between Mean Platelet Volume and In-Hospital Mortality in Geriatric Patients with ST Segment Elevation Myocardial Infarction Who Underwent Primary Percutaneous Coronary Intervention. 2019 , 4, 135-141		3
340	Association Between Multivessel Coronary Artery Disease and Return of Spontaneous Circulation Interval in Acute Coronary Syndrome Patients with Out-of-Hospital Cardiac Arrest. <i>International Heart Journal</i> , 2019 , 60, 1043-1049	1.8	4
339	A drug safety evaluation of apixaban for the treatment of atrial fibrillation, acute coronary syndrome, and percutaneous coronary intervention. 2019 , 18, 1119-1125		2
338	Impact of Nutritional and Inflammation Status on Long-Term Bleeding in Patients Undergoing Percutaneous Coronary Intervention with an Oral Anticoagulant. 2019 , 26, 728-737		6
337	Competing risks of major bleeding and thrombotic events with prasugrel-based dual antiplatelet therapy after stent implantation - An observational analysis from BASKET-PROVE II. <i>PLoS ONE</i> , 2019 , 14, e0210821	3-7	3
336	Transradial access versus transfemoral access: a comparison of outcomes and efficacy in reducing hemorrhagic events. 2019 , 17, 435-447		17
335	Incidence, predictors, and prognosis of premature discontinuation or switch of prasugrel or ticagrelor: the ATLANTIS - SWITCH study. 2019 , 9, 8194		10
334	Impact on long-term mortality of access and non-access site bleeding after primary percutaneous coronary intervention. <i>Heart</i> , 2019 , 105, 1568-1574	5-1	4
333	[Oral anticoagulation and antiplatelet therapy in patients with atrial fibrillation after coronary interventions]. 2019 , 44, 365-378		1
332	The Elevated Soluble ST2 Predicts No-Reflow Phenomenon in ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. 2019 , 26, 970-978		9

331	Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. 2019 , 380, 1509-1524		538
330	Sonothrombolysis with Magnetically Targeted Microbubbles. 2019 , 45, 1151-1163		18
329	Randomized evaluation of ticagrelor monotherapy after 3-month dual-antiplatelet therapy in patients with acute coronary syndrome treated with new-generation sirolimus-eluting stents: TICO trial rationale and design. 2019 , 212, 45-52		20
328	Safety and Efficacy of Low-Dose Prasugrel as Part of Triple Therapy With Aspirin and Oral Anticoagulants in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention - From the TWMU-AF PCI Registry. <i>Circulation Journal</i> , 2019 , 83, 1000-1005	2.9	7
327	The effect of ticagrelor based dual antiplatelet therapy on development of late left ventricular thrombus after acute anterior ST elevation myocardial infarction. 2019 , 287, 19-26		5
326	Dual Antiplatelet Therapy Duration Based on Ischemic and Bleeding Risks After Coronary Stenting. 2019 , 73, 741-754		123
325	Anticoagulation-Related Major Bleeding in Patients With Atrial Fibrillation: Looking Behind the Curtain. <i>Circulation</i> , 2019 , 140, 1802-1804	16.7	1
324	Optimal strategy of switching from clopidogrel to ticagrelor in Chinese acute coronary syndrome patients with complicated coronary artery disease: the switching from clopidogrel to ticagrelor (SHIFT-CACS) study. 2019 , 132, 2292-2299		1
323	Fibrinolysis Shutdown in Trauma: Historical Review and Clinical Implications. 2019 , 129, 762-773		50
322	Suspected Brugada Phenocopy Secondary to Coronary Slow Flow. 2019 , 2019, 9027029		
321	MAGnesium-based bioresorbable scaffold and vasomotor function in patients with acute ST segment elevation myocardial infarction: The MAGSTEMI trial: Rationale and design. 2019 , 93, 64-70		7
320	Treatment of bleeding complications in patients on anticoagulant therapy. 2019 , 133, 425-435		31
319	Effects of Bailout Tirofiban on In-Hospital Outcomes and Long-Term Mortality in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Intervention. 2019 , 70, 431-439		6
318	Gender and age differences in outcomes of patients with acute coronary syndromes referred for coronary angiography. 2019 , 93, 16-24		1
317	The role of perioperative cardiorespiratory support in post infarction ventricular septal rupture-related cardiogenic shock. 2020 , 9, 128-137		15
316	Association between High Platelet Reactivity Following Dual Antiplatelet Therapy and Ischemic Events in Japanese Patients with Coronary Artery Disease Undergoing Stent Implantation. 2020 , 27, 13-24		6
315	Prognosis of patients with previous myocardial infarction, coronary slow flow, and normal coronary angiogram. 2020 , 45, 88-94		
314	Anti-thrombotic strategies in elderly patients receiving platelet inhibitors. 2020 , 6, 57-68		8

313	Resolute zotarolimus-eluting stent in ST-elevation myocardial infarction (resolute-STEMI): A prespecified prospective register from the DAPT-STEMI trial. 2020 , 95, 706-710		2
312	The Effect of Stent Artefact on Quantification of Plaque Features Using Optical Coherence Tomography (OCT): A Feasibility and Clinical Utility Study. <i>Heart Lung and Circulation</i> , 2020 , 29, 874-882	1.8	2
311	Prognostic impact of recanalizing chronic total occlusion in non-infarct related arteries on long-term clinical outcomes in acute myocardial infarction patients undergoing primary percutaneous coronary intervention. <i>Cardiovascular Intervention and Therapeutics</i> , 2020 , 35, 259-268	2.5	3
310	Feasibility and Clinical Significance of In Vivo Cholesterol Crystal Detection Using Optical Coherence Tomography. 2020 , 40, 220-229		9
309	Feasibility and Safety of Low-Dose Intra-Coronary Tenecteplase During Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction (ICE T-TIMI 49). 2020 , 125, 485-490		6
308	Increased plaque rupture forms peak incidence of acute myocardial infarction in winter. 2020 , 320, 18-22		1
307	Circulating miR-1 as a potential predictor of left ventricular remodeling following acute ST-segment myocardial infarction using cardiac magnetic resonance. 2020 , 10, 1490-1503		8
306	Complex Large-Bore Radial percutaneous coronary intervention: rationale of the COLOR trial study protocol. <i>BMJ Open</i> , 2020 , 10, e038042	3	3
305	Rationale and design of a European epidemiological post-authorization safety study (PASS) program: rivaroxaban use in routine clinical practice. 2020 , 19, 1513-1520		2
304	Evaluating an Algorithm and Clinical Prediction Rule for Diagnosis of Bone Stress Injuries. 2020 , 12, 449-455		2
303	Incidence and Impact of Thrombocytopenia in Patients Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. 2020 , 134, 55-61		2
302	A Review of the Incidence Diagnosis and Treatment of Spontaneous Hemorrhage in Patients Treated with Direct Oral Anticoagulants. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	5
301	Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial. 2020 , 324, 761-771		107
300	Impact of Coronary Lesion Stability on the Benefit of Emergent Percutaneous Coronary Intervention After Sudden Cardiac Arrest. 2020 , 13, e009181		3
299	Trial Design Principles for Patients at High Bleeding Risk Undergoing PCI: JACC Scientific Expert Panel. 2020 , 76, 1468-1483		16
298	Major Bleeding Events Are Stronger Predictors of Long-Term Mortality Than Coronary Events in Secondary Prevention Therapy for Ischaemic Heart Disease. 2020 , 2020, 9303750		
297	The prognostic value of elevated matrix metalloproteinase-9 in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: A two-year prospective study. 2020 , 39, 267-276		0
296	Bleeding risk of ticagrelor compared to clopidogrel in intensive care unit patients with acute coronary syndrome: A propensity-score matching analysis. <i>PLoS ONE</i> , 2020 , 15, e0232768	3.7	6

295	Prediction of mortality from 12-lead electrocardiogram voltage data using a deep neural network. 2020 , 26, 886-891		61
294	Bleeding complications with clopidogrel or ticagrelor in ST-elevation myocardial infarction patients - A real life cohort study of two treatment strategies. <i>IJC Heart and Vasculature</i> , 2020 , 27, 100495	2.4	4
293	Impairment of coronary flow velocity reserve and global longitudinal strain in women with cardiac syndrome X and slow coronary flow. 2020 , 76, 1-8		6
292	Sex differences in platelet reactivity in patients with myocardial infarction treated with triple antiplatelet therapy - results from assessing platelet activity in coronary heart disease (APACHE). 2021 , 32, 524-532		1
291	Meta-Analysis of Bleeding Scores Performance for Acute Coronary Syndrome. <i>Heart Lung and Circulation</i> , 2020 , 29, 1749-1757	1.8	0
290	COMPASS criteria applied to a contemporary cohort of unselected patients with stable coronary artery diseases: insights from the START registry. 2021 , 7, 513-520		2
289	Effect on mortality of different routes of administration and loading dose of aspirin in patients with ST-segment elevation acute myocardial infarction treated with primary angioplasty. 2020 , 31, 348-353		1
288	Discharge Hemoglobin Association with Long-Term Outcomes of ST-Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention. 2020 , 2020, 8647837		2
287	Early Escalation of Mechanical Circulatory Support Stabilizes and Potentially Rescues Patients in Refractory Cardiogenic Shock. 2020 , 13, e005853		36
286	One-year clinical outcomes of patients with versus without acute coronary syndrome with 3-month duration of dual antiplatelet therapy after everolimus-eluting stent implantation. <i>PLoS ONE</i> , 2020 , 15, e0227612	3.7	2
285	The prognostic value of elevated matrix metalloproteinase-9 in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: A two-year prospective study. 2020 , 39, 267-276		5
284	Characteristics and Outcomes in Patients Presenting With COVID-19 and ST-Segment Elevation Myocardial Infarction. 2020 , 131, 1-6		46
283	Percutaneous coronary intervention in the very elderly with NSTEMI-ACS: the randomized 80+ study. 2020 , 54, 315-321		2
282	Rotational Atherectomy for Severely Calcified Lesions in Patients With Left Ventricular Systolic Dysfunction: One-Year Outcomes From a Single-Center Registry Analysis. 2020 , 21, 1220-1227		0
281	Optimal Antithrombotic Regimens for Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: An Updated Network Meta-analysis. 2020 , 5, 582-589		34
280	Efficacy and Safety of High Potent P2Y Inhibitors Prasugrel and Ticagrelor in Patients With Coronary Heart Disease Treated With Dual Antiplatelet Therapy: A Sex-Specific Systematic Review and Meta-Analysis. 2020 , 9, e014457		8
279	Anticoagulants for Stroke Prevention in Atrial Fibrillation in Elderly Patients. 2020 , 34, 555-568		9
278	Relation of collateral circulation with reciprocal changes in patients with acute ST-elevation myocardial infarction. 2020 , 60, 36-43		1

277	Impact of bleeding events after percutaneous coronary intervention in patients on hemodialysis. 2020 , 35, 1323-1330		
276	Post resuscitation electrocardiogram for coronary angiography indication after out-of-hospital cardiac arrest. 2020 , 310, 73-79		1
275	Correlation of Hemoglobin & C-Reactive Protein Levels with In-hospital Outcome of Patient with Acute Coronary Syndrome. 2020 , 17, 3-8		
274	qTICI: Quantitative assessment of brain tissue reperfusion on digital subtraction angiograms of acute ischemic stroke patients. 2021 , 16, 207-216		3
273	Anti-thrombotic strategies in patients with atrial fibrillation undergoing PCI. 2021 , 110, 759-774		3
272	Systemic and local factors associated with reduced thrombolysis in myocardial infarction flow in ST-segment elevation myocardial infarction patients with plaque erosion detected by intravascular optical coherence tomography. 2021 , 37, 399-409		2
271	Indigo aspiration thrombectomy for treating acute lower limb ischemia: Technical considerations. 2021 , 73, 355-356		1
270	Angiographic outcomes in STEMI patients receiving fibrinolysis with guideline directed optimal antithrombotic therapy. 2021 , 73, 125-128		0
269	Comparison of clinical and angiographic results in COVID-19 positive and negative patients undergoing primary coronary intervention due to ST-elevation myocardial infarction. 2021 , 7, 78		0
268	Impact of percutaneous reperfusion on ischemic mitral regurgitation in patients presented with inferior ST-segment elevation myocardial infarction. 2021 , 14, 17-22		
267	Primary percutaneous coronary intervention is appropriate in transient ST-elevation myocardial infarction. 2021 ,		
266	Impact of the COVID-19 outbreak on hospitalizations and outcomes in patients with acute myocardial infarction in a Japanese Single Center. 2021 , 36, 1474-1483		6
265	Improvement of long-term clinical outcomes by successful PCI in the very elderly women with ACS. 2021 , 21, 122		0
264	Long term risk and costs of bleeding in men and women treated with triple antithrombotic therapy-An observational study. <i>PLoS ONE</i> , 2021 , 16, e0248359	3.7	0
263	Micro-CT-Based Quantification of Extracted Thrombus Burden Characteristics and Association With Angiographic Outcomes in Patients With ST-Elevation Myocardial Infarction: The QUEST-STEMI Study. <i>Frontiers in Cardiovascular Medicine</i> , 2021 , 8, 646064	5.4	3
262	Periprocedural and In-Hospital Outcomes Among Percutaneous Coronary Intervention in Saphenous Vein Graft: A Retrospective Observational Study at a Tertiary Care Hospital in South Asian Country. 2021 , 13, e14251		
261	Ferumoxitol-enhanced magnetic resonance T1 reactivity for depiction of myocardial hypoperfusion. 2021 , 34, e4518		2
260	Safety and Efficacy of Vacuum Assisted Thrombo-Aspiration in Patients with Acute Lower Limb Ischaemia: The INDIAN Trial. 2021 , 61, 820-828		12

259	Effects of adding TEOS on sintering process, morphology and microwave dielectric properties of Y3Al5O12 ceramics. 2021 , 47, 12826-12832		3
258	Changes in non-culprit lesion severity on follow-up coronary angiography after primary percutaneous coronary intervention.		
257	Impact of Antecedent Aspirin Use on Infarct Size, Bleeding and Composite Endpoint in Patients with de Novo Acute Myocardial Infarction. 2021 , 17, 441-452		0
256	Non-vitamin-K-antagonist oral anticoagulants (NOACs) after acute myocardial infarction: a network meta-analysis.		
255	Predictors of Favorable Angiographic Outcomes After Drug-Coated Balloon Use for de novo Small Vessel Coronary Disease (DCB-ONLY). 2021 , 72, 986-993		0
254	Mechanical Complications of Myocardial Infarction. <i>International Heart Journal</i> , 2021 , 62, 499-509	1.8	0
253	Antiplatelet Therapy in Patients with Atrial Fibrillation: A Systematic Review and Metaanalysis of Randomized Trials. 2021 ,		0
252	Diseases of the Cardiovascular System. 2021 , 505-552		1
251	Bleeding in the Elderly: Risk Factors and Impact on Clinical Outcomes After an Acute Coronary Syndrome, a Sub-study of the Randomized ANTARCTIC Trial. 2021 , 21, 681-691		0
250	Impact of acute total occlusion of the culprit artery on outcome in NSTEMI based on the results of a large national registry. 2021 , 21, 297		0
249	Pre-hospital heparin use for ST-elevation myocardial infarction is safe and improves angiographic outcomes. 2021 ,		1
248	Role of 2-dimensional speckle tracking echocardiography in diagnosis of right ventricular involvement in patients with inferior wall myocardial infarction undergoing primary percutaneous coronary intervention. 2021 , 37, 2625-2634		0
247	Access-Site vs Non-Access-Site Major Bleeding and In-Hospital Outcomes Among STEMI Patients Receiving Primary PCI. 2021 , 3, 864-871		1
246	Duration of dual antiplatelet therapy and stability of coronary heart disease: a 60 000-patient meta-analysis of randomised controlled trials. 2021 , 8,		0
245	Adenosine-Induced Coronary Steal Is Observed in Patients Presenting With ST-Segment-Elevation Myocardial Infarction. 2021 , 10, e019899		1
244	Application of Modern Clinical Risk Scores in the Global Assessment of Risks Related to the Diagnosis and Treatment of Acute Coronary Syndromes in Everyday Medical Practice. 2021 , 18,		1
243	First in man evaluation of a novel circulatory support device: Early experience with the Impella 5.5 after CE mark approval in Germany. 2021 , 40, 850-855		4
242	Functional Coronary Angiography-Derived Index of Microcirculatory Resistance in Patients With ST-Segment Elevation Myocardial Infarction. <i>JACC: Cardiovascular Interventions</i> , 2021 , 14, 1670-1684	5	2

241	Percutaneous Myocardial Revascularization in Late-Presenting Patients With STEMI. 2021 , 78, 1291-1305		3
240	Cardiac Regeneration: New Insights Into the Frontier of Ischemic Heart Failure Therapy. 2020 , 8, 637538		4
239	Novel predictors and adverse long-term outcomes of No-reflow phenomenon in patients with acute ST elevation myocardial infarction undergoing primary percutaneous coronary intervention. 2021 , 73, 35-43		4
238	Predictive Ability of Academic Research Consortium for High Bleeding Risk Criteria in ST-Elevation Myocardial Infarction Patients Undergoing Primary Coronary Intervention. <i>Circulation Journal</i> , 2021 , 85, 159-165	2.9	4
237	Changing Concepts of the Pathophysiology of Cerebral and Myocardial Infarction. 1993 , 1-12		1
236	New Developments in Thrombolytic Therapy. 1990 , 333-354		10
235	The effects of streptokinase and tissue plasminogen activator on left ventricular function. 1990 , 281, 383-7		2
234	Altered rheological properties of blood following administrations of tissue plasminogen activator and streptokinase in patients with acute myocardial infarction. 1990 , 281, 409-17		7
233	Thrombolytic Therapy for Acute Myocardial Infarction With ST-Segment Elevation. 1999 , 201-241		1
232	A Unified Framework to Assess Myocardial Function from 4D Images. 1995 , 327-337		8
231	Coronary Atherosclerosis: Acute Coronary Syndromes. 2002 , 746-779		1
230	Thrombolysis in Stroke: Timing of Recanalization and Its Clinical Consequences. 1991 , 46-59		3
229	The signal averaged ECG in detecting coronary artery disease. 1993 , 485-517		1
228	Adjuvant Agents to Enhance and Sustain Reperfusion with t-PA: Studies in Experimental Dog Models. 1991 , 221-232		1
227	Role of Serum Biochemical Markers in Clinical Trials. 1998 , 189-199		1
226	Characterization of a nonglycosylated single chain urinary plasminogen activator secreted from yeast.. 1990 , 265, 801-807		32
225	Diagnostic Use of CK-MM and CK-MB Isoforms for Detecting Myocardial Infarction. 1989 , 9, 643-654		26
224	Thrombolysis in Acute Myocardial infarction. <i>Cardiology Clinics</i> , 1988 , 6, 119-137	2.5	8

223	Acute MI: Role of Thrombolysis and Intervention. 1989 , 5, 435-453			1
222	Pharmacologic Review of Thrombolytic Agents. 1990 , 2, 613-627			3
221	Thrombolytic Therapy: A Review of the Literature on Streptokinase and Tissue Plasminogen Activator with Implications for Practice. 1989 , 1, 359-372			2
220	Hematologic Causes of Intracerebral Hemorrhage and Their Treatment. 1992 , 3, 637-658			29
219	Thrombolytic therapy versus primary angioplasty in the treatment of acute myocardial infarction. 1999 , 13, 46-59			2
218	Antithrombotic effect of GYKI-14766 in a canine model of arterial and venous rethrombosis: a comparison with heparin. <i>Journal of Cardiovascular Pharmacology</i> , 1996 , 27, 545-55	3.1		15
217	Direct Xa inhibitors in addition to antiplatelet therapy in acute coronary syndrome: meta-analysis of randomized trials. 2017 , 28, 395-405			2
216	Guidelines for the early management of patients with myocardial infarction. British Heart Foundation Working Group. 1994 , 308, 767-71			99
215	Antiplatelet therapy in the primary prevention of cardiovascular disease in patients with chronic obstructive pulmonary disease: protocol of a randomised controlled proof-of-concept trial (APPLE COPD-ICON 2). <i>BMJ Open</i> , 2018 , 8, e020713	3		1
214	Multivessel myocardial infarction: a window to future treatments of myocardial infarction. 2010 , 2, 82-8			3
213	Early and 1-year clinical outcome of patients' evolving non-Q-wave versus Q-wave myocardial infarction after thrombolysis. Results from The TIMI II Study. <i>Circulation</i> , 1995 , 91, 2541-8	16.7		55
212	Thrombolysis and reocclusion in experimental jugular vein and coronary artery thrombosis. Effects of a plasminogen activator inhibitor type 1-neutralizing monoclonal antibody. <i>Circulation</i> , 1995 , 91, 1175-81	16.7		71
211	Noninvasive determination of infarct artery patency by cine magnetic resonance angiography. <i>Circulation</i> , 1995 , 91, 1347-53	16.7		48
210	Long-term prognosis of patients with acute myocardial infarction due to unprotected left main coronary artery disease: a single-centre experience over 14 years. 2016 , 57, 396-400			7
209	Human tissue-type plasminogen activator releases fibrinopeptides A and B from fibrinogen. 1988 , 82, 1700-7			58
208	Enhancement of fibrinolysis in vitro by ultrasound. 1992 , 90, 2063-8			195
207	Relationship of serum vitamin D levels with coronary thrombus grade, TIMI flow, and myocardial blush grade in patients with acute ST-segment elevation myocardial infarction. <i>Egyptian Heart Journal</i> , 2020 , 72, 84	1.3		2
206	Anemia: A significant cardiovascular mortality risk after ST-segment elevation myocardial infarction complicated by the comorbidities of hypertension and kidney disease. <i>PLoS ONE</i> , 2017 , 12, e0180165	3.7		22

205	Antithrombotic therapy strategies for atrial fibrillation patients undergoing percutaneous coronary intervention: A systematic review and network meta-analysis. <i>PLoS ONE</i> , 2017 , 12, e0186449	3.7	9
204	The Impact of Admission Serum Creatinine Derived Estimated Glomerular Filtration Rate on Major Adverse Cardiac Events in ST-Segment Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention. 2016 , 8, 325-30		2
203	Increased hyperkinesia in noninfarcted areas during short-term follow-up in patients with first anterior acute myocardial infarction treated by direct percutaneous transluminal coronary angioplasty. 1999 , 40, 549-60		4
202	Adding cystatin C to the GRACE scale improves the prediction of bleeding complications in non-invasively treated patients with acute coronary syndrome. 2012 , 11, 38-43		1
201	Acute Interventions for Ischemic Stroke: Present Status and Future Directions. 2000 , 7, 423-428		11
200	Arterial Thrombus Dissolution In Vivo Using a Transducer-Tipped, High-Frequency Ultrasound Catheter and Local Low-Dose Urokinase Delivery. 2001 , 8, 282-290		11
199	[Thrombolytic therapy of ischemic stroke]. 2018 , 118, 4-14		3
198	Efficacy and safety of an antithrombotic regimen for atrial fibrillation patients with acute coronary syndrome or those undergoing percutaneous coronary intervention: a meta-analysis. 2020 , 12, 12930-12942		1
197	Coronary artery disease in women: a review on prevention, pathophysiology, diagnosis, and treatment. 2006 , 2, 465-75		3
196	Biomarkers Associated with Bleeding Risk in the Setting of Atrial Fibrillation. 2019 , 26, 824-836		2
195	Coronary collateral circulation: Effects on outcomes of acute anterior myocardial infarction after primary percutaneous coronary intervention. <i>Journal of Geriatric Cardiology</i> , 2011 , 8, 93-8	1.7	9
194	Relationship between cytochrome P450 2C19*17 genotype distribution, platelet aggregation and bleeding risk in patients with blood stasis syndrome of coronary artery disease treated with clopidogrel. 2012 , 10, 647-54		9
193	The coronary slow flow phenomenon: characteristics, mechanisms and implications. 2011 , 1, 37-43		51
192	Early experience with a new approach for percutaneous intervention of totally occluded saphenous vein graft: is the flow the best thrombolytic?. 2010 , 6, 461-6		7
191	A randomised controlled trial of upstream administration of eptifibatid in patients presenting non-ST segment elevation acute coronary syndrome treated with an invasive strategy. 2007 , 3, 228-34		6
190	Ongoing tirofiban in myocardial infarction evaluation (On-TIME) 2 trial: rationale and study design. 2007 , 3, 371-80		21
189	Operator dependence of outcome after primary percutaneous coronary intervention. 2011 , 6, 760-7		10
188	Radial artery access for above the knee angioplasty: a feasibility study. 2011 , 7, 924-9		21

187	Rationale and design of the EXAMINATION trial: a randomised comparison between everolimus-eluting stents and cobalt-chromium bare-metal stents in ST-elevation myocardial infarction. 2011 , 7, 977-84	32
186	Stent for Life Initiative placed at the forefront in Egypt 2011. 2012 , 8 Suppl P, P108-15	8
185	Uninterrupted oral anticoagulation versus bridging in patients with long-term oral anticoagulation during percutaneous coronary intervention: subgroup analysis from the WOEST trial. 2015 , 11, 381-90	28
184	BLEED-Myocardial Infarction Score: Predicting mid-term post-discharge bleeding events. 2013 , 5, 196-206	7
183	Percutaneous Coronary Intervention for Coronary Artery Disease. 2004 , 47, 736	1
182	Atopaxar. A novel player in antiplatelet therapy?. 2012 , 32, 228-33	2
181	Prehospital thrombolysis followed by early angiography and percutaneous coronary intervention where appropriate - an underused strategy for the management of STEMI. 2010 , 193, 234-7	4
180	Effects on the signal-averaged electrocardiogram of opening the coronary artery by thrombolytic therapy or percutaneous transluminal coronary angioplasty during acute myocardial infarction. 2000 , 527-533	
179	Mild Hypothermia for Cerebral Resuscitation in Survivors of Out-of-Hospital Ventricular Fibrillation. 2000 , 195-202	
178	???????????????? : ??????? : 8.????????(64? ?????????). 2000 , 8, 319-320	
177	Adult Heart Disease. 2001 , 1333-1376	
176	Comparative Evaluations of tPA vs SK with Particular Reference to the GUSTO-I Trial. 2001 , 261-286	
175	Tissue-Type Plasminogen Activator (tPA). 2001 , 209-229	
174	Conjunctive Therapy to Reduce the Occurrence of Coronary Reocclusion after Thrombolytic Treatment of AMI. 2001 , 287-322	
173	Q-Wave Myocardial Infarction. 2001 , 177-193	
172	Thrombolysetherapie des akuten Herzinfarktes. 2002 , 140-157	
171	Enhancement of Coronary Blood Flow as Myocardial Salvage Therapy. 2002 , 178-190	
170	The Use of Abciximab in Therapy-Resistant Unstable Angina. 2003 , 203-231	

169 Adult Heart Disease. **2003**, 567-585

168 Advanced Challenge in Resuscitative Hypothermia in Patients with Cardiac Arrest on Arrival at the Emergency Room. **2004**, 308-314

1

167 Differences Between Unstable Angina and Acute Myocardial Infarction: Pathophysiological and Clinical Spectrum. **2004**, 143-170

166 Bleeding Complications as Predictor for Mortality. **2008**, ???-???

165 Platelet Glycoprotein IIb/IIIa Receptor Blockade in Primary Coronary Intervention. **2009**, 169-194

164 Thrombolysis for Acute Ischemic Stroke. **2009**, 301-346

163 Fibrinolysis for Acute Myocardial Infarction. **2009**, 651-666

162 Antithrombin Therapy for Acute ST-Segment Elevation Myocardial Infarction. **2010**, 235-246

161 Thrombolytic Agents. **2010**, 556-570

160 Thrombolytics/Anticoagulants. **2011**, 1-67

159 Bleeding in the Acute Coronary Syndromes. **2011**, 322-329

158 A prospective follow-up study of periprocedural complications in patients undergoing elective coronary angiography and/or PCI. **2011**, 53, 118-123

157 Risk of Renal Dysfunction after Less Invasive Multivessel Coronary Artery Bypass Grafting. **2012**, 7, 180-186

156 New Techniques for the Assessment of Coronary Microvascular Abnormalities. **2013**, 253-263

155 Coronary No-Reflow Following Percutaneous Coronary Intervention. **2013**, 1-26

154 Acute Coronary Syndromes. **2014**, 15-36

1

153 Interventional Management of Acute Myocardial Infarction. **2014**, 207-220

152 Die TIMI-Studien mit rt-PA beim akuten Herzinfarkt. **1987**, 101-113

- 151 Heart Failure in Acute Pulmonary Hypertension. **1988**, 164-180
- 150 Pathophysiology and Treatment of Pulmonary Hypertension. **1988**, 250-262
- 149 Is There a Role for Thrombolysis in Non-Q-Wave Myocardial Infarction and Unstable Angina Pectoris?. **1988**, 128-135
- 148 Elektrokardiographische Muster eines drohenden, unabhängig von instabiler pektanginöser Symptomatik auftretenden Koronarverschlusses. **1989**, 106-117
- 147 Therapie der terminalen Herzinsuffizienz âMöglichkeiten und Probleme der Herztransplantation aus internistischer Sicht. **1989**, 63-73
- 146 Platelet Inhibitor Drugs in Coronary Artery Disease and Coronary Intervention. **1989**, 329-354
- 145 Myocardial Reperfusion: Role of Adjunctive Agents to Improve Reperfusion and Prevent Reperfusion Injury. **1989**, 47-58
- 144 The Use of Cardiovascular Drugs Following Thrombolysis in Humans. **1989**, 199-205
- 143 Internistisch indizierte systemische Lysen im Vergleich zu lokalen Kurzzeitlysen âErgebnisse und Komplikationen aus neurologischer Sicht. **1989**, 1071-1075
- 142 Which Antithrombotic Therapy Has Proven Most Effective for the Treatment of Deep Arterial Injury, Ruptured Plaque, and Post-thrombolysis?. **1989**, 223-233
- 141 New Agents and New Insights for Thrombolytic Therapy in Acute Myocardial Infarction: Focus on Anistreplase, Urokinase, and Prourokinase. **1989**, 29-46
- 140 Coronary thrombolysis. **1989**, 150, 109-109
- 139 Electrocardiographic patterns of impending coronary closure independent of unstable anginal symptoms. **1989**, 96-106
- 138 What are the Overall Strategies for Post-Thrombolytic Care That Include Use of Angioplasty?. **1989**, 99-108
- 137 Intensivtherapie des Myokardinfarktes âLimitierung der Infarktgrö. **1989**, 200-213
- 136 Zukunft und Grenzen der medikamentösen Therapie kardialer Erkrankungen. **1990**, 31-57
- 135 Antithrombotic and Thrombolytic Drugs. **1990**, 326-336
- 134 Implications of the TIMI Trials. **1990**, 281, 361-6

- 133 Therapie des akuten Myokardinfarktes mit Thrombolysse und PTCA. **1990**, 85-102
- 132 Clinical application of tissue plasminogen activator therapy in acute myocardial infarction. **1990**, 281, 395-9
- 131 Clinical trials with alteplase (rt-PA) in acute myocardial infarction. **1990**, 281, 377-82
- 130 Experience with Marketed Biotech Products: rt-PA. **1990**, 219-226
- 129 Thrombolytische Behandlung der Venenthrombose. **1990**, 343-354
- 128 Fibrinolysis: Thrombolytic Agents, Mechanisms, and New Developments. **1991**, 9-23
- 127 Fibrinolysis in Myocardial Infarction: Lessons for Cerebrovascular Disease. **1991**, 24-35
- 126 Intensive Care Therapeutics. **1992**, 237-269
- 125 Anticoagulants, Antithrombotic and Thrombolytic Agents. **1992**, 377-447
- 124 Thrombolytic Therapy in Acute Myocardial Infarction. **1992**, 187-192
- 123 Biotechnology Products: An Overview. **1993**, 381-401
- 122 Clinical and quantitative angiographic results of a randomized trial comparing direct coronary angioplasty with intravenous streptokinase in acute myocardial infarction. **1994**, 387-396
- 121 Thrombolytic Retreatment for Coronary Arterial Reocclusion. **1994**, 175-193
- 120 Bleeding Disorders. **1994**, 117-151
- 119 Future of Coronary Thrombolysis. **1994**, 279-290
- 118 The Thrombolysis in Myocardial Infarction (TIMI) Trial. **1994**, 53-67
- 117 Evaluation of thrombolytic and monoclonal platelet GPIIb/IIIa receptor antibody therapy in refractory unstable angina pectoris: correlation between quantitative assessment of coronary angiograms and clinical course. **1994**, 371-386
- 116 MANAGEMENT OF ACUTEMYOCARDIAL INFARCTION. *Anesthesiology Clinics*, **1995**, 13, 923-942

- 115 Klinik der koronaren Herzerkrankung II: Akuter Herzinfarkt. **1996**, 679-724
- 114 The TEAM Studies: A Review. **1996**, 9, 361-372
- 113 Novel Antithrombotic Strategies. **1998**, 241-275
- 112 Acute Myocardial Infarction. **1998**, 143-197
- 111 Interventional Approaches to the Treatment of Acute Coronary Ischemic Syndromes. **1998**, 277-312
- 110 No Effect of Clot Age or Thrombolysis on Argatrobanâ Inhibition of Thrombin. **1998**, 92, 2064-2074
- 109 The Use of Abciximab in Therapy Resistant Unstable Angina. **1999**, 143-168
- 108 Platelet Glycoprotein IIB/IIIa Integrin Inhibition in Acute Myocardial Infarction. **1999**, 93-105
- 107 Coronary No-Reflow Following Percutaneous Coronary Intervention. **2015**, 1865-1884
- 106 Qualitative and Quantitative Coronary Angiography. **2015**, 47-74
- 105 Re-establishing Blood Flow After Intravascular Thrombosis. **2017**, 337-352
- 104 Complications of Myocardial Infarction. **2017**, 121-127
- 103 IMPACT OF HAEMOGLOBIN LEVELS ON OUTCOMES IN ACUTE CORONARY SYNDROME. **2017**, 4, 3555-3563
- 102 Influence of angiographic spontaneous coronary reperfusion on long-term prognosis in patients with ST-segment elevation myocardial infarction. **2017**, 8, 79767-79774 3
- 101 Acute Hyperglycemia an Independent Risk Factor for Contrast-Induced Nephropathy in Patients Undergoing Primary Percutaneous Coronary Intervention for STEMI. **2017**, 9, 0
- 100 Bleeding Associated with Angiography and Percutaneous Coronary Intervention. **2018**, 503-522
- 99 Management of Cardiogenic Shock. **2018**, 91-116
- 98 Drug-Coated Balloons in STEMI. **2018**, 151-165 0

- 97 Primer perktan koroner giriim uygulanan ST ykismeli miyokart enfarkt hastalarda sol ventriklejeksiyon fraksiyonu ve HAS-BLED skoru kombinasyonunun mortaliteyi igdettii deeri.
- 96 In-hospital Outcomes of Patients with ST-segment Elevation Myocardial Infarction who were Intubated before Primary Percutaneous Intervention: Experience of a tertiary center. **2019**, 53, 179-185
- 95 Clinical outcome of intracoronary versus intravenous high-dose bolus administration of tirofiban in diabetic patients undergoing primary percutaneous coronary intervention. **2019**, 30, 285-289 1
- 94 Impact of Smoking Status on Hospital Outcome of Patients with ST-Segment Elevation Myocardial Infarction Either Treated by Pharmacoinvasive Strategy or Primary Percutaneous Coronary Intervention. *World Journal of Cardiovascular Diseases*, **2020**, 10, 347-356 0
- 93 Oral Antiplatelet Therapy Administered Upstream to Patients With NSTEMI. *Critical Pathways in Cardiology*, **2020**, 19, 166-172 1.3
- 92 Periprocedural and clinical outcomes of percutaneous coronary intervention of chronic total occlusions in patients with low- and mid-range ejection fractions. *Egyptian Heart Journal*, **2020**, 72, 28 1.3 1
- 91 Clopidogrel Monotherapy vs. Aspirin Monotherapy Following Short-Term Dual Antiplatelet Therapy in Patients Receiving Everolimus-Eluting Coronary Stent Implantation. *Circulation Journal*, **2020**, 84, 1483-1492^{3.9} 3
- 90 Coronary Blood Flow Measurement in Conventional Coronary Angiograms by a New Method Based on Contrast Density Detection. A Physiological Insight. *Arquivos Brasileiros De Cardiologia*, **2020**, 115, 503-512 1.2 0
- 89 Delphi Consensus Study Toward a Comprehensive Classification System for Angioplasty-Induced Femoropopliteal Dissection: The DISFORM Study. *JACC: Cardiovascular Interventions*, **2021**, 14, 2391-2405 1 2
- 88 Short- versus long-term dual antiplatelet therapy after second-generation drug-eluting stent implantation in patients with diabetes mellitus: A meta-analysis of randomized controlled trials. *PLoS ONE*, **2020**, 15, e0242845 3.7 0
- 87 Coronary thrombectomy. **2020**, 559-569
- 86 The clinical and coronary angiographic profile of 601 older adult patients with acute coronary syndrome treated at a tertiary hospital in North India and complications of percutaneous coronary intervention with the 30-day mortality. *Journal of the Indian Academy of Geriatrics*, **2020**, 16, 139 0.1
- 85 P2Y12 inhibition in acute coronary syndromes treated with percutaneous intervention - Understanding the debate on Prasugrel or Ticagrelor. *Pharmacology & Therapeutics*, **2021**, 108029 13.9 0
- 84 Experimental Evidence for Enhancement of Thrombolysis by Conventional Thrombolytic Drugs. **1997**, 389-397
- 83 Post-Procedural Anticoagulation After Primary Percutaneous Coronary Intervention for Anterior Acute Myocardial Infarction With Severe Left Ventricular Dysfunction. *Circulation Journal*, **2020**, 84, 1728-1733^{2.9} 0
- 82 The Role of Nuclear Cardiology in Assessment of Acute Myocardial Infarction. *Cardiology Clinics*, **1988**, 6, 81-95 2.5 2
- 81 Unique referral system contributes to long-term net clinical benefits in patients undergoing secondary prevention therapy after percutaneous coronary intervention. *PLoS ONE*, **2020**, 15, e0242707^{3.7}
- 80 Myocardial Salvage: Thrombolytic Therapy. *Emergency Medicine Clinics of North America*, **1988**, 6, 351-359.9

79	Experimental Models of Myocardial Ischemia, Reperfusion, and Coronary Steal: Scientific Foundations and Clinical Significance. <i>Anesthesiology Clinics</i> , 1988 , 6, 485-503		1
78	Cardiologic Reperfusion Treatment for Acute Myocardial Infarction. <i>Anesthesiology Clinics</i> , 1988 , 6, 631-649		
77	Is thrombolysis alone the best therapy for acute myocardial infarction? Current status and emerging strategies. <i>Texas Heart Institute Journal</i> , 1991 , 18, 50-61	0.8	2
76	Thrombolytic therapy for acute myocardial infarction. Lessons to be learned. <i>Texas Heart Institute Journal</i> , 1991 , 18, 103-9	0.8	
75	Current status of thrombolytic therapy in acute myocardial infarction. <i>Texas Heart Institute Journal</i> , 1991 , 18, 250-62	0.8	
74	Therapeutic options in treating acute myocardial infarction. <i>Western Journal of Medicine</i> , 1989 , 151, 440-7		
73	Thrombolytic therapy for myocardial infarction: the problem, the promise and the price. <i>Cmaj</i> , 1988 , 138, 598-601	3.5	2
72	Guidelines for the use of intravenous thrombolytic agents in acute myocardial infarction. Ontario Medical Association Consensus Group on Thrombolytic Therapy. <i>Cmaj</i> , 1989 , 140, 1289-99	3.5	7
71	Streptokinase versus alteplase in acute myocardial infarction. <i>Journal of the Royal Society of Medicine</i> , 1996 , 89, 427-30	2.3	2
70	Thrombolytic therapy for central retinal vein occlusion: results of a pilot study. <i>Transactions of the American Ophthalmological Society</i> , 1996 , 94, 471-504		47
69	Angiographic frame counts 90 minutes after streptokinase predict left ventricular function at 48 hours following myocardial infarction. <i>Heart</i> , 1999 , 81, 128-33	5.1	2
68	Thrombolysis in the air. Air-ambulance paramedics flying to remote communities treat patients before hospitalization. <i>Canadian Family Physician</i> , 2000 , 46, 1313-9	0.9	1
67	Prediction of success and major complications during elective coronary angioplasty. <i>Netherlands Heart Journal</i> , 2001 , 9, 10-15	2.2	
66	Clinical characteristics and outcome of patients with acute myocardial infarction and preinfarction angina. <i>Netherlands Heart Journal</i> , 2001 , 9, 328-333	2.2	
65	Angiographic determination of myocardial reperfusion by primary coronary angioplasty for acute myocardial infarction. <i>Netherlands Heart Journal</i> , 2002 , 10, 111-117	2.2	3
64	Routine pretreatment with abciximab versus standard periprocedural therapy in mechanically ventilated cardiogenic shock patients undergoing primary percutaneous coronary intervention: Subanalysis of the PRAGUE-7 study. <i>Experimental and Clinical Cardiology</i> , 2013 , 18, 81-4		5
63	Impact of admission blood glucose levels on prognosis of elderly patients with ST elevation myocardial infarction treated by primary percutaneous coronary intervention. <i>Journal of Geriatric Cardiology</i> , 2013 , 10, 310-6	1.7	8
62	Efficacy of a new mutated recombinant tissue-type plasminogen activator in beagles with acute coronary artery thrombi. <i>World Journal of Emergency Medicine</i> , 2010 , 1, 126-31	1.9	

61	Efficacy and safety of individually tailored antiplatelet therapy in patients with acute coronary syndrome after coronary stenting: a single center, randomized, feasibility study. <i>Journal of Geriatric Cardiology</i> , 2015 , 12, 23-9	1.7	4
60	Efficacy and safety of cangrelor for patients with coronary artery disease: a meta-analysis of four randomized trials. <i>International Journal of Clinical and Experimental Medicine</i> , 2015 , 8, 800-8		2
59	Efficacy and safety of different doses of tirofiban combined with ticagrelor on diabetic patients with AMI receiving in emergency percutaneous coronary intervention (PCI). <i>International Journal of Clinical and Experimental Medicine</i> , 2015 , 8, 11360-9		6
58	Predictive Value of Elevated Uric Acid in Turkish Patients Undergoing Primary Angioplasty for ST Elevation Myocardial Infarction. <i>Acta Cardiologica Sinica</i> , 2014 , 30, 119-27	1.1	7
57	Effects of Coronary Arterial Injection of Tirofiban on Diabetes Mellitus Complicated with Acute Myocardial Infarction in the Elderly. <i>Acta Cardiologica Sinica</i> , 2013 , 29, 550-6	1.1	1
56	The Management and Prognostic Factors of Acute Coronary Syndrome: Evidence from the Taiwan Acute Coronary Syndrome Full Spectrum Registry. <i>Acta Cardiologica Sinica</i> , 2017 , 33, 329-338	1.1	18
55	Impact of Cytochrome P450 2C19 Reduced-Function Polymorphism on Lesions and Clinical Outcome in Japanese Patients After Drug-eluting Stent Implantation. <i>Kobe Journal of Medical Sciences</i> , 2018 , 64, E56-E63	0.6	
54	Clinical, Laboratory, and Procedural Predictors of No-Reflow in Patients Undergoing Primary Percutaneous Coronary Intervention. <i>The Journal of Tehran Heart Center</i> , 2020 , 15, 50-56	0.3	
53	Combined intraarterial/intravenous thrombolysis for acute ischemic stroke. <i>American Journal of Neuroradiology</i> , 2001 , 22, 352-8	4.4	63
52	Stroke Prognosis: Monitoring the Hemodynamics and Blood Pressure by TCD/TCCS. 2022 , 505-525		
51	Comparison of door-to-balloon time and in-hospital outcomes in patients with ST-elevation myocardial infarction between before versus after COVID-19 pandemic.. <i>Cardiovascular Intervention and Therapeutics</i> , 2022 , 1	2.5	3
50	No-reflow phenomenon and in vivo cholesterol crystals combined with lipid core in acute myocardial infarction.. <i>IJC Heart and Vasculature</i> , 2022 , 38, 100953	2.4	0
49	Clinical, Laboratory, and Procedural Predictors of NoReflow in Patients Undergoing Primary Percutaneous Coronary Intervention. <i>Journal of Tehran University Heart Center</i> , 2020 , 15, 50-56	0.2	1
48	 <i>Sovremennaya Nauka: Aktual'nye Problemy Teorii i Praktiki Seriy Estestvennyye i Tehnicheskie Nauki</i> , 2021 , 175-179	0.1	
47	Predictors of Survival and Ventricular Recovery Following Acute Myocardial Infarction Requiring Extracorporeal Membrane Oxygenation Therapy.. <i>ASAIO Journal</i> , 2022 ,	3.6	0
46	Adjunctive Catheter-Directed Thrombolysis during Primary PCI for ST-Segment Elevation Myocardial Infarction with High Thrombus Burden.. <i>Journal of Clinical Medicine</i> , 2022 , 11,	5.1	1
45	Incidence and Timing of Thrombocytopenia in Patients Receiving Impella Ventricular Assist Device Support. <i>ASAIO Journal</i> , 2022 , Publish Ahead of Print,	3.6	1
44	Safety and Efficacy Evaluation of Antithrombotic Therapy with Rivaroxaban and Clopidogrel After PCI in Chinese Patients.. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2022 , 28, 10760296221074681	3.3	0

43	Prognostic Significance of a Combination of Cardiogenic Shock and the Critical Culprit Lesion Location in ST-Elevation Myocardial Infarctions.. <i>International Heart Journal</i> , 2022 , 63,	1.8	0
42	The outcomes of reperfusion therapy with streptokinase versus tenecteplase in ST-elevation myocardial infarction (STEMI): a propensity-matched retrospective analysis in an Asian population.. <i>International Journal of Clinical Pharmacy</i> , 2022 , 1	2.3	0
41	A Narrative Review of the Classical and Modern Diagnostic Methods of the No-Reflow Phenomenon.. <i>Diagnostics</i> , 2022 , 12,	3.8	0
40	Real-World Use of Clopidogrel and Ticagrelor in Patients With Myocardial Infarction With Nonobstructive Coronary Arteries: Patient Characteristics and Long-Term Outcomes.. <i>Frontiers in Cardiovascular Medicine</i> , 2021 , 8, 807494	5.4	0
39	Randomised controlled trial to investigate optimal antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention: a study protocol of the OPTIMA-AF trial.. <i>BMJ Open</i> , 2021 , 11, e048354	3	1
38	Percutaneous Transluminal Coronary Angioplasty for Unstable Angina: Predictors of Outcome in a Multicenter Study. <i>Journal of Thrombosis and Thrombolysis</i> , 1994 , 1, 73-78	5.1	7
37	Saruplase in Myocardial Infarction. <i>Journal of Thrombosis and Thrombolysis</i> , 1995 , 2, 195-204	5.1	3
36	Efficacy and safety of de-escalation of antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome: a meta-analysis of randomized clinical trials.. <i>Journal of Cardiovascular Pharmacology</i> , 2022 ,	3.1	0
35	Investigating the association between blood transfusion and clinical outcomes in patients with acute coronary syndromes: a data linkage approach to Patient Blood Management. <i>Blood Transfusion</i> , 2020 ,	3.6	
34	Primary and Rescue PCI in STEMI. 2022 , 154-166		
33	Balance of Ischemia and Bleeding in Selecting Intensity and Duration of Antithrombotic Regimens. 2022 , 465-474		
32	Clinical profile and predictors of 30-day all-cause mortality of ST-elevation myocardial infarction (STEMI) patients receiving fibrinolytic therapy in an Asian population.. <i>Heart and Lung: Journal of Acute and Critical Care</i> , 2022 , 55, 68-76	2.6	
31	The Incidence and Impact of In-Hospital Bleeding in Patients with Acute Coronary Syndrome during the COVID-19 Pandemic. <i>Journal of Clinical Medicine</i> , 2022 , 11, 2926	5.1	1
30	Relevance of pre-existing anemia for patients admitted for acute coronary syndrome to an Intensive Care Unit: A retrospective cohort analysis of 7,418 patients. <i>European Heart Journal Open</i> ,		
29	Safety and efficacy of flow diverter therapy for unruptured intracranial aneurysm compared to traditional endovascular strategy: A multi-center, randomized, open-label trial. <i>Journal of Korean Neurosurgical Society</i> ,	2.3	
28	Association of Increased Pulse Wave Velocity With Long-Term Clinical Outcomes in Patients With Preserved Ankle-Brachial Index After Acute Myocardial Infarction. <i>Heart Lung and Circulation</i> , 2022 ,	1.8	
27	TIMI flow and myocardial blushing after rescue PCI and cardiac magnetic resonance: Results from the Myocardial Salvage After Rescue Angioplasty: Evaluation by Magnetic Resonance (SAVE-ME) study. 2022 ,		0
26	Preoperative treatment with clopidogrel and ticagrelor on bleeding complications in off-pump coronary artery bypass grafting. 2022 , 219, 70-76		0

25	Patient Radiation Dose for Percutaneous Coronary Intervention by Treatment Area-Dosimetry Using DRLs 2020. 2022,	o
24	Obesity Paradox in Coronary Thrombus Burden of Patients with Acute Coronary Syndrome.	o
23	Alprostadil vs. isosorbide dinitrate in ameliorating angina episodes in patients with coronary slow flow phenomenon: A randomized controlled trial. 9,	o
22	Impact of concomitant COVID-19 on the outcome of patients with acute myocardial infarction undergoing coronary artery angiography. 9,	o
21	Sex-related differences in clinical outcomes and predictive factors in the very elderly patients with ACS undergoing PCI. 9,	o
20	The Clinical Value of the Predicting Bleeding Complications in Patients Undergoing Stent Implantation and Subsequent Dual Antiplatelet Therapy Score in Predicting Long-Term Major Adverse Cardiovascular And Cerebrovascular Events and Major Bleeding in Acute Coronary Syndrome Patients Who Underwent Percutaneous Coronary Intervention. 000331972211270	o
19	Microvascular damage after rescue PCI âA prognostic marker for left ventricular function?. 2022,	o
18	Comparison of 6-Month and Prolonged Dual Antiplatelet Therapy after Percutaneous Coronary Intervention with Biodegradable Polymer Everolimus-Eluting Stent. 2022, 2022, 1-9	o
17	Correlation between endothelial dysfunction and occurrence of no-reflow in patients undergoing post-thrombolysis early invasive percutaneous intervention for ST-elevation myocardial infarction. 2022, 74,	o
16	Clinical Outcomes of Biodegradable versus Durable Polymer Drug Eluting Stents in Rotational Atherectomy: Results from ROCK Registry. 2022, 11, 6251	o
15	Performance of the Academic Research Consortium High Bleeding Risk Criteria in Patients With ST-Segment Elevation Myocardial Infarction: A Single Center Study. 000331972211357	o
14	Association between the Angle of the Left Subclavian Artery and Procedural Time for Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome. 2022, 2022, 1-11	o
13	Management of no reflow during percutaneous transcatheter angioplasty with catheter-directed intracoronary thrombolysis: A retrospective observational study. 2022, 12, 260	o
12	Safety of Bivalirudin Combined with Ticagrelor in the Emergency PCI in Patients with Acute ST-Segment Elevation Myocardial Infarction. 2022, 28, 107602962210779	o
11	Short and Long-Term Prognostic Significance of Galectin-3 in Patients with ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. 000331972211498	4
10	Pharmacogenetics of P2Y 12 receptor inhibitors.	o
9	Predictors of outcome in ST-segment elevation myocardial infarction. 2023, 1-12	o
8	Intervention in Acute Myocardial Infarction. 1989, 27, 1205-1215	o

- 7 Long-term use of clopidogrel versus ticagrelor or prasugrel in patients with acute myocardial infarction after percutaneous coronary intervention. **2023**, 18, e0278993 ○
- 6 Prophylactic Efficacy and Safety of Antithrombotic Regimens in Patients with Stable Atherosclerotic Cardiovascular Disease (S-ASCVD): A Bayesian Network Meta-Regression Analysis. ○
- 5 Post-percutaneous coronary intervention CYP2C19 genotyping in an Irish population: The potential role in identifying clopidogrel therapy-related bleeding risks. ○
- 4 Prasugrel Monotherapy After Percutaneous Coronary Intervention With Biodegradable-Polymer Platinum-Chromium Everolimus Eluting Stent for Japanese Patients With Chronic Coronary Syndrome (ASET-JAPAN). **2023**, ○
- 3 Infarct-Related Artery as a Donor of Collaterals in ST-SegmentâElevation Myocardial Infarction With Concomitant Chronic Total Occlusion: Challenge of the Double-Jeopardy Thesis. **2023**, 12, ○
- 2 Clinical profile and prognosis of young patients with ST-elevation myocardial infarction managed by the emergency-intervention Codi IAM network. **2023**, ○
- 1 Pre-Percutaneous Coronary Intervention Zaltefiban Dose-Response Relationship to Target Vessel Blood Flow at Initial Angiogram in ST-Elevation Myocardial Infarction âA Post Hoc Analysis of the Cel-02 Phase IIa Study. **2023**, ○